

AUTHOR INDEX

- Aakvaag, A., 89
 Aanderud, S., 89
 Aarons, J., 1140
 Abdel-Rahman, E., 788
 Abelman, A., 1180
 Acerini, C.L., 1481
 Ackermans, M.T., 217
 Adams, M.R., 391
 Adler, R.A., 425
 Adlercreutz, H., 1440
 Agami, O., 1
 Agardh, C.-D., 269
 Agardh, E., 269
 Agha, N., 420
 Aglialoro, A., 1490
 Aida, K., 699
 Alagona, P., 1097
 Al-Ashwal, A., 900
 Al Banchaabouchi, M., 355
 Al-Bassam, A., 900
 Alberti, K.G.M. M., 250
 Aldaghlis, T.A., 1504
 Alex, S., 154
 Alford, F.P., 522
 Al-Rabeeh, A., 900
 Alsalmi, I., 1337
 Al-Sheikh, N., 420
 Anand, S.S., 182
 Anderson, J.H., 371
 Anderson, R.A., 396
 Ando, S., 1083
 Andreasen, F., 83
 Andrés, C., 637
 Anker, S.D., 1156
 Ansari, B.M., 541
 Apstein, M.D., 367
 Arai, S., 44
 Araújo-Vilar, D., 313
 Arii, K., 598
 Arikawa, E., 1037
 Arisaka, T., 257
 Arita, N., 804
 Armiento, A., 993
 Arnesen, H., 292
 Arslanian, S., 309
 Asagami, T., 493
 Ascaso, J.F., 508
 Aso, Y., 362
 Aspelin, T., 292
 Asplund, K., 384
 Assmann, G., 336
 Astorri, E., 915
 Attalah, M., 503
 Attali, J.-R., 503, 934
 Aubó, C., 1040
 Audouin-Chevallier, I., 301
 Auer, C., 965
 Aussedat, B., 799
 Averbukh, E., 1331
 Azuma, N., 456
 Babazono, T., 1325
 Bahouth, S.W., 1455
 Bahr, R., 439
 Bakker, O., 1052
 Ballesta, A.M., 560
 Balogh, Z., 1070
 Balsano, F., 993
 Bansch, D., 336
 Banyai, S., 1058
 Bao, W., 998
 Barakat, H., 1048, 1222
 Barazzoni, R., 669
 Baron, A.D., 573
 Barreca, A., 1490
 Barrett, P.H.R., 478, 484
 Barton, B.A., 514
 Basson, M.D., 133
 Batta, A.K., 878
 Battezzati, A., 713
 Baur, L.A., 106
 Båvenholm, P., 113
 Beck-Nielsen, H., 522
 Bedair, S.M.A., 1337
 Begay, C.K., 223
 Begum, N., 54
 Behar, A., 503
 Beisiegel, U., 1160
 Bell, B.M., 484
 Bell-Farrow, A.D., 401
 Bendahan, D., 769
 Benický, J., 1269
 Bennett, F., 617
 Berenson, G.S., 757, 998
 Berger, V., 1499
 Berman, D.M., 467
 Berry, G.T., 1423
 Beucler, I., 965
 Bhathena, S.J., 1199
 Biesalski, H., 1
 Birkenhäger, J.C., 675
 Biro, F.M., 514
 Bistran, B.R., 345
 Björntorp, P., 1187
 Blachar, Y., 264
 Black, B.L., 1354
 Boddie, A.M., 207
 Bode, B.P., 608
 Bojanovski, D., 1160
 Bolognino, M., 1315
 Bønaa, K.H., 848
 Bonilla, S., 301
 Bories, D., 1413
 Borsheim, E., 439
 Bosch, M., 1040
 Botion, L.M., 1217
 Bozzola, M., 1490
 Bradfield, J., 1048
 Braverman, L.E., 154
 Bravi, M.C., 993
 Bremme, K.A., 840
 Brewer, H.B., Jr., 1160
 Brindley, D.N., 1383
 Brito, M.N., 1217
 Brito, N.A., 1217
 Brito, S.R.C., 1217
 Brna, R., 309
 Brousse, N., 1366
 Brouwer, E.M.C., 1462
 Brown, J.A., 377
 Bugianesi, E., 792
 Buongiorno, A., 129
 Buzzetti, R., 1205
 Byun, Y., 955
 Cabana, V.G., 234
 Cabezas-Cerrato, J., 313
 Caccese, D., 97
 Caffarri, G., 50, 814
 Cagen, L.M., 869
 Caiazza, A., 893
 Caiola, S., 129
 Caixàs, A., 371
 Calcutt, N.A., 650
 Calvo, C., 297
 Calzoni, F., 988
 Cameron-Smith, D., 149
 Camilleri, M., 7
 Campbell, J.D., 1199
 Capretti, L., 50, 814
 Carantoni, M., 535, 831
 Carey, K.D., 731
 Carey, T.E., 955
 Carmena, r., 508
 Carreras, G., 371
 Caruso, A., 158
 Casals, E., 560
 Casimirri, F., 988
 Cassone-Faldetta, M., 993
 Caumo, A., 135, 1009
 Cavagnini, F., 143
 Cavallo, M.G., 1205
 Cazes, P., 934
 Cefalu, W.T., 401, 947
 Ceseña, R.M., 650
 Chalkley, S.M., 1121
 Chaudhuri, A., 788
 Cheetham, S.T., 31
 Chen, C.-F., 1211
 Chen, J.-J., 1211
 Chen, L.-D., 731
 Chen-Haudenschild, C., 336
 Cherrington, A.D., 135
 Chiao, Y.-C., 1211
 Chiodera, P., 50, 814, 893, 897
 Chisholm, D.J., 1121
 Choi, J.-H., 955
 Chou, C.-J., 1211
 Chow, J.C., 345
 Christiansen, J.S., 83, 1134
 Chrousos, G.P., 1289, 1419
 Chua, T.-P., 1156
 Chung, J.W., 955
 Ciampelli, M., 158
 Cianci, J., 1315
 Ciaraldi, T.P., 940

- Ciechanowicz, A., 844
 Clark, J.S.C., 844
 Clarke, J.T.R., 836
 Claus, R., 1105
 Clevenger, C.M., 1112
 Coast, A.J.S., 1156
 Coates, R.J., 207
 Cobanov, B., 1127
 Cobelli, C., 135, 484, 1009
 Cohen, A.M., 1274
 Cohen, W.R., 121
 Cohen-Boulakia, F., 503
 Coiro, V., 50, 814, 893, 897
 Colla, R., 50, 814
 Collier, G.R., 125, 1308
 Colomb, V., 1366
 Colvin, P.L., Jr., 391
 Colzani, R., 154
 Conley, M., 1140
 Cooney, G.J., 149, 409
 Corsetti, J.P., 1315
 Cortese, C., 97
 Coudray-Lucas, C., 1366
 Cowett, R.M., 1239
 Cozzzone, P.J., 769
 Craveri, A., 915
 Croft, K., 1180
 Croom, J., 1354
 Crouse, J.R., III, 401
 Crouse, S.F., 377
 Crowne, E.C., 31
 Cruickshank, K., 617
 Cushman, S.W., 3
 Cynober, L., 1366

 Dacou-Voutetakis, C., 1408
 D'Adamo, M., 129
 Daimon, M., 1167
 Dalferes, E.R., Jr., 998
 Dall, R., 1134
 Dall'Aglio, P., 915
 Dal Ponte, D.B., 982
 Dandona, P., 788
 Daniels, M.C., 449
 Darmaun, D., 497, 549, 1429
 Davidson, M., 1097
 Davidson, N.O., 869
 Davis, S.N., 135
 Davoren, P.M., 250
 De Bandt, J.P., 1366
 Deckers, J.W., 675
 De Deyn, P.P., 355
 De Faire, U., 113
 Defensor, R., 1289
 DeFerri, A., 50
 Dekker, E., 217
 De la Bretonne, J.A., 1520
 De Leiva, A., 371
 Delitala, G., 143
 De Martin, M., 143
 De Mattia, G., 993
 Dembure, P.P., 207
 Dengel, D.R., 1075
 Dennis, K.E., 467
 Denver, A.E., 637

 Derfler, K., 1058
 De Riva, C., 4194
 Desjeux, F., 1429
 DeSouza, C.A., 1112
 Deutsch, J., 121
 Devlin, A.M., 20
 Dhillon, A.S., 1180
 D'Hooge, R., 355
 Diehl, E., 63
 Dines, K.C., 650
 Dinneen, S.F., 7
 Dirkes-Kersting, A., 336
 Dobbins, R.L., 135
 Doi, T., 1303
 Dolnikowski, G.G., 922
 Donckier, J., 592
 Donner, M.G., 273, 863
 Donohoue, P., 584
 Dörner, G., 855
 Dornhorst, A., 1245
 Douskas, G., 1379
 Dracopoulou, M., 1408
 Drake, K., 121
 Drash, A.L., 309
 Drukker, A., 264
 Dubuc, G.R., 429
 Dumas, F., 1366
 Dumon, H., 549
 Dunbar, J.C., 185
 Dunger, D.B., 31, 1481
 Dutra, S.L., 1429

 Ebbeling, C.B., 1434
 Edwards, C.L., 1354
 Efendic, S., 627
 Egloff, M., 965
 Eisen, E.J., 1354
 Elam, M.B., 869
 El Banna, N., 541
 Elkasabani, A., 998
 Elkasabany, A., 757
 Ellsworth, J.L., 325
 Elsas, L.J., II, 207
 ElZalabani, M.M., 541
 Enas, E.A., 182
 Endert, E., 217
 Endoh, A., 474
 Ericsson, C.-G., 113
 Ericsson, U.-B., 89
 Erkintalo, M., 769
 Evani, R., 425
 Even, P.C., 777
 Ezaki, O., 724

 Fabreguettes, C., 769
 Facchini, F.S., 831
 Fain, J.N., 1455
 Falkner, B.E., 70
 Fang, S.L., 154
 Fang, V.S., 1468
 Fantus, I.G., 630
 Fattah, M.A., 541
 Feinglos, M.N., 1089
 Fellin, R., 535
 Fendri, S., 1372

 Feng, J.Y., 751
 Fernandez, M.L., 883
 Ferri, C., 993
 Fink, L.M., 686
 Fiorina, P., 915
 Fisher, L., 836
 Fisker, S., 1514
 Fjiyawa, K., 1152
 Flamia, R., 792
 Flores, G., 1127
 Flyvbjerg, A., 817, 1331
 Fogt, D.L., 982
 Fonda, M.L., 168
 Fonseca, V.A., 686
 Fóris, G., 1070
 Forrester, T., 617
 Foster, D.M., 484
 Fouda, K., 900
 Foy, C.A., 622
 Frangos, M., 1423
 Frank, J.W., 7
 Frishberg, Y., 264
 Frost, G., 1245
 Fu, C.L., 1360
 Fujimura, T., 177
 Fujisawa, K., 333
 Fujita, T., 1005
 Fujitani, J., 874
 Fukuo, K., 195
 Fukushima, T., 1528
 Fukuzawa, M., 977
 Fulghesu, A.M., 158
 Funahashi, T., 929
 Furler, S.M., 409
 Furukawa, L.N., 493
 Fusegawa, T., 1348

 Gabriel, H., 1058
 Galal, D.O., 420
 Gambineri, A., 988
 Gandley, R.E., 1281
 Gangnerau, M.N., 799
 Gao, T.Q., 1528
 García-Estévez, D.A., 313
 Garcin, H., 301
 Garfinkel, M.R., 809
 Gateva, E., 121
 Gautier, V., 965
 Gelardi, N.L., 1239
 Genma, R., 1083
 George, B.C., 367
 Georgiou, E., 1379
 Gerich, J., 1227
 Getz, G.S., 234
 Giaccari, A., 129
 Gielkens, H.A.J., 321
 Giral, P., 965
 Giuliani, N., 814, 893
 Godslan, I.F., 113, 657
 Goff, D., 1174
 Goldberg, A.C., 1097
 Goldberg, A.P., 467, 1075
 Golde, H., 484
 Goldstein, M., 409
 Goto, N., 724

- Gottsauner-Wolf, M., 1058
 Gottschalk, W.K., 449
 Goulet, O., 1366
 Graham, S.E., 1383
 Grandjean, P.W., 377
 Grant, P.J., 622
 Green, T., 1048
 Gregg, R.E., 1160
 Gries, F.A., 250
 Grøfte, T., 83
 Grønbeek, H., 817
 Guido, M., 158
 Gylling, H., 744

 Hafeez, R., 788
 Haffner, S., 182
 Haffner, S.M., 230, 1174
 Hagberg, J.M., 1075
 Hales, C.N., 1450
 Hallmans, G., 384
 Halpert, M., 1331
 Hamada, K., 1303
 Hamadeh, M.J., 1145
 Hamman, R.F., 1174
 Hamsten, A., 113
 Han, I.S., 955
 Hansen, C.T., 1199
 Hara, T., 149
 Harada, T., 1472
 Harder, T., 855
 Harris, A.G., 1419
 Harris, D.A., 1481
 Hartley, C.J., 1295
 Hashimoto, K., 598, 804
 Hassager, C., 212
 Hasslacher, C., 63
 Hata, I., 1344
 Hata, K., 333
 Hattori, J., 351, 783
 Hautanen, A., 1440
 Havel, P.J., 429
 Håwa, M., 1205
 Hayakawa, T., 804
 Hayashi, H., 1391
 Haynes, W., 584
 Hector, R., 663
 Heikkinen, S., 1397
 Heimberg, M., 869
 Heinemann, L., 1263
 Heise, T., 1263
 Hennig, B., 566
 Henriksen, E.J., 982
 Henriksen, J.E., 522
 Henry, R.R., 686
 Hettiarachchi, M., 1121
 Heuman, D.M., 285
 Hew, L.F., 522
 Hickey, M., 1222
 Hickman, M.G., 940
 Higaki, Y., 874
 Higashino, K., 695, 739, 1005
 Higashiyama, M., 1391
 Higuere, P., 301
 Hilton, F.K., 168
 Hilton, M.A., 168

 Hiltunen, T.P., 1258
 Hinson, W.H., 401
 Hirano, K.-I., 869
 Hiraoka, M., 1403
 Hiroishi, K., 695, 739, 1005
 Ho, L.-T., 1468
 Hobensack, K., 663
 Hoffer, L.J., 1145
 Höfling, B., 863
 Holaday, N.J., 223
 Holeček, M., 681
 Holleran, A.L., 1504
 Holly, J.M.P., 31
 Holmes, L., 1140
 Honda, N., 257
 Hoogerbrugge, N., 675
 Hooi, S.C., 603
 Hori, C., 1403
 Hori, M., 908
 Horikawa, S., 1295
 Horiuchi, R., 1083
 Hörl, W.H., 1058
 Hosoda, K., 456
 Høstmark, T., 439
 Howard, B.V., 1174
 Howell, S., 617
 Howell, T., 751
 Hsu, Y.-P., 1468
 Hu, Y., 799
 Huang, X.-H., 1258
 Hubel, C.A., 1281
 Hubinger, A., 250
 Hudig, F., 1052
 Hultberg, B., 269
 Humaloja, K., 644
 Hwu, C.-M., 1211

 Ichihara, S., 177
 Ichikawa, Y., 94
 Ichino, I., 1494
 Idriss, S., 934
 Igaki, T., 456
 Igarashi, M., 1167
 Igawa, K., 1295
 Ikeda, M., 44
 Ikeda, T., 1152
 Ikeda, Y., 598
 Ikemoto, S., 724
 Innis, S.M., 20
 Inoue, M., 598
 Inukai, T., 362
 Invitti, C., 143
 Ishida, T., 1295
 Ishii, Y., 1403
 Ishikawa, K., 493
 Ishikawa, S.-e., 1391
 Ishimori, M., 351, 783
 Isobe, A., 1528
 Israel, R.G., 1222
 Ito, H., 598
 Itoh, H., 456
 Ivandić, A., 13
 Iwamoto, Y., 1325
 Iwase, E., 699

 Jacob, S., 982
 Janosky, J.E., 309
 Jansen, H., 675
 Jeevanandam, M., 223
 Jenkins, S., 1097
 Jensen, M.D., 280
 Jenssen, T., 848
 Jeppesen, J., 831
 Ježová, D., 1269
 Jiang, Z.L., 1472
 Jones, P.J.H., 751
 Jones, P.P., 1112
 Jørgensen, J.O.L., 83, 1134, 1514
 Jovanovic, L., 1140
 Jovinge, S., 113
 Juan, C.-C., 1468
 Jurić, M., 13

 Kafonek, S.D., 1097
 Kagawa, T., 874
 Kager, P.A., 217
 Kalayoglu, M., 200
 Kalhan, S.C., 309
 Kang, K.W., 39
 Kanmatsuse, K., 493
 Kano, H., 1065
 Kaplan, L.M., 603
 Karam, G., 934
 Karjalainen, L., 1397
 Kasayama, S., 804
 Kashyap, M., 1097
 Katsumori, K., 27
 Kawahara, R., 27
 Kawakami, A., 1391
 Kawamori, R., 44, 257, 908
 Kawanishi, K., 1295
 Kelleher, J.K., 1504
 Kelly, W., 250
 Keltikangas-Järvinen, L., 1440
 Kemmer, H., 1105
 Kern, P.A., 686
 Ketelslegers, J.-M., 592
 Kettelhut, I.C., 1217
 Khan, A., 627
 Khurana, R., 1315
 Kiehl, D., 844
 Kim, S.H., 955
 Kim, S.Y., 955
 Kinoshita, J., 257
 Kinsley, B.T., 1252
 Kishimoto, T., 804
 Kitahara, A., 1083
 Kitano, S., 195
 Kiyonaga, A., 874
 Kjeldsen, S., 292
 Klein, G.K., 273
 Klein, J.C., 799
 Klein, S., 706
 Knardahl, S., 439
 Knopp, R., 1140
 Knopp, R.H., 1097
 Knowler, W.C., 622
 Knuutila, M.L.E., 578
 Kodama, H., 1233
 Koenig, J.I., 603

- Koga, M., 804
 Kohno, M., 1065
 Kohzuki, M., 1472
 Koike, T., 1348
 Koivula, T., 1258
 Kokkaku, K., 1391
 Kolanowski, J., 592
 Kotsuji, F., 1344
 Kovács, É., 1070
 Kovács, P., 1070
 Kraegen, E.W., 409, 1121
 Kraemer, F.B., 555
 Krauss, R.M., 1174
 Kreider, M., 1227
 Krempf, M., 497, 549
 Krieg, R.J., Jr., 425
 Kriketos, A.D., 106
 Kristensen, K., 1514
 Kubota, M., 44, 908
 Kumar, V., 461
 Kume, S., 699
 Kumon, Y., 598
 Kurahashi, Y., 257
 Kurzawski, G., 844
 Kusaka, I., 1391
 Kushiro, T., 493
 Kushner, H., 70
 Kushwaha, R.S., 731
 Kusunoki, M., 149
 Kuwajima, S., 1348
 Kuznetsov, N.K., 903
 Kwok, C.-F., 1468
 Kyriakidis, M., 1379

 Laakso, M., 1397
 Lagrost, L., 965
 Laher, I., 1037
 Lala, A., 97
 Lalau, J.-D., 1372
 Lam, W.F., 321
 Lamarche, B., 234
 Lambrinoudaki, I., 1379
 Lamers, C.B.H. W., 321
 Landau, B.R., 627
 Lanfredini, M., 915
 Lanzone, A., 158
 Lardner, A.L., 163
 Larue-Achagiotis, C., 777
 Lau, D.C.W., 461
 Laurenti, O., 993
 Lavie, S., 1366
 Laws, A., 1174
 Lazarus, D.D., 75
 Le Boucher, J., 1366
 Lee, H.R., 955
 Lee, K.-S., 955
 Lee, S., 125
 Lee, Y.-C., 1468
 Lee, Y.J., 1140
 Leeds, A., 1245
 Lehotay, D.C., 836
 Lehtimäki, T., 1258
 Leibel, R.L., 584
 Leiser, R., 1105
 Lemonnier, F., 799

 Lenders, J.W.M., 243
 Leslie, R.D.G., 1205
 Levi, S., 264
 Levillain, O., 355
 Levine, J., 280
 Levy, J., 185
 Levy, J.R., 285
 Lewis, G.F., 234
 Leyva, F., 657, 1156
 Li, G., 824
 Liang, J., 959
 Lichtenstein, A.H., 922
 Lien, E.A., 89
 Lin, H., 1211
 Lin, L.-C., 1211
 Lin, S.-H., 1468
 Lindahl, B., 384
 Lindal, S., 848
 Lindenthal, B., 1504
 Ling, P.-R., 345
 Littman, E.D., 809
 Litwak, K.N., 947
 Liu, Y.-J., 474
 Livieri, C., 1490
 Lohmann, R., 608
 Longui, C.A., 1419
 Lorente, R.I., 508
 Lorneau, B., 1372
 Lotan, D., 264
 Lotsikaš, A.J., 1289
 Louheranta, A.M., 529
 Louisot, P., 1499
 Lovejoy, J.C., 1520
 Lu, B., 630
 Lu, C.-C., 1211
 Luo, J., 663
 Lutterman, J.A., 243
 Luzzi, L., 713
 Lyall, F., 1281

 Ma, D., 1233
 McArthur, M.D., 1383
 McClain, C.J., 566
 McClain, D., 449
 McCormick, K., 1360
 MacDougall, D.E., 751
 McFarlane-Anderson, N., 617
 McGill, H.C., Jr., 731
 Macho, L., 1269
 MacLean, P., 1048, 1222
 McNamara, D.J., 883
 McNeill, J.H., 1037
 Macor, C., 988
 Magotti, M.G., 893
 Makita, Z., 1348
 Manaka, H., 1167
 Mancuso, S., 158
 Mandal, A.K., 1065
 Manglik, S., 1127
 Manns, M.P., 1160
 Mansouri, A., 425
 Marchesi, C., 50, 814
 Marchesini, G., 792
 Marchini, J.S., 497, 549
 Marcovina, S., 1097

 Marescau, B., 355
 Margara, R., 1245
 Marietti, G., 1205
 Marks, L.M., 497
 Marks, R.H., 1222
 Maroccia, E., 129
 Martin, A., 1499
 Martinez, A.J., 301
 Martinez-Valls, J., 508
 Maruyama, K., 724
 Masclee, A.A.M., 321
 Masuda, T., 977
 Masuzaki, H., 456
 Mathes, P.B., 273
 Matsuhisa, M., 44, 908
 Matsumoto, K., 1303
 Matsuo, Y., 94
 Matsuoka, N., 456
 Matsuura, F., 929
 Matsuzawa, Y., 929
 Mattéi, J.-P., 769
 Matthews, D.E., 713
 Mattila, P.T., 578
 Matyka, K.A., 1481
 Maugère, P., 549
 Mayer-Davis, E.J., 1174
 Mayumi, M., 333, 1344, 1403
 Meeter, K., 675
 Mello, A., 915
 Menzinger, G., 97
 Merchante, A., 508
 Messaoudi, L., 592
 Messing, B., 1429
 Metz, S.A., 824
 Metzger, B., 1140
 Meyer, C., 1227
 Mezzetti, A., 535
 Michaelis, O.E., IV., 1199
 Mick, G., 1360
 Miettinen, T.A., 744
 Migliorini, R.H., 1217
 Mikami, T., 1083
 Millar, J.S., 922
 Mills, J.L., 1140
 Minami, M., 1065
 Minehira, K., 1303
 Miossec, P., 934
 Miura, M., 333, 1344
 Miyaguchi, S., 977
 Miyamoto, Y., 456
 Moan, A., 292
 Mochizuki, K., 257
 Mohamed-Ali, V., 622, 637
 Moldawer, L.L., 75
 Montano, C.E., 883
 Morales, A.J., 940
 Morgan, D., 584
 Morgan, T., 401
 Morimoto, S., 195
 Morishima, T., 908
 Morita, T., 598
 Moriwaki, Y., 695, 739, 1005
 Morrison, J.A., 514
 Morviducci, L., 129
 Moshe, R., 1331

- Motomura, T., 804
 Motti, C., 97
 Mourad, M., 420
 Moussa, M.A.A., 420
 Mudaliar, S., 686
 Murgia, F., 158

 Nadjafi, R., 1127
 Nagasaka, S., 1391
 Nagi, D.K., 622
 Naim, M., 1
 Nakagawa, Y., 474
 Nakahara, I., 908
 Nakai, Y., 874
 Nakajima, M., 195
 Nakamura, H., 1083
 Nakamura, M., 257
 Nakamura, T., 929, 1391
 Nakano, T., 695, 739, 1005
 Nakao, K., 456
 Nakashima, K., 351, 783
 Nakauchi, Y., 598
 Naliboff, B.D., 39
 Naruse, M., 27
 Naruszewicz, M., 844
 Nasuda, K., 474
 Natsume, H., 1083
 Natsu, V., 555
 Naveas, R., 297
 Nawata, H., 1494
 Neal, D., 135
 Nedrebo, B.G., 89
 Nelson, A., 1274
 Nephesh, I., 1331
 Nestle, P.J., 1308
 Newsome, C., 617
 Nguyen, P., 549
 Nguyen, T.N., 934
 Nicklas, B.J., 467
 Nicolosi, R.J., 959
 Nicolson, M., 1525
 Nijima, A., 1167
 Niinobu, T., 195
 Nikkari, T., 1258
 Nikodémová, M., 1269
 Nilsson, J., 113
 Nilsson, T.K., 384
 Nishi, S., 456
 Nishida, M., 929
 Nishimura, H., 456
 Nishiyama, K., 1083
 Nishizawa, H., 44
 Nkansa-Dwamena, D., 420
 Noel-Suberville, C., 301
 Normand, S., 1499
 Nørrelund, H., 83, 1514
 Nowaczyk, M.J.M., 836
 Nowotny, P., 119, 974, 1376
 Nozaki, S., 929
 Nygård, O., 89

 O'Brien, B.C., 377
 O'Brien, W.T., 878
 O'Connor, J., 106
 Odom-Ford, R., 940

 O'Donovan, D.J., 163
 Ogihara, T., 195
 Ohara, M., 101
 Ohata, H., 695, 1005
 Ohnuma, H., 1167
 Ohsawa, N., 101
 Ohzeki, T., 474
 Ojuel, J., 560
 Okamura, K., 1303
 Okumura, S., 351, 783
 Olefsky, J.M., 940
 Omori, Y., 27, 1325
 Onaya, T., 699
 Onishi, T., 195
 Opara, E.C., 401, 809
 Ordóñez-Llanos, J., 371
 Ordovas, J.M., 922
 Ørskov, H., 817
 Otal, C., 371
 Otvos, J., 1222
 Ozaki, Y., 699
 Ozand, P.T., 900
 Ozanne, S.E., 1450

 Pachiaudi, C., 1499
 Pacini, G., 792
 Paganini, C., 1490
 Pallet, V., 301
 Palmer, T.N., 1180
 Palmieri, E., 535
 Palmieri, M., 1423
 Pan, D.A., 106
 Panahloo, A., 637
 Pandak, W.M., 285
 Papanicolaou, D.A., 1289
 Paragh, G., 1070
 Parekh, P.I., 1089
 Parhofer, K.G., 478
 Pariès, J., 503, 934
 Park, E., 1140
 Parsons, W., 751
 Parviainen, M.T., 529
 Pasquali, M., 207
 Pasquali, R., 988
 Pasquino, B., 1490
 Pasternack, A., 1258
 Patel, B.K., 603
 Patterson, B.W., 706
 Payés, A., 371
 Pearson, T., 182
 Peca, M.G., 915
 Pecka, M., 681
 Pedersen, S.B., 1514
 Peppas-Patrikiou, M., 1408
 Pérez, A., 371
 Périer, S., 1499
 Perriello, G., 1227
 Peters, T.J., 1180
 Petersen, S.C., 223
 Peterson, R.G., 1042, 1315
 Petro, A.E., 1089, 1354
 Petry, C.J., 1450
 Phanumas, L., 39
 Phillips, H., 836
 Phiney, S.D., 429

 Phung, T.L., 1315
 Piercy, V., 1477
 Pignon, J.-M., 1413
 Pihlajamäki, J., 1397
 Piloquet, H., 549
 Pirsch, J.D., 200
 Pitchumoni, S., 809
 Plagemann, A., 855
 Platt, B.-A., 836
 Pogue, J., 182
 Polansky, M.M., 396
 Pomeroy, S.E., 1308
 Poretsky, L., 690
 Portillo, M.P., 301
 Poulsen, P.L., 83
 Pouteau, E., 549
 Pozzilli, P., 1205
 Pratley, R.E., 1075
 Pritsker, A., 3
 Proudier, A., 113
 Proukakis, C., 1379
 Prpić-Križevac, I., 13

 Qi, R., 699
 Qian, Y., 269
 Qiang, X., 977
 Qu, Z., 345
 Quan, J., 663

 Raab, S., 1105
 Radetti, G., 1490
 Raghov, R., 869
 Ragolia, L., 54
 Rääkkönen, K., 1440
 Rajab, A., 1337
 Rajpal, S., 200
 Ramachandran, A., 230
 Rantalaiho, V., 1258
 Rantau, C., 522
 Rapoza, R.E., 1239
 Raslich, M., 200
 Ravaja, N., 1440
 Ravussin, E., 1525
 Raz, I., 1331
 Reach, G., 799
 Real, J.T., 508
 Reaven, G.M., 663, 831
 Refsum, H., 89
 Reifen, R., 1, 264
 Reviriego, J., 371
 Reynolds, R., 1423
 Rice, K.S., 731
 Richelsen, B., 1514
 Richter, W.O., 273, 863
 Ricour, C., 1366
 Rieth, N., 777
 Rios, M., 297
 Rioux, M.F., 20
 Rissanen, J., 1397
 Rizza, R.A., 7
 Robbins, D.C., 1174
 Roberts, J.M., 1281
 Rodriguez, N.R., 1434
 Rodriguez-Villar, C., 560
 Rogus, E.M., 467, 1075

- Rohac, M., 1058
 Rohack, J.J., 377
 Rohde, W., 855
 Roine, R.P., 644
 Romano, C., 959
 Romijn, J.A., 217
 Ronchi, M., 792
 Rood, J.C., 1520
 Ros, E., 560
 Roseau, S., 777
 Rosenfalck, A.M., 1514
 Rosenthal, M.J., 39
 Rosmond, R., 1187
 Roth, M.D., 1042
 Roussel, B., 1372
 Rubio, S.I., 690
 Russell, J.C., 1383
 Russell-Jones, D.L., 1481

 Saad, M.F., 1174
 Saegusa, H., 474
 Sagara, M., 977
 Saïdi, Y., 965
 Saito, T., 1391
 Sakamoto, M., 874
 Salaspuro, M., 644
 Salen, G., 878
 Samra, J.S., 31
 Sanllehy, C., 560
 Saris, W.H.M., 1462
 Sarkkinen, E.S., 744
 Sasahara, T., 1308
 Sasaki, A., 783
 Sasaki, H., 1167
 Sato, T., 1472
 Satoh, J., 977
 Satoh, K., 699
 Satoh, N., 456
 Satyavani, K., 230
 Sauerwein, H.P., 217
 Sbraccia, P., 129
 Scalbert, E., 1199
 Schaefer, E.J., 922
 Schalch, D.S., 200
 Schiffelers, S.L.H., 1462
 Schmidt, B., 686
 Schmidt, H.J.-H., 1160
 Schulte, H., 336
 Schumitzky, A., 484
 Schwab, U.S., 529
 Schwandt, P., 273, 863
 Scoppola, A., 97
 Seals, D.R., 1112
 Segal, S., 1423
 Segu, V.B.G., 824
 Sekine, K., 1344
 Selby, J., 1174
 Seljeflot, I., 292
 Sentf, M., 1040
 Sepúlveda, J., 297
 Sepúlveda, S., 297
 Servatius, R.J., 878
 Sgambati, S.A., 133
 Shaltout, A.A., 420
 Shankar, R.R., 573
 Shefer, S., 878

 Shen, H.-Q., 1042
 Sherif, K., 70
 Shi, Z.Q., 1274
 Shiba, Y., 908
 Shigemoto, M., 456
 Shillabeer, G., 461
 Shimizu, S., 1303
 Shimoike, T., 1494
 Shindo, M., 874
 Shiroshita, K., 1348
 Shiwaku, K., 1528
 Shukin, R., 20
 Shukla, N., 1048
 Shuldiner, A.R., 1525
 Sich, D., 965
 Silver, K., 1525
 Simonson, D.C., 713, 1252
 Simpson, J.L., 1140
 Sivitz, W.I., 584
 Skjærboek, C., 817
 Smith, J.M., 1450
 Smith, R.J., 345
 Smits, P., 243
 Smolyar, D., 690
 Snelhalatha, C., 230
 Snitker, S., 1525
 Soliman, A.T., 541, 1337
 Song, M.K., 39
 Sorci-Thomas, M.G., 391
 Souba, W.W., 608
 Sowden, M.P., 1315
 Sparks, C.E., 1315
 Sparks, J.D., 1315
 Sprecher, D., 514, 1097
 Štrngl, L., 681
 Srinivasan, S.R., 757, 998
 Starke, A.A.R., 1263
 Starr, J.R., 325
 Steen, M.T., 207
 Stern, J.S., 429
 Stevens, W., 285
 Stevenson, J.C., 435, 657
 Stock, S.M., 840
 Stoffel, M., 592
 Stolarczyk, R., 690
 Storlien, L.H., 106, 149
 Štrbák, V., 1269
 Streicher, J., 1058
 Striffler, J.S., 396, 1199
 Strobl, W., 1058
 Stumvoll, M., 1227
 Sučić, M., 13
 Suehiro, T., 598
 Suga, J., 456
 Sugahara, K., 1233
 Sugimoto, M., 351, 783
 Sugiyama, K., 1167
 Sulikowski, T., 844
 Sullivan, C., 663
 Sullivan, K.M., 207
 Superko, H.R., 1097
 Suprasongsin, C., 309
 Surwit, R.S., 1089, 1354
 Suzuki, M., 190
 Svanberg, M.J., 578
 Svendsen, O.L., 212

 Szabó, J., 1070
 Szabolcs, M., 1070
 Sztalryd, C., 555

 Tack, C.J.J., 243
 Takahara, J., 1295
 Takahashi, A., 493
 Takahashi, K., 977
 Takahashi, M., 724
 Takahashi, S., 695, 739, 1005
 Takami, K., 351, 783
 Takami, R., 351, 783
 Takayanagi, R., 1494
 Takeda, D., 555
 Takeda, N., 351, 783
 Takemura, Y., 362
 Takeuchi, M., 333, 1348
 Tamatani, M., 195
 Tamburrano, G., 129
 Tan, R., 836
 Tanaka, H., 874, 1112
 Tanaka, T., 456
 Tang, S., 630
 Taniguchi, A., 874
 Taveroff, A., 1145
 Tawata, M., 699
 Tayek, J.A., 1127
 Teraoka, S., 1325
 Terry, J.G., 401
 Tessari, P., 669
 Thibault, N., 1199
 Thien, H.V., 217
 Thien, T., 243
 Thomaseth, K., 792
 Thomé-Duret, V., 799
 Thomforde, G.M., 7
 Thorngate, F.E., 869
 Thuillier, F., 1429
 Thusu, K., 788
 Thuy, L.T.D., 217
 Tibbo, E., 461
 Tichý, M., 681
 Tietge, U.J.F., 1160
 Tiller, J.M., 1089
 Tint, G.S., 878
 Toborek, M., 566
 Toft, I., 848
 Tohjima, T., 257
 Tokuyama, K., 190, 874
 Tominaga, M., 1167
 Tomita, T., 908
 Tomonaga, O., 1325
 Tonetti, C., 1413
 Tong, W.-M., 415
 Tønnessen, T., 292
 Tornvall, P., 113
 Torpy, D.J., 1289
 Toseland, C.D.N., 1477
 Toya, K., 474
 Toyota, T., 977
 Trew, G., 1245
 Tribout, B., 1372
 Trimble, L.A., 75
 Tsai, J., 663
 Tsai, S.-C., 1211
 Tsekcs, G., 1379

- Tsigos, C., 1289
 Tsukahara, H., 333, 1344, 1403
 Tsunooka, Y., 94
 Tsunoda, N., 724
 Tsutsumi, K., 101, 149
 Tsutsumi, Z., 695, 739, 1005
 Tulliez, M., 1413
 Turner, N.C., 1477
 Turpeinen, A.K., 529
 Turpin, G., 965

 Ueda, T., 1348
 Ueland, P.M., 89
 Uffelman, K.D., 234
 Ulloa, N., 297
 Umeda, F., 1494
 Umpleby, A.M., 1481
 Uusitupa, M.I.J., 529, 744

 Vaag, A., 522
 Vadlamudi, S., 1048, 1222
 Vague, P., 769
 Vahl, N., 1134
 Valasquez, M.T., 1199
 Valensi, P., 503, 934
 Valve, R., 1397
 Van Baak, M.A., 1462
 Van Daele, A., 355
 Vanderbloomer, T., 1360
 Van Druten, J., 243
 Van Marck, E., 355
 Veldhuis, J.D., 143
 Verdugo, C., 297
 Verentsov, G.E., 903
 Vergnani, L., 535
 Verkijk, M., 321
 Verma, S., 1037
 Veronelli, A., 915
 Vettor, R., 988
 Vettore, M., 669
 Vicennati, V., 988
 Vicini, P., 484
 Vidgren, H.M., 529
 Vierhapper, H., 119, 974, 1376
 Vijay, V., 230
 Virici, F., 1194
 Virkamäki, A., 449
 Visalli, N., 1205
 Volpato, S., 535
 Volpi, R., 50, 814, 893, 897
 Von Eckardstein, A., 336
 Von Wronski, M.A., 869
 Vore, S., 1048

 Vottero, A., 1419
 Wagner, J.D., 391, 947
 Walder, K., 125
 Waldhäusl, W., 119, 974, 1376
 Walsh, S., 584
 Walton, C., 435
 Wang, C.L., 1450
 Wang, F., 415
 Wang, G.-J., 1211
 Wang, J., 1274
 Wang, P.S., 1211
 Wang, S.-W., 1211
 Wang, Z.Q., 401
 Ward, G.M., 522
 Wasada, T., 27
 Watanabe, H., 724
 Watanabe, K., 257
 Watanabe, Y., 94
 Watts, A.P., 31, 1481
 Weidinger, F., 1058
 Weinstein, S.P., 3
 Weiser, H., 1
 Weiss, O., 1331
 Weissfeld, L., 1281
 Welt, C.K., 1252
 Werbel, S., 401
 Werle, E., 63
 Whately-Smith, C., 250
 Wherli, S., 1423
 Whitcomb, L., 1274
 Wiersinga, W.M., 1052
 Wilcox, H.G., 869
 Wilks, R., 617
 Willemsen, J.J., 243
 Williamson, J.R., 1423
 Wilson, C.M., 3
 Wilson, G.S., 799
 Wilson, T.A., 959
 Windhauser, M.M., 1520
 Wingrove, C.S., 435, 657
 Wirta, O., 1258
 Wolthers, T., 83

 Xu, D., 1180
 Xu, G., 878

 Yamada, M.A., 177
 Yamakita, J.-i., 695, 739, 1005
 Yamamoto, K., 333, 1403
 Yamamoto, S., 257
 Yamamoto, T., 695, 739, 1005
 Yamamoto, Y., 456
 Yamane, Y., 1528

 Yamasaki, Y., 44, 908
 Yamashita, S., 929
 Yamashita, T., 1308
 Yamatani, K., 1167
 Yanagisawa, K., 1348
 Yanase, T., 1494
 Yang, F., 566
 Yang, H., 200
 Yanko, L., 1331
 Yanko, R., 1331
 Yao, L., 1037
 Yaroshenko, Y.Y., 903
 Yasuda, K., 351, 783
 Yasunari, K., 1065
 Yen, S.S.C., 940
 Yki-Järvinen, H., 449
 Yokokawa, K., 1065
 Yokokawa, M., 1472
 Yokota, M., 177
 Yoshikawa, J., 1065
 Yoshimasa, T., 456
 Yoshimasa, Y., 456
 Yoshimi, T., 1083
 Yoshimoto, T., 257
 Yoshino, K., 351, 783
 Young, I.S., 690
 Young, V.M., 566
 Young, V.R., 497
 Yu, H.K., 955
 Yudkin, J.S., 622, 637
 Yusuf, S., 182

 Zaccaro, D.J., 1174
 Zadik, Z., 264
 Zakrzewski, K., 608
 Zambón, D., 560
 Zanetti, M., 669
 Zech, L.A., 1160
 Zhang, J., 1233
 Zhang, M., 1233
 Zhang, Y., 799
 Zhao, G., 706
 Zhu, J.-S., 573
 Zhu, Z., 185
 Zillikens, M.C., 675
 Zimmet, P., 125
 Zittoun, J., 1413
 Zong-Chao, L., 627
 Zorbas, Y.G., 903
 Zorretta, D., 129
 Zulet, M.O., 301
 Zuliani, G., 535

SUBJECT INDEX

A, *see* Androstenedione

A-3826G promoter variant of UCP-1 gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402

AA(s), *see* Amino acids

AAAs (aromatic amino acids), plasma, relationship between Phe hydroxylation and concentrations of, 669-674

Abdominal adipose tissue (AT)

body composition, insulin resistance, and IAT, 402, 404, 406
exercise effects, 191

related to anxiety and depression, endocrine and metabolic aberrations in men with, 1187-1193

Absorptiometry, *see* Dual-energy x-ray absorptiometry, assessment of body composition with

- ACAT (acyl coenzyme A:cholesterol acyltransferase), effects of inhibition of, on C uptake in Caco-2 cells, 325-332
- ACE, *see entries beginning with terms*: Angiotensin-converting enzyme
- [1-¹³C]Acetate, role of glucose and glutamine in differential recovery of ¹³CO₂ from infused [2-¹³C]acetate versus, 549-554
- Acetoacetate
blood, in offspring of protein-malnourished subjects, 1451-1452
IGF-I effects on, in young IDDM adults, 34
- α (alpha)-N-Acetylarginine, nephrectomy effects on, 358-359
- N-Acetyl-glucosamine, O-linked, insulin and GLcN effects on level of, in muscle proteins, 449-455
- N-Acetyl-β-glucosaminidase (NAG)
in NIDDM, 363
urinary excretion of, in newborns, 1345
- Acetylhydrolase gene, PAF, G⁹⁹⁴ → T missense mutation in, as risk factor for CAD in Japanese men, 177-181
- Acidosis, HCl, 163-167
- Aciduria, methylsuccinic and ethylmalonic, in ethylmalonic encephalopathy, due to abnormal Ile, 836-839
- Acipimox
effects of, on dyslipidemia and glucose metabolism in NIDDM, 250-256
lipolysis inhibition with, effects of, on β₁-adrenoceptor-mediated thermogenesis in men, 1462-1467
- Acquired immunodeficiency syndrome (AIDS), urinary free cortisol in, 690-694
- ACTH, *see* Corticotropin
- Actinomycin D, RA catabolism inhibited by, 956
- Active celiac disease, leucine and glutamine kinetics in, in assessment of whole-body protein metabolism, 1429-1433
- Acute hyperinsulinemia
ET-1 in, with ANG II type 1 receptor antagonist-treated essential hypertension, 292-296
plasma HcY regulated by, in nondiabetics but not in NIDDM, 686-689
- Acute insulin resistance due to alcohol-related diols, 1180-1186
- Acute single-dose interleukin-6 (IL-6), effects of, on thyroid function in healthy subjects, 1289-1293
- Acute spinal cord injury (SCI), serum lipids following, 367-370
- Acyl coenzyme A, long-chain, effects of FFA elevation on, 1122-1123
- Acyl coenzyme A:cholesterol acyltransferase (ACAT), effects of inhibition of, on C uptake in Caco-2 cells, 325-332
- Acyltransferase, *see* Acyl coenzyme A:cholesterol acyltransferase; Lecithin:cholesterol acyltransferase
- Adaptation, intestinal, after small bowel resection, enteral OKG effects on, 1366-1371
- Adenoma, pituitary, inhibition of signal transduction by splice variant of GHRH receptor expressed in, 804-808
- Adenosine-5'-diphosphate (ADP)
NIDDM complications and platelet aggregation induced by, 702
skeletal muscle, in hyperthyroidism, 771
- Adenosine monophosphate, *see* cAMP
- Adenosine triphosphatase, *see* ATPase
- Adenosine triphosphate (ATP), skeletal muscle, in hyperthyroidism, 771, 774-775
- Adhesion molecule-1, vascular cell, and LDLs in hyperlipidemia of preeclampsia, 1281-1288
- Adipocytes
adrenoceptor binding and lipolysis of, in obese postmenopausal women, AT distribution and, 467-473
ET-1 inhibition of insulin-stimulated glucose uptake in, through ETA receptors, 1468-1471
leptin and, *see* Adipocytes, leptin and
in NIDDM, insulin signaling in, 54-62
- Adipocytes (*Continued*)
[¹²⁵I]transferrin binding and ⁵⁹Fe uptake in, stimulated by vanadate, 630-636
in women with risk factors for CHD, 1248
see also Lipoprotein lipase activity in adipocytes
- Adipocytes, leptin and
leptin effects on glucose metabolism in, 1360-1365
leptin release in hypothyroidism, 1455-1461
- Adipose tissue (AT; body fat)
body composition, insulin resistance and, 402, 404, 406
distribution of, *see* Adipose tissue distribution
and family history of NIDDM, 523
and HRT effects on plasma lipids and Lps, 1224
NO-1886 effects on, 104, 150
in OC users, 281
restricted caloric intake effects on, 429-434
and RMR in normal subjects, 1135, 1136
SHBG and, in insulin-resistant women, race and, 71
see also Adipocytes; Adipose tissue, exercise and; Adipose tissue, leptin and; Adipose tissue distribution in postmenopausal women; Fat mass; Obesity
- Adipose tissue (AT; body fat), exercise and
AT as risk factor for CHD in postmenopausal exercising women, 1112-1120
exercise effects on abdominal AT, 191
glucose effectiveness in endurance exercise and, 875
menopausal status and exercise effect on serum lipids and, 378, 379
- Adipose tissue (AT; body fat), leptin and
insulin secretion and therapy mode association with serum leptin and, in IDDM and NIDDM, 1391-1396
leptin receptor isoforms expressed in AT, 844-847
and plasma leptin in children, 310
serum leptin in obese PCOS women correlated with BW and AT but not with androgen and insulin levels, 988-992
- Adipose tissue (AT; body fat) distribution
low- and high-fat diet effects on, 1091-1092
in premenopausal IDDM and NIDDM women, DXA measuring, 212-216
serum leptin in obese PCOS women correlated with BW and, but not with androgen and insulin levels, 988-992
see also Abdominal adipose tissue; Adipose tissue distribution in postmenopausal women; Intraabdominal adipose tissue; Subcutaneous adipose tissue; Visceral adipose tissue
- Adipose tissue (AT) distribution in postmenopausal women
IDDM or NIDDM women, DXA measuring, 212-216
in obese women, adrenoceptor binding and adipocyte lipolysis in, 467-473
- Adipose tissue lipoprotein lipase (ATLPL), activity of, in adipocytes, AT distribution and, 469
- Adolescents
hepatic 11β-HSD1 activity and mRNA in hypothyroidic, T₄ and T effects on, 474-478
IDDM, urinary ET-1 excretion in, 1408-1412
racial difference in HDL-C and TG levels in, 514-521
see also Puberty
- ADP, *see* Adenosine-5'-diphosphate
- Adrenal catecholamines, *see* Epinephrine; Norepinephrine
- Adrenal function
long-term alcohol intake effects on, at puberty, 1270-1271
see also specific aspects of adrenal functions
- Adrenal sterol 27-hydroxylase, protein level and activity of, 734
- Adrenaline, *see* Epinephrine
- Adrenoceptor(s)
adipocyte lipolysis and binding of, in obese postmenopausal women, AT distribution and, 467-473

Adrenoceptor(s) (*Continued*)

- see also β -Adrenoceptor blockade; Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- β (beta)-Adrenoceptor, effects of blockade of, on EPOC and TG/FA cycling, 439-448
- β_1 (beta₁)-Adrenoceptor, effects of lipolysis inhibition on thermogenesis mediated by, in men, 1462-1467
- β_3 -Adrenoceptor gene, see Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- Adrenocorticotrophic hormone, see Corticotropin
- Adrenomedullary system, insulin effects on, 247-248
- Advanced glycation end (AGE) products in DM
 - aminoguanidine effects on role of, in NIDDM progression, 1477-1480
 - fluorescence assay of blood and urine, 1348-1353
- Adverse effects
 - of acipimox, 254
 - of IL-6 injection, 1291
 - of LDL apheresis, 866
 - of pyridostigmine, 815
- Aerobic exercise, effects of weight loss and, on BP, glucose metabolism, and Lps in obese hypertensive middle-aged men, 1075-1082
- African American subjects, see Race and ethnicity
- AGE products, see Advanced glycation end products in DM
- Age
 - of AIDS patients, urinary free cortisol and, 691
 - CAD and, see Age, CAD and
 - of celiac disease patients, 1430
 - and CHD, see Age, CHD and
 - of CHF patients, 1157
 - of cirrhotic subjects, 793
 - and cortisol response to ACTH, 1253
 - of DM subjects, blood and urine AGE products and, 1349; see also Age of IDDM subjects; Age of NIDDM subjects
 - of endogenous depression subjects, 51
 - of exercising subjects, see Age of exercising subjects
 - of falciparum malaria subjects, 219
 - of familial HBLP subjects, 1162
 - of FCHL, see Age of FCHL subjects
 - GH and, 340, 1517
 - of gout subjects, 337
 - of HALP subjects, 968, 1162
 - and HRT effects on plasma lipids and Lps, 1224
 - of hypercholesterolemic subjects, see Age of hypercholesterolemic subjects
 - of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 - of hyperinsulinemic subjects, see Age of hyperinsulinemic subjects
 - of hyperthyroidic and hypothyroidic subjects, 90, 91
 - of hypertriglyceridemic subjects, 236
 - and insulin resistance, see Age, insulin resistance and
 - leptin and, see Age, leptin and
 - and Lp(a) levels, 183
 - maternal, and FPG reduction in pregnancy, 1141
 - of nondiabetic subjects, see Age of nondiabetic subjects
 - of non-obese IGT subjects, insulin kinetics, muscle morphology and, 850
 - of obese subjects, see Age of obese subjects
 - of OC users, 281
 - of osteopenic men, 196
 - of PCOS subjects, 941, 989
 - of postmenopausal women, see Age of postmenopausal women
 - of premenopausal women, see Age of premenopausal women
 - race and, see Age, race and

Age (*Continued*)

- and RMR, 1135, 1136
- of Robinow syndrome patients, 1341
- of subjects with family history of NIDDM, 523, 525
- of syndrome X subjects, 536, 537
- see also Adolescents; Aging; Children; Older subjects and entries
 - beginning with terms: Middle-aged, Young
- Age, CAD and
 - age as risk factor, 179
 - of nondiabetics with metabolic syndrome and electrocardiographic CAD, 624
- Age, CHD and
 - age as risk factor, 114
 - with NIDDM, 1246
 - total plasma HcY and, 274
- Age, insulin resistance and
 - and body composition, 402, 404, 406
 - Hct, Hb and, 832, 834
 - SHBG, race and, in insulin-resistant women, 71
- Age, leptin and
 - and effects of HF versus LF diets on S₁ and serum leptin in women, race and, 1521
 - and insulin secretion and mode of therapy association with leptin and AT in IDDM, 1394, 1395
 - see also Age, plasma leptin and
- Age, plasma leptin and
 - in obese women, and effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin, 1309, 1312
 - in pregnant nondiabetics, 841
 - and Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, 1526
- Age, race and
 - of adolescent males, HDL-C and TG levels and, 516
 - and distribution of serum LpA-I and LpA-I:A-II, 758, 759
 - and effects of HF versus LF diets on S₁ and serum leptin in women, 1521
 - of nondiabetics, relationship between Lps and insulin resistance in, 1176, 1177
 - SHBG and, in insulin-resistant women, 71
- Age of exercising subjects
 - β -adrenoceptor blockade effects on EPOC, 440
 - of exercising postmenopausal women, AT as risk factor for CDH and, 1113
 - glucose effectiveness in endurance exercise and, 875
 - menopausal status and exercise effects on serum lipids, 378, 379
 - with NIDDM, hemodynamic response to handgrip test and, 935, 936
- Age of FCHL subjects
 - and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398, 1400
 - of nondiabetic FCHL subjects, insulin resistance and, 509, 510
- Age of hypercholesterolemic subjects
 - and efficacy of plain niacin versus Niaspan, 1099
 - and fat-modified diet effects on concentrations of serum C precursors and phytosterols, 745
 - LDL apheresis and, 1059
 - with polygenic hypercholesterolemia, 98
 - with primary hypercholesterolemia, 561
 - with severe heterozygous FH, 864, 866
- Age of hyperinsulinemic subjects
 - with acute hyperinsulinemia, 687
 - healthy non-obese, 832, 834
 - premenopausal, 16, 17
- Age of IDDM subjects
 - CFA and, 504

- Age of IDDM subjects (*Continued*)
 at IDDM onset, immune parameters and, 1208
 and insulin secretion and mode of therapy association with leptin and AT, 1394, 1395
 of postmenopausal and premenopausal subjects, DXA measuring body composition and AT in, 213
 of pregnant IDDM subjects, plasma leptin and, 841
 and proinsulin levels following whole pancreas-kidney transplantation, 1326
 and urinary ET-1 excretion, 1409, 1410
- Age of NIDDM subjects
 acipimox effects and, 251
 CFA and, 504
 CHD and, 1259, 1260
 dietary protein restriction effects and, 1147
 and glucose and GLP-1 stimulation effects on insulin release, 1043
 and GSH effects on glucose metabolism, 994
 hemodynamic response to handgrip test and, 935, 936
 IR isoform mRNA and, 130
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 obese, *see* Age of obese subjects with NIDDM
 platelet 12-LOX activity and, 258-260
 postmenopausal and premenopausal, DXA measuring body composition and AT in, 213
 serum PON activity and, 599
 and SPA relationship to NIDDM complications, 701-703
 tHcy and microalbuminuria and, 916
 Trp 64 Arg mutation of β_3 -adrenoceptor gene and, 457
 urinary and serum TM and, 363, 364
- Age of nondiabetic subjects
 with FCHL, insulin resistance and, 509, 510
 with metabolic syndrome, and electrocardiographic CAD, 624
 pregnant, plasma leptin and, 841
 relationship between Lps, insulin resistance and, race and, 1176, 1177
- Age of obese subjects
 with IGT, insulin kinetics, muscle morphology and, 850
 with NIDDM, *see* Age of obese subjects with NIDDM
 of obese men, VAT accumulation effects on uric acid metabolism in, 930
see also Age of obese women
- Age of obese subjects with NIDDM
 LDL receptors and lipid metabolism and, 1071
 S₁, insulin action, fibrinolysis and, 1372-1375
- Age of obese women
 and effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin, compared, 1309, 1312
 of hyperinsulinemic premenopausal women, 14, 16
 with PCOS, serum leptin in, 989
 postmenopausal, adrenoceptor binding, adipocyte lipolysis and, 469
- Age of postmenopausal women
 exercising, AT as risk factor for CHD and, 1113
 with IDDM or IDDM, DXA measuring body composition and AT in, 213
 non-obese, serum uric levels and, 437
 obese, adrenoceptor binding, adipocyte lipolysis and, 469
- Age of premenopausal women
 hyperinsulinemic, 14, 16
 with IDDM or IDDM, DXA measuring body composition and AT in, 213
 non-obese, serum uric levels and, 437
- Aging
 insulin resistance and body composition related to, CV disease risk factors and, 401-408
see also Older subjects
- AIDS (acquired immunodeficiency syndrome), urinary free cortisol in patients with, 690-694
- Alanine (Ala)
 endotoxin effects on, 683, 684
 in exercise, glucose and AA infusion effects on, 1306
 in familial HALP and HBLP, 1164
 plasma, *see* Plasma alanine
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- Alanine aminotransferase (ALT)
 in elderly NIDDM subjects, Pro-Z effects on, 42
 endotoxin effects on, 682
 in LT recipients, 201
 in prepubertal children with β -thalassemia and/or CSS, 543
 serum, *see* Serum alanine aminotransferase
- Albumin
 in celiac disease, 1430
 in cirrhosis, 793
 in IDDM, *see* Albumin in IDDM
 in LT recipients, 201
 in NIDDM, *see* Albumin in NIDDM
 NO-1886 effects on, in Leydig cell tumor-associated cachexia, 102
 in osteopenic elderly men, 196
 in prepubertal children with β -thalassemia and/or CSS, 543
 urinary excretion of, *see* Urinary excretion, albumin
- Albumin in IDDM
 with normoalbuminuria, serum laminin levels and, 64-65
 relationship of capillary filtration of, to gender, hypertension, microangiopathy, and neuropathy, 503-507
- Albumin in NIDDM
 CV risk factors, fibrinolysis, and urinary excretion of, 639
 in elderly subjects, Pro-Z effects on, 42
 microalbuminuria and vascular damage in NIDDM, tHcy levels and, 915-921
 relationship of capillary filtration of, to gender, hypertension, microangiopathy, and neuropathy, 503-507
 TM and, 363
- Alcohol intake
 in fat-modified diet for hypercholesterolemia, 745
 in gout, 337
 long-term, effects of, on food intake, BW, plasma leptin, corticosterone, and insulin levels at puberty, 1269-1273
 maternal, and FPG reduction in pregnancy, 1141
 by non-obese premenopausal and postmenopausal women, serum uric acid levels and, 437
- Alcohol-related diols, acute insulin resistance due to, 1180-1186
- Alkaline phosphatase (ALP)
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in LT recipients, 201
 in prepubertal children with β -thalassemia and/or CSS, 543
 serum, in CRF children, 265
- Allele frequency
 for ACE genotype, metabolic syndrome and, 622, 623
 for Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457, 458, 618, 619
- All-trans-retinoic acid (RA), cytochrome P450-mediated oxidation of, by retinoids in HNSCC cell lines, 955-958
- All-trans-retinoic acid (RA) receptors, effects of hypercholesterolemia-inducing diet on expression of, 301-308
- ALP, *see* Alkaline phosphatase
- Alpha (α)-N-acetylarginine, nephrectomy effects on, 358-359
- Alpha (α)-ketoglutarate, enteral ornithine, effects of, on intestinal adaptation after small bowel resection, 1366-1371
- Alpha (α)-keto- δ -guanidinovaleic acid (α -keto- δ -GVA), nephrectomy effects on, 358-359

- Alpha-lipoprotein, *see* High-density lipoprotein
- Alpha tocopherol, *see* Vitamin E
- ALT, *see* Alanine aminotransferase
- Amino acids (AAs)
- effects of glucose and, on ureagenesis before and during exercise, 1303-1307
 - endotoxin effects on, 683, 684
 - incorporation of, into LDL apo B, 488-490
 - in post-small bowel resection enteral diet, 1367
 - in trauma, 226, 227, 608-616
 - see also* Hepatic amino acids; Plasma amino acids and specific amino acids
- Aminoguanidine, effects of, on role of AGE products in NIDDM progression, 1477-1480
- Aminotransferases
- branched-chain, effects of tyrosine-deficient TPN on, 168-176
 - see also* Acyl coenzyme A:cholesterol acyltransferase; Alanine aminotransferase; Aspartate aminotransferase; Galactose-1-phosphate uridylyltransferase deficiency; Galactosyltransferase; γ Glutamyl transferase; Lecithin:cholesterol acyltransferase; Tyrosine aminotransferase
- Amiodarone, effects of, on LDL receptor mRNA and protein, 1052-1057
- AMP (adenosine monophosphate), cyclic, glucagon effects on concentrations of, 696, 697
- Anaerobic threshold, uric acid in CHF and, 1156-1159
- Androgens
- serum leptin in obese PCOS women correlated with BW and AT distribution but not with levels of insulin, 988-992
 - see also* specific androgens
- Androstenedione (A; Δ_4 -DIONE)
- in hyperinsulinemic obese premenopausal women, 13-19
 - in PCOS, 159, 990
- ANF (atrial natriuretic factor), very-low-calorie diet effects on, in obesity, 592-597
- Angiotensin-converting enzyme (ACE) gene polymorphism
- with CHD in NIDDM, 1258-1262
 - plasma ACE levels and, associated with metabolic syndrome and electrocardiographic CAD in Pima Indians, 622-626
- Angiotensin-converting enzyme (ACE) inhibitors, verapamil and captopril as, effects of, on glucose tolerance and insulin action in insulin resistance, 982-987
- Angiotensin II (ANG II) type I receptor antagonist
- AVP and OT responses to, in men, 893-896
 - ET-1 in acute hyperinsulinemia and essential hypertension treated with, 292-296
- 1,5-Anhydroglucitol in NIDDM
- platelet 12-LOX activity and, 258
 - urine and serum TM and, 363
- Anthropometrics
- relationship between fasting plasma insulin, metabolic parameters and, in very old subjects, 535-540
 - see also* specific anthropometric data; for example: Waist-to-hip ratio
- Antiatherogenic effects of Cholesterol H, 959-964
- Antibodies
- against oxidized LDLs, effects of ERT on, in hypercholesterolemic postmenopausal women with CHD, 675-680
 - TNF, effects of, on hepatic AA transport in burn injury, 612
- Anxiety, endocrine and metabolic aberrations in men with abdominal obesity related to depression and, 1187-1193
- Apheresis (immunoapheresis), LDL, in FH
- LDL apo B metabolism following, simulation studies of tracer kinetics of, 478-483
- Apheresis (immunoapheresis), LDL, in FH (Continued)
- long-term effects of, on plasma Lps and CHD in native vessels and coronary bypass in severe heterozygous FH, 863-868
 - Lp(a) reduction by, 1058-1064
- Apo(s), *see* Apolipoprotein(s)
- Apobec-1 mRNA (messenger ribonucleic acid), insulin effects on abundance of, in hepatocytes, 869-873
- Apolipoprotein(s) (apo)
- serum, in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 - see also* specific apolipoproteins
- Apolipoprotein A (apo A), insulin resistance and, SHBG, race and, 72
- Apolipoprotein A-I (apo A-I)
- BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 - effects of stearic and oleic acid diets on, 532
 - gemfibrozil effects on, 236, 562
 - lovastatin effects on, in primary hypercholesterolemia, 562
 - in NIDDM, *see* Apolipoprotein A-I in NIDDM
 - plasma, *see* Plasma apolipoprotein A-I
 - race, sex, and LpA-I and LpA-I:A-II relation to, in children, 760
 - relationship of GH to HDL-C and, independently of IGF-I and insulin, in women, 339-344
 - serum, menopausal status and exercise effect on, 378, 379
 - synthesis of, in familial HALP and HBLP, 1160-1166
 - in very old syndrome X subjects, 536
- Apolipoprotein A-I (apo A-I) in NIDDM
- acipimox effects on, 252
 - insulin versus sulfonylurea therapy effects on, 641
 - serum PON activity effects on, 599
- Apolipoprotein A-I/B (apo A-I/B), plasma, HRT effects on, 1224
- Apolipoprotein A-II (apo A-II)
- GH levels in women correlated with, 340-342
 - in NIDDM, *see* Apolipoprotein A-II in NIDDM
 - plasma, in HALP, 968, 969
- Apolipoprotein A-II (apo A-II) in NIDDM
- insulin versus sulfonylurea therapy effects on, 641
 - serum PON activity effects on, 599
- Apolipoprotein B (apo B)
- in adolescent males, race and, 516, 517
 - BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 - in familial HALP and HBLP, 1160-1166
 - GH levels in women correlated with, 340-342
 - lovastatin and gemfibrozil effects on, in primary hypercholesterolemia, 562
 - plasma, *see* Plasma apolipoprotein B
 - regulation of Lp-containing, by vitamin C level and dietary fat saturation, 883-891
 - serum, *see* Serum apolipoprotein B
 - stearic and oleic acid diet effects on, 532
 - in very old syndrome X subjects, 536, 537
 - see also* Apolipoprotein B, LDL; Apolipoprotein B in FCH; Apolipoprotein B in insulin resistance; Apolipoprotein B mRNA editing complex; Apolipoprotein B in NIDDM
- Apolipoprotein B (apo B), LDL, 487-490
- AA incorporation into, 488-490
 - metabolism of, following apheresis, 478-483
 - multicompartmental model of kinetics of, 487-488
- Apolipoprotein B (apo B) in FCH
- and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398, 1399
 - in nondiabetic FCH, insulin resistance and, 509, 510

- Apolipoprotein B (apo B) in insulin resistance
in insulin resistant women, SHBG, race and, 72
and nondiabetic FCH, 509, 510
- Apolipoprotein B (apo B) mRNA (messenger ribonucleic acid) editing complex, insulin effects on expression of catalytic subunit of, 869-873
- Apolipoprotein B (apo B) in NIDDM
acipimox effects on, 252
insulin versus sulfonylurea therapy effects on, 641
serum PON activity effects on, 599
- Apolipoprotein B48 (apo B48) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1320
- Apolipoprotein B100 (apo B100) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1320
- Apolipoprotein E (apo E)
multicompartmental model in study of metabolism of, 922-928
in NIDDM, LDL receptor-induced secretion of, 1072
see also Apolipoprotein E genotype; Apolipoprotein E phenotype in hypercholesterolemia
- Apolipoprotein E (apo E) genotype, cholesterologenesis in polygenic hypercholesterolemia and, 97-100
- Apolipoprotein E (apo E) phenotype in hypercholesterolemia and Lp response to lovastatin or gemfibrozil for primary hypercholesterolemia, 560-565
- noncholesterol sterol and plant sterol relationship to, 746, 747
- Apoptosis, small intestinal cell, effects of energy intake and purines on, 1105-1111
- A posteriori identifiability in compartmental modeling, 1016-1018
- A priori identifiability in compartmental modeling, 1015-1016
- Aquaporin-2 (AQP-2), renal water channel expression and urinary excretion of, in newborns, 1344-1347
- Arachidonic acid metabolites, LOX and COX pathways of, in preadipocyte differentiation regulation, 461-466
- Arginine (Arg)
in familial HALP and HBLP, 1164
nephrectomy effects on, 358-359
in NIDDM *see* Arginine in NIDDM
plasma, *see* Plasma arginine
in post-small bowel resection enteral diet, 1368
reduced energy intake effects on, in obese children, 1438
and RMR in healthy adults, 1135, 1136
in trauma, 226, 227
see also Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- Arginine (Arg) in NIDDM
insulin secretion stimulating by, 575
and Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese NIDDM subjects, 456-460
- Arginine vasopressin (AVP)
responses of OT and, to angiotensin II type 1 receptor antagonist, in men, 893-896
urinary excretion of, in newborns, 1344-1347
- Argininic acid, nephrectomy effects on, 358-359
- Aromatic amino acids (AAAs), plasma, relationship between Phe hydroxylation and concentrations of, 669-674
- Arterial compliance, systemic, effects of weight loss with meat-based or plant-based diet on BP, plasma leptin, and plasma lipids in women, compared, 1308-1314
- Arterial insulin
G effects, 1228
plasma, in exercise, glucose and AA infusion effects on, 1305, 1306
- Arterial low-density lipoprotein (LDLs) in STZ-DM, chronic hyperglycemia effects on atherosclerosis and metabolism of, 947-954
- Arterial pressure, *see* Blood pressure
- Ascorbic acid, *see* Vitamin C
- Asian Indians
insulin and proinsulin levels in nondiabetic, 230-233
Lp(a) levels in, CHD and, 182-184
- Asn, *see* Asparagine
- Asp (aspartic acid), reduced energy intake effects on, in obese children, 1438
- Asparagine (Asn)
in familial HALP and HBLP, 1164
plasma, *see* Plasma asparagine
reduced energy intake effects on, in obese children, 1438
in trauma, 226, 227
- Aspartate, endotoxin effects on, 683, 684
- Aspartate aminotransferase (AST)
endotoxin effects on, 682
in falciparum malaria, 219
in Keshan disease, 416, 417
in LT recipients, 201
serum, *see* Serum aspartate aminotransferase
- Aspartic acid (Asp), reduced energy intake effects on, in obese children, 1438
- AST, *see* Aspartate aminotransferase
- AT, *see* Adipose tissue
- Atherosclerosis
antiatherogenic effects of Cholesterol H, 959-964
in STZ-DM, chronic hyperglycemia effects on arterial LDL metabolism and, 947-954
- Athletes, *see* Exercise
- ATLPL (adipose tissue lipoprotein lipase), activity of, in adipocytes, AT distribution and, 469
- ATP (adenosine triphosphate), skeletal muscle, in hyperthyroidism, 771, 774-775
- ATPase (adenosine triphosphatase)
Na⁺, K⁺, activity of, in RBCs of women on levothyroxine therapy following total thyroidectomy for Graves' disease, 1194-1198
pancreatic islet Ca²⁺-, in NIDDM, glucose and Ca effects on, 185-189
- At-rest subjects, heart rate of NIDDM, in response to handgrip test, 935, 936
- Atrial natriuretic factor (ANF), very-low-calorie diet effects on, in obesity, 592-597
- Autonomic nervous system, GH and prednisolone effects on, 84-85
- AVP, *see* Arginine vasopressin
- B cells, PKW mitogen stimulating, 79
- BA:CA (bone age-to-chronological age) ratio in CRF children, 265
- BCAAs (branched-chain amino acids), *see* Amino acids
- BCAT (branched-chain aminotransferase), effects of tyrosine-deficient TPN on, 168-176
- Beta (β)-adrenoceptor, effects of blockade of, on EPOC and TG/FA cycling, 439-448
- Beta₁ (β_1)-adrenoceptor, effects of lipolysis inhibition on thermogenesis mediated by, in men, 1462-1467
- Beta₃-adrenoceptor gene, *see* Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- Beta (β) cells
MTS and metabolic activation of, 824-830
selenium and vitamin E effects on Keshan disease-induced alterations in, 415-419
sensitivity of, and insulin signaling, 1031-1033
in young children of NIDDM parents, 1000
zinc supplementation effects on secretion of, 795
see also Non-insulin-dependent diabetes mellitus, beta-cell function in
- Beta (β)-guanidinopropionic acid, nephrectomy effects on, 358, 359
- Beta-hydroxybutyrate, *see* β -Hydroxybutyrate

- 11Beta (β)-hydroxysteroid dehydrogenase 1 (11 β -HSD1) mRNA (messenger ribonucleic acid), hepatic, in pubertal hypothyroid male subjects, T₄ and T effects on activity of, 474-478
- Beta lipoprotein, *see* Low-density lipoprotein
- Beta₂-microglobulin, *see* β_2 -Microglobulin
- Beta (β)-thalassemia, BMD in prepubertal children with, 541-548
- BH₄ (tetrahydrobiopterin), insulin-induced vasodilation dependent on synthesis of, 1037-1039
- Bile, endotoxin effects on production of, 683
- Bile acid(s)
breast milk and/or formula effects on, during development, 23
effects of enterohepatic circulation manipulation and composition of, on *Lep* gene regulation, 285-291
- Bile acid sequestrant, Cholestyramine H as, 959-964
- Biliary dolichols, effects of Triton WR 1339 and orotic acid on, 644-649
- Bilirubin
in cirrhosis, 793
in falciparum malaria, 219
in prepubertal children with β -thalassemia and/or CSS, 543
total, *see* Total bilirubin
- Binding protein, *see* Growth hormone-binding protein; Insulin-like growth factor-binding protein(s)
- Black Americans, *see* Race and ethnicity
- Blood acetoacetate in offspring of protein-malnourished subjects, 1451-1452
- Blood advanced glycation end (AGE) products in DM, fluorescence assay for, 1348-1353
- Blood flow
regional, in exercise, glucose and AA infusion effects on, 1305, 1306
renal, glucagon effects on, 1228
- Blood glucose
hyperglucagonemia effects on, 499, 500
IDDM and PP, CFA and, 504
in NIDDM, *see* Blood glucose in NIDDM
in offspring of protein-malnourished subjects, 1451
in PAM, 1265
in STZ-DM, *see* Blood glucose in STZ-DM
- Blood glucose in NIDDM
platelet 12-LOX activity and, 258
PP, CFA and, 504
see also Fasting blood glucose in NIDDM
- Blood glucose in STZ-DM
levels of, gliclazide inhibiting diabetic neuropathy in, irrespective of, 977-981
plasma leptin and, 604
- Blood β (beta)-hydroxybutyrate (BOHB), acipimox effects on, in NIDDM, 253
- Blood inorganic phosphate, xylitol effects on, 741
- Blood lactic acid, xylitol effects on, 741, 742
- Blood pH, HCl effects on, 164
- Blood pressure (BP)
in adolescent males, race and, 516, 517
in CHF, 1157
diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
epinephrine effects on, 246, 247
and ETA receptor antagonist-induced osteopenia, 1404
in FCH, *see* Blood pressure in FCH
in Graves' disease, 1195
and HRT effects on plasma lipids and Lp, 1224
in hyperinsulinemia, 687, 832, 834, 835
insulin resistance and, *see* Blood pressure, and insulin resistance
lipolysis inhibition effects on, 1465
in NIDDM, *see* Blood pressure in NIDDM
- Blood pressure (BP) (*Continued*)
in non-obese Kuwaiti children, serum lipids and, associated with fasting insulin levels in, 420-424
in obesity, *see* Blood pressure in obesity
relationship between ET-1 excretion and, in IDDM adolescents and young adults, 1408-1412
and serum uric acid levels in non-obese premenopausal and postmenopausal women, 437, 438
and Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457-458
in young children of NIDDM parents, 999
see also Hypertension
- Blood pressure (BP), and insulin resistance
body composition, 402, 404, 406
Hb, Hct and, 832, 834, 835
SHBG, race and, in insulin-resistant women, 72
- Blood pressure (BP) in FCH
FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
in nondiabetics with insulin resistance, 509, 510
- Blood pressure (BP) in NIDDM
CHD and, 1259, 1260
CV risk factors, fibrinolysis and, 639
GSH effects on, 994
tHcy and microalbuminuria and, 916
urinary and serum TM and, 363
- Blood pressure (BP) in obese men
middle-aged hypertensive, effects of aerobic exercise and weight loss on glucose metabolism, Lps and, 1075-1082
and VAT accumulation effects, 930
- Blood pressure (BP) in obesity
changes in vasoactive regulatory hormones, volume regulatory hormones and, with very-low-calorie diet, 592-597
SAC, plasma leptin, plasma lipids and, in women, effects of weight loss with meat-based or plant-based diet on, compared, 1308-1314
serum lipids and, associated with fasting insulin levels in obese Kuwaiti children, 420-424
see also Blood pressure in obese men
- Blood pyruvic acid, xylitol effects on, 741
- Blood urea nitrogen (BUN) in elderly NIDDM subjects, Pro-Z effects on, 42
- BM 15.766 [4-(2-[1-(4-chlorocinnamyl)piperazin-4-yl]ethyl)-benzoic acid], effects of, on cholesterol synthesis, 878-882
- BMC (bone mineral content), and ETA receptor antagonist-induced osteopenia, 1404, 1405
- BMD, *see* Bone mineral density
- BMI, *see* Body mass and body mass index
- BNP (brain natriuretic peptide), plasma, very-low-calorie diet effects on, in obesity, 592-597
- Body composition
effects of high-sucrose and HF diets on, 1354-1359
insulin resistance and, related to aging, CV disease risk factors and, 401-408
plasma leptin level in children related to sex, puberty, S₁, EE and, 309-312
see also Dual-energy x-ray absorptiometry, assessment of body composition with; Fat-free mass; Fat mass
- Body fat, *see* Adipose tissue
- Body mass and body mass index (BMI)
CHD and, 114, 115, 1246
of cirrhotic subjects, 793
and cortisol response to ACTH, 1253
of CRF children, 265

- Body mass and body mass index (BMI) (*Continued*)
- and dietary specific sugars for serum protein enzymatic glycosylation, 1500
 - exercise and, 386-387, 875
 - of falciparum malaria subjects, 219
 - and family history of NIDDM, 523, 525
 - of FCH, *see* Body mass and body mass index of FCH subjects
 - GH and, 340, 1516
 - of gout subjects, 337
 - HRT effects on, 1224
 - of hypercholesterolemic subjects, *see* Body mass and body mass index of hypercholesterolemic subjects
 - hyperglycemia and, associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 617-621
 - of hyperinsulinemic subjects, *see* Age of hyperinsulinemic subjects
 - of hypertriglyceridemic subjects, gemfibrozil effects on, 236
 - of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
 - of IGT subjects, insulin kinetics, muscle morphology and, 850
 - insulin resistance and, *see* Body mass and body mass index, insulin resistance and
 - maternal, and FPG reduction in pregnancy, 1141
 - of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
 - of osteopenic elderly men, 196
 - of PCOS subjects, 159, 941
 - plasma leptin and, *see* Body mass and body mass index, plasma leptin and
 - of postmenopausal women, *see* Body mass and body mass index of postmenopausal women
 - of premenopausal women, 213, 437
 - race and, *see* Body mass and body mass index, race and
 - serum lipids and BP associated with fasting insulin levels and, 421
 - of very old syndrome X subjects, 536, 537
 - of young children of NIDDM parents, 999
 - see also* Fat-free mass; Fat mass; Obesity
- Body mass and body mass index (BMI), insulin resistance and body composition and, 402, 404, 406
- Hct, Hb and, 832, 834, 835
 - see also* Body mass and body mass index, insulin resistance, race and
- Body mass and body mass index (BMI), insulin resistance, race and effects of HF versus LF diets on S_1 and serum leptin in women, 1521
- of nondiabetics, 1176, 1177
 - SHBG, race and, in insulin-resistant women, 71, 72
- Body mass and body mass index (BMI), plasma leptin and in children, 310
- Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, 1526
- Body mass and body mass index (BMI), race and
- of adolescent males, HDL-C and TG levels and, 516, 517
 - see also* Body mass and body mass index, insulin resistance, race and
- Body mass and body mass index (BMI) of FCH subjects
- FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398, 1399
 - in nondiabetics with insulin resistance, 509, 510
- Body mass and body mass index (BMI) of hypercholesterolemic subjects
- fat-modified diet effects on, 745
 - plain niacin versus Niaspan effects on, 1099
 - with polygenic hypercholesterolemia, 98
 - with primary hypercholesterolemia, 561
- Body mass and body mass index (BMI) of hyperinsulinemic subjects
- with acute hyperinsulinemia, 687
 - healthy non-obese, 832, 834
- Body mass and body mass index (BMI) of IDDM subjects
- CFA and, 504
 - effects of insulin Lispro versus regular insulin on lipid metabolism and, 372
 - and insulin secretion and mode of therapy associated with leptin and AT in, 1394, 1395
 - postmenopausal and premenopausal, DEXA measuring body composition and AT in, 213
 - Trp 64 Arg mutation of β_3 -adrenoceptor gene and, 457-459
 - and urinary ET-1 excretion, 1409, 1410
- Body mass and body mass index (BMI) of NIDDM subjects
- acipimox effects and, 251
 - CFA and, 504
 - CHD and, 1259, 1260
 - CV risk factors, fibrinolysis and, 639
 - dietary protein restriction effects on, 1147
 - hemodynamic response to handgrip test and, 935, 936
 - and insulin secretion and mode of therapy associated with leptin and AT, 1394, 1395
 - LDL receptors, lipid metabolism and, 1071
 - of nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 - platelet 12-LOX activity and, 258, 259
 - in prediabetic stage of NIDDM, 910
 - premenopausal, DXA measuring body composition and AT in, 213
 - serum PON activity and, 599
 - urinary and serum TM and, 363
- Body mass and body mass index (BMI) of postmenopausal women
- exercising, and AT as risk factor for CHD, 1113
 - with IDDM and NIDDM, DXA measuring body composition and AT in, 213
 - of non-obese healthy women, serum uric acid and, 437
- Body temperature, IL-6 effects on, in healthy subjects, 1291
- Body weight (BW)
- bile acid and cholestyramine effects on, 286
 - of celiac disease patients, 1430
 - DEXA measurement of, in prone and supine position, 1379-1382
 - dexamethasone effects on, 4
 - and dietary specific sugars for serum protein enzymatic glycosylation, 1500
 - and ETA receptor antagonist-induced osteopenia, 1404
 - exercise effects on, *see* Body weight, exercise and
 - of familial HALP and HBLP subjects, 1162
 - of GH-deficient subjects, 1516, 1517
 - HCl effects on, 164
 - and HRT effects on plasma lipids and Lp, 1224
 - of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 - of hypokinetic subjects, 904
 - of IDDM subjects, 213
 - of injured subjects, spermidine effects on, 224
 - insulin resistance and, *see* Body weight, insulin resistance and
 - long-term alcohol intake effects on, at puberty, 1269-1273
 - loss in, *see* Weight loss
 - neonatal insulin treatment effects on, 857
 - and nephrectomy for renal failure, 356
 - nicotine effects on, 155, 156
 - of NIDDM subjects, *see* Body weight of NIDDM subjects
 - NO-1886 effects on, 102-103, 150
 - of OC users, 281
 - of osteopenic elderly men, 196
 - PKW mitogen effects on, 77
 - race and, of adolescent males, HDL-C and TG levels and, 516
 - of STZ-DM subjects, *see* Body weight of STZ-DM subjects

Body weight (BW) (*Continued*)

- Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526
- vitamin C and dietary fat saturation effects in regulation of apo B-containing Lps on, 885-886
- of young children, *see* Body weight of young children
- see also* Non-obese subjects; Obesity
- Body weight (BW), exercise and
- and β -adrenoceptor blockade effects on EPOC, 440
- diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
- endurance exercise and, 191
- menopausal status and exercise effects on, 378, 379
- substrate oxidation, diet selection and, 779, 780
- Body weight (BW), insulin resistance and
- body composition and, 402, 404, 406
- in insulin-resistant women, SHBG, race and, 71, 72
- troglitazone effects on dexamethasone-induced resistance, 352
- Body weight (BW) of NIDDM subjects
- and effects of stimulation with glucose and GLP-1 on insulin release, 1043
- IR isoform mRNA and, 130
- metabolic rate and, 1146-1147
- postmenopausal and premenopausal, DXA measuring, 213
- in prediabetic stage of NIDDM, 910
- Body weight (BW) of STZ-DM subjects
- with diabetic neuropathy, 978
- food intake and insulin-dependent plasma *Lep* mRNA and, 604
- in insulin-treated STZ-DM subjects, 591
- Body weight (BW) of young children
- breast-feeding and, 108
- of NIDDM parents, 999
- BOHB, *see* β -Hydroxybutyrate
- Bone age-to-chronological age (BA:CA) ratio in CRF children, 265
- Bone age of Robinow syndrome patients, 1341
- Bone loss due to hyperprolactinemia and estrogen deficiency, 425-428
- Bone mineral content (BMC), and ETA receptor antagonist-induced osteopenia, 1404, 1405
- Bone mineral density (BMD)
- and ETA receptor antagonist-induced osteopenia, 1404, 1405
- in prepubertal children with β -thalassemia, 541-548
- Borderline hypertension, stress and relationship of ACTH and cortisol to insulin and glucose in middle-aged men, 1440-1449
- BP, *see* Blood pressure
- Brain guanidino compounds, nephrectomy effects on, 359
- Brain HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase, BM 15.766 effects on, 880, 881
- Brain natriuretic peptide (BNP), plasma, very-low-calorie diet effects on, in obesity, 592-597
- Bran, oat and wheat, in diet regulating small intestinal cell turnover, 1106
- Branched-chain amino acids, *see* Amino acids
- Branched-chain aminotransferase (BCAT), effects of tyrosine-deficient TPN on, 168-176
- Breast development, Tanner stage of, with recessive Robinow syndrome, 1341, 1342
- Breast milk
- influence of formula and, on hepatic HMG-CoA reductase and C7H mRNA but not on LDL receptor mRNA during development, 20-26
- see also* Phospholipids, breast milk effects on
- Brewer's yeast in diet regulating small intestinal cell turnover, 1106
- Brush-border enzymes, rectosigmoid mucosal colonocyte, SCFA effects on, 133-134
- Bucladesine sodium, effects of, on plasma concentrations and urinary excretion of purine bases, 1005-1008
- BUN (blood urea nitrogen)
- in elderly NIDDM subjects, Pro-Z effects on, 42
- in IDDM, urinary ET-1 and, 1409
- Burn injury, transport of hepatic AAs in, 608-616
- 1-[14 C]Butyrate in ethylmalonic encephalopathy, 837
- BW, *see* Body weight
- Bypass, coronary, long-term effects of LDL apheresis on plasma Lps and CHD in native vessels and, in severe heterozygous FH, 863-868
- C, *see* Cholesterol
- Ca (calcium)
- in osteopenic elderly men, 196
- in post-small bowel resection enteral diet, 1367
- in prepubertal children with β -thalassemia and/or CSS, 543, 545
- serum, *see* Serum Ca
- see also* Ca in NIDDM; Ca^{2+} -ATPase
- Ca (calcium) in NIDDM
- effects of glucose and, on pancreatic islet Ca^{2+} -ATPase, 185-189
- in elderly subjects, Pro-Z effects on, 41
- Ca^{2+} -ATPase (calcium-adenosine triphosphatase), pancreatic islet, in NIDDM, glucose and Ca effects on, 185-189
- Cachexia with Leydig cell tumors, NO-1886 effects on, 101-105
- Caco-2 cells, effects of ACAT inhibition on C uptake by, 325-332
- CAD, *see* Coronary artery disease
- Calcitriol, *see* 1,25-Dihydroxyvitamin D_3
- Calcium, *see* Ca
- Caloric intake
- with high-sucrose and/or HF diets, 1354-1355
- restricted, *see* Calorie restriction
- suboptimal, effects of excessive dietary protein and, on growth of CRF children before and during GH therapy, 264-268
- Calorie restriction
- effects of, on serum leptin, insulin, cortisol, glucose, ketones, and NEFAs, 429-434
- very-low-calorie diet effects on BP, vasoactive regulatory hormones, and volume regulatory hormones in obesity, 592-597
- cAMP (cyclic adenosine monophosphate)
- Chanu effects on production of, 1213-1214
- glucagon effects on concentrations of, 696, 697
- Campesterol, relationship of, to apo E phenotype in hypercholesterolemia, 747
- Capillary filtration of albumin (CFA) in IDDM and NIDDM, relationship of, to gender, hypertension, microangiopathy, and neuropathy, 503-507
- Captopril, effects of verapamil and, on glucose tolerance and insulin action in insulin resistance, 982-987
- Carbohydrates (CHOs)
- in diet regulating apo B-containing Lps, 884
- effects of exercise and, on PAI-1 activity, 385
- effects of glucose contribution on FA and glyceride-glycerol synthesis with high-protein, carbohydrate-free diet, 1217-1221
- in fat-modified diet for hypercholesterolemia, 745
- in high-sucrose and/or HF diets, 1354-1355
- in low glycemic diet, 1247
- in NIDDM diet, 664
- in obesity- and DM-inducing diet, 1090
- PP, G effects on metabolism of, in nondiabetics, 7-12
- in protein-restricted diet, 1147
- in reduced energy intake, effects of, on protein utilization, in obese children, 1436
- in stearic and oleic acid diets, 531
- see also specific carbohydrates*

- Carbon dioxide, *see* CO₂; ¹³CO₂
- Carboxylase, pyruvate, in ethylmalonic encephalopathy, 837
- Cardioprotective profile in HALP associated with increased levels of HDL₂ and decreased HL activity, 965-973
- Cardiovascular disease, *see* Chronic heart failure; Coronary artery disease; Coronary heart disease; Risk factors for CV disease
- Carnitine in ethylmalonic encephalopathy, 837
- Casein
in diet regulating small intestinal cell turnover, 1106
in high-monounsaturated fat diet, 725
in obesity- and DM-inducing diet, 1090
- Catecholamines, *see* Dopamine; Epinephrine; Norepinephrine
- Celiac disease, active, whole-body protein metabolism assessed by leucine and glutamine kinetics in, 1429-1433
- Cell differentiation
preadipocyte, arachidonic acid metabolites of COX and LOX pathways regulating, 461-466
small intestinal, effects of energy intake and purines on, 1105-1111
- Cell proliferation, small intestinal, effects of energy intake and purines on, 1105-1111
- Cell surface, skeletal muscle, insulin-stimulated GLUT4 recruitment to, dexamethasone effects on, 3-6
- Cellulose in high-monounsaturated fat diet, 725
- Central venous access devices, implantable, in children with metabolic diseases, 900-902
- Cerebrospinal fluid (CSF), AAs in, in trauma, 227
- CETP, *see* Cholesteryl ester transfer protein
- CFA (capillary filtration of albumin) in IDDM and NIDDM, relationship of, to gender, hypertension, microangiopathy, and neuropathy, 503-507
- C7H, *see* Cholesterol 7 α -hydroxylase mRNA
- Chansu, effects of methanol extract of, on hypothalamic-pituitary-testicular function, 1211-1216
- CHD, *see* Coronary heart disease
- CHF (chronic heart failure), anaerobic threshold and uric acid in, 1156-1159
- Children
with metabolic diseases, implantable central venous access devices in, 900-902
non-obese Kuwaiti, serum lipids and BP associated with fasting insulin levels in, 420-424
obese, *see* Children, obese
race and distribution of serum LpA-I and LpA-I:A-II in, 757-763
see also Newborns; Young children
- Children, obese
prepubertal, *see* Prepubertal children, obese
reduced energy intake effects on whole-body protein utilization in, 1434-1439
- Chloride, *see* Cl
- 4-(2-[1-(4-Chlorocinnamyl)piperazin-4-yl]ethyl)-benzoic acid (BM 15.766), effects of, on cholesterol synthesis, 878-882
- CHO(s), *see* Carbohydrates
- Cholazol H, bile acid sequestrant properties of, and its hypocholesterolemic and antiatherogenic effects, 959-964
- Cholesterol, relationship of, to apo E phenotype in hypercholesterolemia, 747
- Cholesterologenesis in polygenic hypercholesterolemia, apo E genotype and, 97-100
- Cholesterol (C)
abdominal obesity and, 1189, 1190
abnormal synthesis of, and retarded learning, 878-882
diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
extrahepatic sterol 27-hydroxylase activity and high-cholesterol, high-fat diet, 731-738
- Cholesterol (C) (*Continued*)
and family history of NIDDM, 523
GH levels in women correlated with, 340
in hypertriglyceridemia, gemfibrozil effects on, 236
NO-1886 effects on, in Leydig cell tumor-associated cachexia, 103
in obese postmenopausal women, adrenoceptor binding and adipocyte lipolysis and, 470
OC effects on, 281
in skeletal muscle membrane PLs of young children, 108
tamoxifen effects on synthesis of, in HepG2 cells and hepatocytes, 1504-1513
see also Acyl coenzyme A:cholesterol acyltransferase; Cholesterolgenesis; Cholesterol in CHD; Cholesterol 7 α -hydroxylase mRNA; Cholesterol in hyperinsulinemia; Cholesterol in IDDM; Cholesterol in NIDDM; Dietary cholesterol; Hepatic cholesterol; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Lecithin:cholesterol acyltransferase; Low-density lipoprotein-cholesterol; Plasma cholesterol; Serum cholesterol; Total cholesterol
- Cholesterol (C) in CHD
Lp(a) level and, 183, 276
and total plasma HcY as risk factor, 1246
- Cholesterol 7 α -hydroxylase (C7H) mRNA (messenger ribonucleic acid)
breast milk and formula influence on hepatic HMG-CoA mRNA and, but not on LDL receptor mRNA during development, 20-26
sex hormone effects on 391-395
- Cholesterol (C) in hyperinsulinemia
in acute hyperinsulinemia, 687
in hyperinsulinemic NIDDM with obesity, 1317
- Cholesterol (C) in IDDM
CFA and, 504
urinary ET-1 and, 1409, 1410
- Cholesterol (C) in NIDDM
CFA and, 504
in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
see also Total cholesterol in NIDDM
- Cholesteryl ester transfer protein (CETP)
in female transgenic subjects, sex steroids regulating, 1048-1051
GH levels in women correlated with, 340, 342
in HALP, 969
HRT effects on, 1224
in IDDM, effects of insulin Lispro versus regular insulin on activity of, 373-374
plasma, effects of vitamin C and dietary fat saturation in regulation of apo B-containing Lps on, 888
- Cholestyramine (CSTY)
effects of, on BW and *Lep* gene, 286
hypocholesterolemic effects of, 959-964
- Choline in obesity- and DM-inducing diet, 1090
- Chorionic gonadotropin, human, T response to, in recessive Robinow syndrome, 1337-1343
- Chromatography, mass spectrometry with gas, of metabolic tracers, 706-712
- Chromium, dietary, effects of, on insulin resistance due to high-fat, mineral-imbalanced diet, 396-400
- Chromium (Cr), dietary, effects of, on insulin resistance due to high-fat, mineral-imbalanced diet, 396-400
- Chronic heart failure (CHF), anaerobic threshold and uric acid in, 1156-1159
- Chronic hyperglycemia, effects of, on arterial LDL metabolism and atherosclerosis in STZ-DM, 947-954
- Chronic renal failure (CRF), excessive dietary protein and suboptimal caloric intake effects on growth of children with, before and during GH therapy, 264-268

- Cigarette smoking, *see* Smoking
- Circulation, enterohepatic, effects of bile acid composition and manipulation of, on *Lep* gene regulation, 285-291
- Cirrhosis, effects of zinc supplementation on glucose disposal in, 792-798
- Citrate synthase in ethylmalonic encephalopathy, 837
- Citrulline in post-small bowel resection enteral diet, 1368
- CK (creatine kinase), serum, in hypoglycemia, 1471-1476
- Cl (chloride)
- bucladesine sodium effects on, 1006-1007
 - in elderly NIDDM subjects, Pro-Z effects on, 42
 - in hypoglycemia, 1472
 - NaCl in obesity- and DM-inducing diet, 1090
- Cl 316,243, effects of, on dexamethasone regulation of 18S RNA, *Lep* mRNA, and leptin release in adipocytes of hypothyroidic subjects, 1455-1461
- Classic glucose minimal model, 490
- Clonidine, GH response to serum IGF-I and, in recessive Robinow syndrome, 1337-1343
- CO₂ (carbon dioxide) in elderly NIDDM subjects, Pro-Z effects on, 42
- ¹³CO₂ (carbon dioxide), role of glucose and glutamine in differential recovery of, from infused [2-¹³C] versus [1-¹³C]acetate, 549-554
- CoA (coenzyme A), *see* Acyl coenzyme A:cholesterol acyltransferase; HMG-CoA reductase
- Coagulation factors, 529-540
- effects of stearic and oleic acid diets on, 529-534
 - in very old syndrome X subjects, 535-540
- Cobalamin, serum, in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
- Coconut oil in obesity- and DM-inducing diet, 1090
- Coenzyme A, *see* Acyl coenzyme A; Acyl coenzyme A:cholesterol acyltransferase; HMG-CoA reductase
- Collagen pyridinium cross-links in osteopenic preterm infants, urinary excretion of, 333-335
- Colon of protein-depleted subjects, effects of dietary protein and TNF on IGF-I pathway components of, 345-350
- Colonocyte brush-border enzymes, rectosigmoid mucosal, SCFA effects on, 133-134
- Combined hormone replacement therapy (HRT), effects of, on plasma lipids and Lps, 1222-1226
- Compartmental modeling, 1011-1018
- a priori identifiability in, 1015-1016
 - estimation of parameters used and a posteriori identifiability in, 1016-1018
 - fundamentals of, 1011-1012
 - measurement equations in, 1015
 - optimal experimental design in, 1018, 1028
 - tracee model, 1012-1013
 - tracer model, 1013-1014
 - tracer-tracee model, 1014-1015
 - see also* Multicompartmental model
- Compensatory hyperinsulinemia, insulin resistance and, in healthy non-obese subjects, Hb and Hct related to, 831-835
- Computational algorithms of SAAM II, 486-487
- Computer models, *see* Simulation studies; Systems model
- Connecting peptide, *see* C-peptide
- Conscious subjects, glucose in
- effects of portal venous and hepatic glucose positive and negative gradients on hepatic glucose uptake following glucose infusion in splanchnic bed of, 1295-1302
 - G activation and deactivation of HGP in, 135-142
 - ICV leptin effects on utilization of systemic glucose in, 1274-1280
- Constitutional short stature (CSS), BMD in prepubertal children with, 541-548
- Contraceptives, oral, effects of, on FFA metabolism, 280-284
- Corn in diet regulating small intestinal cell turnover, 1106
- Corn starch in obesity- and DM-inducing diet, 1090
- Coronary artery disease (CAD)
- with FH, LDL apheresis and, 1059
 - in Japanese men, G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene as risk factor for, 177-181
 - metabolic syndrome and electrocardiographic, in Pima Indians, associated with ACE gene polymorphism and plasma ACE levels, 622-626
 - and primary hypercholesterolemia, 1099
- Coronary artery smooth muscle cells (SMCs), heparin effects on migration of, 1065-1069
- Coronary bypass, long-term effects of LDL apheresis on plasma Lps and CHD in native vessels and, in severe heterozygous FH, 863-868
- Coronary heart disease (CHD)
- ACE gene polymorphism with, in NIDDM, 1258-1262
 - glycolysis and, 657-662
 - hypercholesterolemic postmenopausal women with, effects of ERT on level of antibodies against oxidized LDLs in, 675-680
 - long-term effects of LDL apheresis on plasma Lps and, in native vessels and coronary bypass in severe heterozygous FH, 863-868
 - Lp(a) level and, 182-184, 276
 - risk factors for, *see* Risk factors for CHD
 - total plasma HcY in, 273-280
- Corticosterone
- long-term alcohol intake effects on, at puberty, 1269-1273
 - see also* Corticosterone in obesity
- Corticosterone in obesity
- with hyperinsulinemic and insulinopenic NIDDM, 1317
 - stress effects on, 1385, 1387
- Corticotropin (ACTH: adrenocorticotrophic hormone)
- GH therapy effects on, 1377
 - see also* Corticotropin, cortisol and
- Corticotropin (ACTH: adrenocorticotrophic hormone), cortisol and
- in PCOS, nighttime and morning release of pulsatile cortisol and, 143-148
 - plasma cortisol response to IM ACTH 1-24 in healthy men, 1419-1422
 - recurrent hypoglycemia effects on cortisol response to ACTH in normal subjects, 1252-1259
 - stress and relationship of ACTH and cortisol to insulin and glucose in middle-aged men, 1440-1449
- Cortisol (hydrocortisone)
- ACTH and, *see* Corticotropin, cortisol and
 - effects of, on free radical generation by MNCs, 788-791
 - and G effects on glutamine uptake and release, 716
 - GH and, *see* Growth hormone, cortisol and
 - in PAM, 1264, 1265
 - in PCOS, 143-148, 159
 - plasma, *see* Plasma cortisol
 - in prepubertal children with β -thalassemia and/or CSS, 543, 545-546
 - restricted caloric intake effects on, 429-434
 - sex differences in production of, 974-976
 - urinary free, in AIDS patients, 690-694
- COX (cyclooxygenase) pathway of arachidonic acid metabolites in preadipocyte differentiation regulation, 461-466
- C-peptide
- fasting, *see* Fasting C-peptide
 - GH levels in women correlated with, 340
 - in hyperinsulinemic obese premenopausal women, 14, 15
 - in IDDM, 1208, 1328
 - in IGT, insulin kinetics, muscle morphology and, 851
 - in NIDDM, *see* C-peptide in NIDDM

- C-peptide (*Continued*)
 plasma, *see* Plasma C-peptide and TNF α in CHD, 116
 in young children of NIDDM parents, 1001
- C-peptide in NIDDM
 acipimox effects and, 253
 insulin versus sulfonylurea therapy effects and, 640
see also Serum C-peptide in NIDDM
- CPK (creatine phosphokinase) in Keshan disease, vitamin E and selenium effects on, 416, 417
- Creatine kinase (CK), serum, in hypoglycemia, 1471-1476
- Creatine phosphokinase (CPK) in Keshan disease, vitamin E and selenium effects on, 416, 417
- Creatinine
 bucladesine sodium effects on, 1006
 in CHF, 1157
 in CRF children, 265
 in falciparum malaria, 219
 in IDDM, 213; *see also* Serum creatinine in IDDM
 in LT recipients, 201
 nephrectomy effects on, 356
 in NIDDM, *see* Creatinine in NIDDM
 in obesity, 593, 930
 in osteopenic elderly men, 196
 plasma, *see* Plasma creatinine
 serum, *see* Serum creatinine
 in trauma, spermidine effects on, 224
 urinary ET-1 and, 1409, 1410
- Creatinine in NIDDM
 serum TM and, 363, 364
 tHcy, microalbuminuria and, 916
- Creatinine in obesity
 in semistarved subjects, 593
 urinary, effects of reduced energy intake on, in obese children, 1437
 in visceral fat obesity, 930
- Creatininemia in IDDM and NIDDM, CFA and, 504
- Creatininuria
 in NIDDM, 363, 364
 in polygenic hypercholesterolemia, 98
- CRF (chronic renal failure) children, excessive dietary protein and suboptimal caloric intake effects on growth of, before and during GH therapy, 264-268
- CBS (cystathionine- β -synthase), deficiency of, in homocystinuria, 207-211
- CS-O45, *see* Troglitazone effects on insulin resistance
- CsA (cyclosporine), effects of prednisolone and, on renal and serum IGF-I, IGFBPs, and renal growth following unilateral nephrectomy, 817-823
- CSF (cerebrospinal fluid), AAs in, in trauma, 227
- CSS (constitutional short stature), BMD in prepubertal children with, 541-548
- CSTY, *see* Cholestyramine
- Cushing's syndrome, sex and cortisol production in, 974-976
- CV (cardiovascular) disease, *see* Chronic heart failure; Coronary artery disease; Coronary heart disease; Risk factors for CV disease
- Cyclic adenosine monophosphate, *see* cAMP
- Cycloheximide, RA catabolism inhibited by, 956
- Cyclooxygenase (COX) pathway of arachidonic acid metabolites in preadipocyte differentiation regulation, 461-466
- Cyclosporine (CsA), effects of prednisolone and, on renal and serum IGF-I, IGFBPs, and renal growth following unilateral nephrectomy, 817-823
- CYP2D6 gene in Parkinson's disease, 94-96
- Cystathionine, liver and kidney, in D,L-propargylglycine-treated subjects, 1233-1238
- Cystathionine ketimine, liver and kidney, in D,L-propargylglycine-treated subjects, 1233-1238
- Cystathionine- β -synthase (CBS), deficiency of, in homocystinuria, 207-211
- Cysteine
 in CHD, 276
 in trauma, 226, 227
- Cytochrome C reductase, NADH-, in ethylmalonic encephalopathy, 837
- Cytochrome oxidase in ethylmalonic encephalopathy, 837
- Cytochrome P450-mediated oxidation of RA by retinoids in HNSCC cell lines, 955-958
- Cytokines
 in falciparum malaria, 219
 in prepubertal children with β -thalassemia and/or CSS, 545
 serum, in burn injury, 612
see also specific cytokines
- Daily Mg (magnesium) supplementation, effects of, on Mg deficiency during prolonged restriction of motor activity, 903-907
- DBP (diastolic blood pressure), *see* Blood pressure
- Deconvolution problem in input-output modeling, 1019
- Dehydroepiandrosterone sulfate (DHEAS; β -hydroxy-5-androsten-17-one)
 in hyperinsulinemic obese premenopausal women, 13-19
 in PCOS, 159, 990
- Dehydrogenase
 pyruvate, in ethylmalonic encephalopathy, 837
 T and T $_2$ effects on hepatic 11 β -HSD1 mRNA and activity in pubertal hypothyroid males, 474-478
see also Glyceraldehyde-3-phosphate dehydrogenase; Lactate dehydrogenase
- Delayed single-dose interleukin-6 (IL-6), effects of, on thyroid function in healthy subjects, 1289-1293
- Delta $_4$ -DIONE, *see* Androstenedione
- [3 H]Deoxyglucose (DG), PKW mitogen effects on uptake of, 79
- 2-[3 H]Deoxyglucose (DG), dexamethasone effects on, 4
- 3-Deoxy-D-glucose (DG), 3-fluoro-, exercise effects muscle and liver uptake of, 44-49
- Depression
 endocrine and metabolic aberrations in men with abdominal obesity related to anxiety and, 1187-1193
 endogenous, pyridostigmine effects on TSH response to TRH in, 50-53
 relationship of ACTH and cortisol to insulin and glucose in middle-aged men with depressive behavior, 1440-1449
- Des-31,32 proinsulin
 in NIDDM, insulin versus sulfonylurea therapy and, 640
 and TNF α in CHD, 116
- Des-32,33 proinsulin in NIDDM and nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- Desmosterol, relationship of, to apo E phenotype in hypercholesterolemia, 747
- Development, *see* Growth and development
- DEXA, *see* Dual-energy x-ray absorptiometry, assessment of body composition with
- Dexamethasone (DXM)
 effects of, on insulin-stimulated GLUT4 recruitment to skeletal muscle cell surface, 3-6
 effects of, on regulation of 18S RNA, *Lep* mRNA, and leptin release in adipocytes of hypothyroid subjects, 1455-1461
 troglitazone effects on insulin resistance induced by, 351-354
- DG, *see* [3 H]Deoxyglucose; 2-[3 H]Deoxyglucose; 3-Deoxy-D-glucose
- DHEAS, *see* Dehydroepiandrosterone sulfate
- Diabetes mellitus (DM)
 CHD, Lp(a) level and, 183

Diabetes mellitus (DM) (*Continued*)

- fluorescence assay of blood and urine AGE products in, 1348-1353
- HF diet-induced, *see* High-fat diet-induced diabetes mellitus and obesity
- and primary hypercholesterolemia, 1099
- see also* Advanced glycation end products in DM; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus and *entries beginning with term:* Diabetic

Diabetic nephropathy, SPA and, 702

Diabetic neuropathy

- CFA relationship to gender, hypertension, microangiopathy and, 503-507
- HP228 effects on, 650-656
- SPA relationship to, 702, 703
- in STZ-DM inhibited by gliclazide irrespective of blood glucose levels, 977-981

Diabetic retinopathy

- in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
- plasma IR-VEGF in, 28
- retinal GSH levels in STZ-DM and, effects of retinal ischemia followed by recirculation on, 269-272
- SPA relationship to, 701, 702

Diastolic blood pressure, *see* Blood pressure

Diet

- choice of, and substrate oxidation during exercise, 777-782
- effects of plasma glucose level and type of, on skeletal muscle membrane LCPUFAs in young children, 106-112
- hypercholesterolemia-inducing, effects of, on expression of T₃, RA, and glucocorticoid receptors, 301-308
- see also* Caloric intake; Fasting; Food intake; Refeeding; Starvation; Supplementation; Total parenteral nutrition *entries beginning with terms:* Dietary, Postprandial specific food groups and substances

Dietary Ca (calcium) in post-small bowel resection diet, 1367

Dietary cholesterol (C)

- in diet regulating apo B-containing Lps, 884
- effects of exercise and, on PAI-1 activity, 385
- in stearic and oleic acid diets, 531

Dietary chromium (Cr), effects of, on insulin resistance due to high-fat, mineral-imbalanced diet, 396-400

Dietary fat

- effects of exercise and, on PAI-1 activity, 385
- fat-modified diet effects on serum C precursors and phytosterol in hypercholesterolemia, 744-750
- in low glycemic diet, 1247
- in NIDDM diet, 664, 665
- in protein-restricted diet, 1147
- in reduced energy intake, effects of, on protein utilization, in obese children, 1436
- vitamin C level and saturation with, in regulation of apo B-containing Lps, 883-891
- see also* Fatty acids and *entries beginning with terms:* High-fat, Low-fat

Dietary K (potassium)

- in obesity- and DM-inducing diet, 1090
- in post-small bowel resection enteral diet, 1367

Dietary leucine (Leu), hyperglucagonemia and kinetics of, 497-502

Dietary Mg (magnesium) in post-small bowel resection enteral diet, 1367

Dietary protein

- with celiac disease, 1430
- contents of, in fasting and refeeding, PDI activity during, 1083-1088
- in diet regulating apo B-containing Lps, 884

Dietary protein (*Continued*)

- effects of TNF and, on colon and small intestine IGF-I pathway components in protein-depleted subjects, 345-350
- excessive, effects of suboptimal caloric intake and, on growth of CRF children before and during GH therapy, 264-268
- in fat-modified diet for hypercholesterolemia, 745
- in high-sucrose and/or HF diets, 1354-1355
- 27-hydroxylase effects on, 733-734
- ketosis resistance in offspring of protein-malnourished subjects, 1450-1454
- in obesity- and DM-inducing diet, 1090
- in reduced energy intake, effects of, on protein utilization, in obese children, 1436
- spermidine effects on utilization of, in trauma and injury, 223-229
- in stearic and oleic acid diets, 531
- see also* Dietary protein, exercise and; Dietary protein in NIDDM; High-protein, carbohydrate-free diet

Dietary protein, exercise and

- effects of, on PAI-1 activity, 385
- protein intake and, 779, 780

Dietary protein in NIDDM

- in hyperinsulinemic insulinopenic obese subjects, 664
- restriction of, altering glucose but not protein metabolism, 1145-1151
- Dietary specific sugars for serum protein enzymatic glycosylation, 1499-1503

Dihydroxyphenylalanine (DOPA), synthesis of, in neural tissue, effects of tyrosine-deficient TPN on, 168-176

1,25-Dihydroxyvitamin D₃ [1,25(OH)₂D₃; calcitriol; 1,25-dihydrocholecalciferol D₃]

- in osteopenic elderly men, 196
- serum, in gout, 336-338

3-[4,5-Dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfo-phenyl]-2H-tetrazolium, inner salt (tetrazolium salt; MTS), metabolic activation of beta cells and, 824-830

Diols, alcohol-related, acute insulin resistance due to, 1180-1186

Δ₄-DIONE, *see* Androstenedione

Diphosphate

- adenosine-5', *see* Adenosine-5'-diphosphate
- UDP-linked hexosamine and hexose, GLcN effects on, 451

Disulfide isomerase, activity of protein, during fasting and refeeding, protein contents and, 1083-1088

DM, *see* Diabetes mellitus

Dolichols, serum and biliary, effects of Triton WR 1339 and orotic acid on, 644-649

DOPA (dihydroxyphenylalanine), synthesis of, in neural tissue, effects of tyrosine-deficient TPN on, 168-176

Dopamine, very-low-calorie diet effects on urinary excretion of, in obesity, 594

Dual-energy x-ray absorptiometry (DEXA; DXA), assessment of body composition with

- and AT distribution in premenopausal and postmenopausal IDDM and NIDDM women, 212-216
- in prone and supine position, 1379-1382

Duration of obesity in hyperinsulinemic premenopausal women, sex hormones and, 13-19

DXA, *see* Dual-energy x-ray absorptiometry, assessment of body composition withDXM, *see* Dexamethasone

Dynamic data in systems models, 1009

Dyslipidemia

- acipimox effects on glucose metabolism and, in NIDDM, 250-256
- see also* Hyperlipidemia

E, *see* EpinephrineE₂, *see* Estradiol

- ECU (electronic control unit), continuous glucose monitoring with, in STZ-DM, 799-803
- EE, *see* Energy expenditure
- EGF (epidermal growth factor), effects of, on leptin release in adipocytes, 1457-1458
- Elderly subjects, *see* Older subjects
- Electrocardiographic coronary artery disease (CAD), metabolic syndrome and, in Pima Indians, associated with ACE gene polymorphism and plasma ACE levels, 622-626
- Electrolytes
very-low-calorie diet effects on, in obesity, 593
see also specific electrolytes
- Electronic control unit (ECU), continuous glucose monitoring with, in STZ-DM, 799-803
- EMA (ethylmalonic acid), abnormal isoleucine metabolism and elevated MSA and, in ethylmalonic encephalopathy, 836-839
- Encephalopathy, ethylmalonic, abnormal isoleucine metabolism and elevated EMA and MSA in, 836-839
- Endocrine disorders
in men with abdominal obesity related to depression and anxiety, 1187-1193
see also specific conditions
- Endocrine functions
with recessive Robinow syndrome, 1337-1343
see also specific endocrine functions
- Endogenous depression, pyridostigmine effects on TSH response to TRH in, 50-53
- Endothelial cells, linoleic acid effects on inflammatory mediators of, 566-572
- Endothelial growth factor (GF), plasma immunoreactive vascular, smoking relation to concentration of, 27-30
- Endothelial injury, urinary and serum TM in NIDDM as marker for, 362-365
- EndothelinA (ETA) receptors
ET-1 inhibition of insulin-stimulated glucose uptake in adipocytes through, 1468-1471
osteopenia induced by antagonists to, 1403-1407
- Endothelin-1 (ET-1)
in acute hyperinsulinemia with ANG II type 1 receptor antagonist-treated essential hypertension, 292-296
plasma, very-low-calorie diet effects on, in obesity, 592-597
urinary, in IDDM adolescents and young adults, 1408-1412
see also EndothelinA receptors
- Endotoxin, leucine metabolism in liver and, 681-685
- Endurance (strenuous) exercise, glucose effectiveness and, IVGTT measuring, 190-194, 874-877
- Energy expenditure (EE)
exercise effects on, 443
GH and prednisolone effects on leptin levels and, 83-88
lipolysis inhibition effects on, 1463
relationship of plasma leptin in children to sex, puberty, body composition, S₁ and, 309-312
- Energy intake
effects of purines and, on small intestinal cell proliferation, differentiation, and apoptosis, 1105-1111
reduced, effects of, on whole-body protein utilization in obese children, 1434-1439
see also Caloric intake; Diet
- Enteral ornithine α -ketoglutarate (OKG), effects of, on intestinal adaptation after small bowel resection, 1366-1371
- Enterohepatic circulation, effects of bile acid composition and manipulation of, on *Lep* gene regulation, 285-291
- Epidermal growth factor (EGF), effects of, on leptin release in adipocytes, 1457-1458
- Epinephrine (E; adrenaline)
in acute hyperinsulinemia with losartan-treated hypertension, 293
and cortisol response to ACTH, 1254
and G effects on glutamine uptake and release, 716
insulin-induced release of, 243-249
in obesity, *see* Epinephrine in obesity
in PAM, 1264, 1265
plasma, *see* Plasma epinephrine
sex and response of, to hypoglycemia, 121-124
- Epinephrine (E; adrenaline) in obesity
stress effects on, 1387
very-low-calorie diet effects on urinary excretion of, 594
- EPOC (excess postexercise O₂ consumption), β -adrenoceptor blockade effects on TG/FA cycling and, 439-448
- Equations, measurement, in compartmental modeling, 1015
- ERT, *see* Estrogen replacement therapy in postmenopausal women
- Erythrocytes, *see* Red blood cell(s)
- Estradiol (E₂)
and HRT effects on plasma lipids and Lps, 1224
in hyperinsulinemic obese premenopausal women, 13-19
menopausal status and exercise effects on, 378, 379
in PCOS, opioid tone and, 159
and plasma leptin in children, 310
- Estrogen
bone loss due to hyperprolactinemia and deficiency in, 425-428
and CETP regulation in female transgenic subjects, 1048-1051
see also Estrogen replacement therapy in postmenopausal women
- Estrogen replacement therapy (ERT) in postmenopausal women
hypercholesterolemic with CHD, effects of, on level of antibodies against oxidized LDLs, 675-680
LCAT during short-term estrogen-progestin replacement therapy, 297-300
- ETA, *see* Endothelin A receptors
- ET-1, *see* Endothelin-1
- Ethanol, *see* Alcohol intake
- Ethnicity, *see* Race and ethnicity
- Ethylmalonic acid (EMA), abnormal isoleucine metabolism and elevated MSA and, in ethylmalonic encephalopathy, 836-839
- Ethylmalonic encephalopathy, elevated EMA and MSA in, due to abnormal isoleucine metabolism, 836-839
- Excess postexercise O₂ consumption (EPOC), β -adrenoceptor blockade effects on TG/FA cycling and, 439-448
- Exercise, 377-390
diet selection and substrate oxidation during, 777-782
effects of low-fat, high-fiber diet and, in subjects with multiple CV disease risk factors, 384-390
effects of menopausal status and, on intravascular enzymes related to serum lipid transport, 377-383
glucose and, *see* Glucose in exercise
isometric, effects of parasympathetic dysfunction and hyperinsulinemia on hemodynamic response to, in NIDDM, 934-939
liver 3-FDG uptake enhanced by, 44-49
metabolic efficiency of skeletal muscle during, measured with ³¹P MRS in hyperthyroidic subjects, 771-774
O₂ consumption and, *see* O₂ consumption, exercise and
see also Men, exercising; Women, exercising
- Exon 9 of PAF acetylhydrolase gene, G⁹⁹⁴ \rightarrow T missense mutation in, as risk factor for CAD in Japanese men, 177-181
- Extrahepatic sterol 27-hydroxylase, high-cholesterol, high-fat diet and activity of, 731-738
- FA(s), *see* Fatty acids
- Factor VII in very old syndrome X subjects, 535-540
- Falci-parum malaria, indomethacin effects on glucose production in, 217-222

Familial combined hyperlipidemia (FCH; FCHL)

FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene in, 1397-1402

minimal model in study of insulin resistance in nondiabetics with, 509-513

Familial hyperalphalipoproteinemia (HALP) and hyperbetalipoproteinemia (HBLP), apo A-I and apo B synthesis in, 1160-1166

Familial hypercholesterolemia, *see* Apheresis, LDL, in FH

Family history of NIDDM

beta cell function and, 522-528

race and characteristics of young children of NIDDM parents, 998-1004

Fasting

effects of sex, GH therapy and, on serum leptin and *Lep* mRNA in GH-deficient and healthy adults, 1514-1519

by obese insulin-resistant subjects, leptin response to, 125-128

and refeeding, protein contents and activity of PDI during, 1083-1088

see also entries beginning with term: Fasting

Fasting blood glucose in NIDDM

and CHD, 1259, 1260

and family history of NIDDM, 523

GSH effects on, 994

Fasting cholesterol (C), and CHD, 1246

Fasting C-peptide

in cirrhosis, effects of zinc supplementation on, 794

and family history of NIDDM, 523-524

in hyperglycemia associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620

in NIDDM, *see* Fasting C-peptide in NIDDM

serum, in IDDM, and insulin secretion and therapy mode associated with leptin and AT in, 1394

in young children of NIDDM subjects, 1000

Fasting C-peptide in NIDDM

acipimox effects on, 253

serum, and insulin secretion and mode of therapy associated with leptin and AT in, 1394

Fasting free fatty acids (FFAs; nonesterified fatty acids)

in IGT, insulin kinetics, muscle morphology and, 851

plasma, in prediabetic stage of NIDDM, 910

in young children of NIDDM parents, 1000

Fasting glucagon (G)

in prediabetic stage of NIDDM, 910

in young children of NIDDM parents, 1000

Fasting glucose

CHD and, 1119, 1246

in cirrhosis, effects of zinc supplementation on, 794

and effects of HF versus LF diets on, 1521

in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400

in Graves' disease, 1195

in hyperglycemia associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620

in IGT, insulin kinetics, muscle morphology and, 850, 851

in men with abdominal obesity, 1189, 1190

in NIDDM, 640, 1202; *see also* Fasting blood glucose in NIDDM;

Fasting plasma glucose in NIDDM

in PCOS, 941, 990

plasma, *see* Fasting plasma glucose

in postmenopausal women, 437, 438, 470

race and, in nondiabetics, relationship between insulin resistance and, 1176

Fasting glucose (*Continued*)

and serum uric acid levels in non-obese premenopausal women, 437, 438

stress effects on, in middle-aged men, 1442, 1445

in very old syndrome X subjects, 536, 537

in young children of NIDDM parents, 1000

Fasting glycated hemoglobin (Hb) in young children of NIDDM parents, 1000

Fasting homocyst(e)ine (tHcy), correlation between microalbuminuria, vascular damage and, in NIDDM, 915-921

Fasting β (beta)-hydroxybutyrate (BOHB), acipimox effects on, in NIDDM, 253

Fasting insulin

β_3 -adrenoceptor gene and, *see* Fasting insulin, β_3 -adrenoceptor gene and

in cirrhosis, effects of zinc supplementation on, 794

and effects of HF versus LF diets on S₁ and serum leptin in women, 1521

in exercising postmenopausal women, CHD and, 1119

and family history of NIDDM, 523-525

in IGT, insulin kinetics, muscle morphology and, 850, 851

in men with abdominal obesity, 1189, 1190

in NIDDM, *see* Fasting insulin in NIDDM

in non-obese subjects, *see* Fasting insulin in non-obese subjects

in obese women, 470, 990

in PCOS, 941, 990

plasma, *see* Fasting plasma insulin

race and, of nondiabetics, relationship between insulin resistance and, 1176

serum lipids, BP and, in Kuwaiti children, 420-424

stress effects on, in middle-aged men, 1442, 1443, 1445

in subjects with multiple CV disease risk factors, effects of low-fat, high-fiber diet and exercise on, 384-390

in very old syndrome X subjects, 536

in young children of NIDDM parents, 1000

Fasting insulin, β_3 -adrenoceptor gene and

in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400

in hyperglycemia associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620

Fasting insulin in NIDDM

effects of, on hemodynamic response to isometric exercise, 935, 936

with hypertension, perindopril effects on, 1202

see also Fasting plasma insulin in NIDDM

Fasting insulin in non-obese subjects

menopause effects on, 437, 438

serum lipids, BP and, in children, 420-424

Fasting intermediate-density lipoprotein (IDL) in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373

Fasting lipids

gemfibrozil effects on, 236

see also specific lipids

Fasting low-density lipoprotein (LDL) in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373

Fasting plasma free fatty acids (FFAs) in prediabetic stage of NIDDM, 910

Fasting plasma glucagon (G) in prediabetic stage of NIDDM, 910

Fasting plasma glucose (FPG)

diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387

dietary Cr effects on, 397, 398

in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398

Fasting plasma glucose (FPG) (*Continued*)

- in hyperinsulinemia, plasma HcY concentrations and, 687
- in IDDM, and mode of therapy associated with leptin and AT, 1394
- low- and high-fat diet effects on, 1093
- in NIDDM, *see* Fasting plasma glucose in NIDDM
- in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- physiological reduction of, in first trimester of normal pregnancy, 1140-1144
- Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526

VAT accumulation effects on, in obese men, 930, 931

Fasting plasma glucose (FPG) in NIDDM

- and insulin secretion and therapy mode associated with leptin and AT, 1394

IR isoform mRNA and, 130

- with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- in prediabetic stage of NIDDM, 910
- urinary and serum TM and, 363

Fasting plasma insulin (FPI)

- dietary Cr effects on, 397, 398
- in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398
- in hyperinsulinemia, plasma HcY concentrations and, 687
- low- and high-fat diet effects on, 1093-1094
- in NIDDM, *see* Fasting plasma insulin in NIDDM
- in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- relationship between anthropometrics, metabolic parameters and, in very old syndrome X subjects, 535-540
- Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526

Fasting plasma insulin (FPI) in NIDDM

- GSH effects on, 994
- IR isoform mRNA and, 130
- with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- in prediabetic stage, 910

Fasting plasma lactate in prediabetic stage of NIDDM, 910

Fasting plasma leptin, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, 1526

Fasting plasma pyruvate in prediabetic stage of NIDDM, 910

Fasting plasma triglycerides (TGs)

- dietary Cr effects on, 397, 398
- in prediabetic stage of NIDDM, 910

Fasting proinsulin

- in IGT, insulin kinetics, muscle morphology and, 850, 851
- in young children of NIDDM parents, 1000

Fasting serum C-peptide in IDDM and NIDDM, and insulin secretion and therapy mode associated with leptin and AT, 1394

Fasting serum glucose, perindopril effects on, in NIDDM with hypertension, 1202

Fasting serum insulin, perindopril effects on, in NIDDM with hypertension, 1202

Fasting triglycerides (TGs)

- in IGT, insulin kinetics, muscle morphology and, 850, 851
- in nondiabetic South Indians, 232
- plasma, *see* Fasting plasma triglycerides
- as risk factors for CHD, 1246

Fasting very-low-density lipoprotein (VLDL) in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373

Fat, *see* Dietary fat entries beginning with terms: Fat, Fatty elements: Adip-, Lip- and specific fats

Fat-free mass (FFM)

- DEXA measurement of, in prone and supine position, 1379-1382
- exercise effects on, *see* Fat-free mass, exercise effects on

Fat-free mass (FFM) (*Continued*)

- in GH-deficient subjects, 1516, 1517
- and HRT effects on plasma lipids and Lps, 1224
- of NIDDM subjects, effects of dietary protein restriction on, 1147
- in obese prepubertal subjects, GH bioactivity and, 1491
- OC effects on, 281
- and plasma leptin in children, 310
- and RMR in normal subjects, 1135, 1136

Fat-free mass (FFM), exercise effects on

- of endurance exercise, 875
- in postmenopausal women, 1141

Fat mass (FM)

- DEXA measurement of, in prone and supine position, 1379-1382
- of exercising postmenopausal women, CHD and, 1141
- in GH-deficient subjects, 1516, 1517
- and HRT effects on plasma lipids and Lps, 1224
- leptin and, *see* Fat mass, leptin and
- in obese prepubertal subjects, GH bioactivity and, 1491
- see also* Adipose tissue; Obesity

Fat mass (FM), leptin and

- in IDDM and NIDDM subjects, insulin secretion and therapy mode associated with leptin and AT in, 1394
- and plasma leptin in children, 310

Fatty acids (FAs)

- β -adrenoceptor blockade effects on EPOC and TG/FA cycling, 439-448
- composition of, in skeletal muscle membrane PLs, in young children, 106-112
- glucose contribution to synthesis of, in subjects on high-protein, carbohydrate-free diet, 1217-1221
- in hypercholesterolemia-inducing diet, 302
- reoxygenation injury effects on response of pancreatic islets to, 809-813
- short-chain, effects of, on rectosigmoid mucosal colonocyte brush-border enzymes, 133-134
- see also* Free fatty acids; Monounsaturated fatty acids; Polyunsaturated fatty acids; Saturated fatty acids

FCH (FCHL), *see* Familial combined hyperlipidemia

3-FDG (3-fluoro-3-deoxy-D-glucose), exercise enhancing muscle and liver uptake of, 44-49

⁵⁹Fe (⁵⁹iron), vanadate and uptake of, in adipocytes, 630-636

Female subjects

- adolescent, *see* Adolescents
- transgenic, sex steroids regulating CETP in, 1048-1051
- see also* Sex; Women

Ferritin in prepubertal children with β -thalassemia and/or CSS, 543FFAs, *see* Free fatty acidsFFM, *see* Fat-free massFH (familial hypercholesterolemia), *see* Apheresis, LDL, in FH

Fiber

- in dietary regulation of apo B-containing Lps, 884
- effects of high-fiber, low-fat diet and exercise in subjects with multiple CV disease risk factors, 384-390
- in fat-modified diet for hypercholesterolemia, 745
- in NIDDM diet, 664
- in protein-restricted diet, 1147
- in stearic and oleic acid diets, 531

Fibrin in exercising postmenopausal women, CHD and, 1119

Fibrinogen

- in exercising postmenopausal women, CHD and, 1119
- in NIDDM, 641, 703
- in very old syndrome X subjects, 536

Fibrinolysis in NIDDM

- effects of insulin versus sulfonylurea therapy on, 637-643
- with obesity, S₁, insulin action and, 1372-1375

Fibroblasts in PCOS, insulin resistance in, 940-946

- First trimester of normal pregnancy, physiological reduction of FPG in, 1140-1144
- Fitness, *see* Exercise
- Fluorescence assay for blood and urine AGE products in DM, 1348-1353
- 3-Fluoro-3-deoxy-D-glucose (3-FDG), exercise enhancing muscle and liver uptake of, 44-49
- FM, *see* Fat mass
- Folate
- in homocystinuria, 208, 209
 - in NIDDM, tHcy, microalbuminuria and, 916
 - see also* Folate, plasma HcY and
- Folate, plasma HcY and
- plasma HcY levels related to folate status and MTHFR gene mutation in healthy subjects, 1413-1418
 - total plasma HcY and serum folate in hyperthyroidism and hypothyroidism, 90, 91
- Follicle-stimulating hormone (FSH)
- in PCOS, 159, 941
 - in recessive Robinow syndrome, 1337-1343
- Food intake
- by hypokinetic subjects, 904, 905
 - and insulin-dependent increase in *Lep* mRNA and plasma leptin in STZ-DM, 603-607
 - long-term alcohol intake effects on, at puberty, 1269-1273
 - PKW mitogen effects on, 77
 - see also* Diet
- Forcing function describing AA incorporation into LDL apo B, 488-490
- Formula, influence of breast milk and, on hepatic HMG-CoA reductase and C7H mRNA but not LDL receptor mRNA during development, 20-26
- FPG, *see* Fasting plasma glucose
- FPI, *see* Fasting plasma insulin
- Free cortisol, urinary, in AIDS patients, 690-694
- Free fatty acids (FFAs; nonesterified fatty acids)
- body composition, insulin resistance and, 404, 406
 - breast milk and/or formula effects on, during development, 22
 - effects of elevated, on muscle lipids and muscle glycogen synthesis, 1121-1126
 - in FCH, *see* Free fatty acids in FCH
 - in GH-deficient subjects, 1516
 - high-monounsaturated fat diet effects on, 726
 - in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 - in hypertriglyceridemia, gemfibrozil effects on, 236
 - IGF-I effects on, in young IDDM adults, 34
 - in IGT, insulin kinetics, muscle morphology and, 851
 - in insulin resistance, 983
 - OC effects on metabolism of, 280-284
 - in PAM, 1265
 - plasma, *see* Plasma free fatty acids
 - restricted caloric intake effects on, 429-434
 - serum, *see* Serum free fatty acids
 - stress-induced release of, in obesity, 1383-1390
 - in young children of NIDDM parents, 1001
- Free fatty acids (FFAs) in FCH
- nondiabetic, insulin resistance in, 509-511
 - regulation of glucose oxidation and levels of, by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of UCP-1 gene in, 1397-1402
- Free radicals, cortisol effects on generation of, by MNCs, 788-791
- Fructosamine
- in IDDM, CFA and, 504
 - see also* Fructosamine in NIDDM
- Fructosamine in NIDDM
- acipimox effects on, 252
 - CFA and, 504
- Fructosamine in NIDDM (*Continued*)
- hemodynamic response to handgrip test and, 935, 936
 - insulin versus sulfonyleurea therapy of NIDDM and, 640
 - platelet 12-LOX activity and, 258
- Fructose
- in NIDDM, 259, 664, 665
 - NO-1886 effects on hypertriglyceridemia induced by, 149-153
 - pioglitazone effects on glucose metabolism and muscle and liver insulin uptake with high-fructose diet, 1152-1155
- FSH, *see* Follicle-stimulating hormone
- G, *see* Glucagon
- G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene, as risk factor for CAD in Japanese men, 177-181
- Galactitol, elevated RBC redox potential and synthesis of, 1424-1425
- Galactonate, elevated RBC redox potential and synthesis of, Tolrestat effects on, 1423-1428
- Galactose
- in cirrhosis, zinc supplementation effects on, 793
 - effects of elevated RBC redox potential on, 1425-1426
- Galactose-1-phosphate, RBC redox potential and synthesis of, 1425
- Galactose-1-phosphate uridylyltransferase (GALT) deficiency, hereditary galactosemia due to, 1423-1428
- Galactosemia, hereditary, due to GALT deficiency, 1423-1428
- Galactosyltransferase, GLcN effects on, 452
- GALT (galactose-1-phosphate uridylyltransferase) deficiency, hereditary galactosemia due to, 1423-1428
- Gamma glutamyl transferase, *see* γ Glutamyl transferase
- Gamma (γ) guanidinobutyric acid (GBA), nephrectomy effects on, 358, 359
- GA3PDH, *see* Glyceraldehyde-3-phosphate dehydrogenase
- Gas chromatography/mass spectrometry (GC/MS) of metabolic tracers, 706-712
- Gastric emptying, G effects on, in nondiabetics, 7-12
- Gastrointestinal (GI) hormones
- G effects on, in nondiabetics, 9
 - see also specific hormones*
- GBA (gamma guanidinobutyric acid), nephrectomy effects on, 358-359
- GC/MS (gas chromatography/mass spectrometry) of metabolic tracers, 706-712
- Gemfibrozil
- for hypertriglyceridemia, 234-242
 - for primary hypercholesterolemia, apo E phenotype and Lp response to, 560-565
- Gene
- CYP2D6, in Parkinson's disease, 94-96
 - expression of, *see* mRNA
 - GP1IIa, smoking and, and TG-rich Lps, 1040-1041
 - Lep*, *see: Lep* gene
 - see also* Allele frequency; Apolipoprotein E phenotype in hypercholesterolemia; Genotype; Mutation; Polymorphism
- Genetics
- of S_{II}, 493-496
 - see also* Gene entries beginning with term: Familial, Hereditary, Heterozygous, Recessive and specific hereditary conditions
- Genotype
- ACE, metabolic syndrome and electrocardiographic CAD and, 622-626
 - apo E, cholesterologenesis in polygenic hypercholesterolemia and, 97-100
 - genotype frequency of Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457, 618, 619
 - PON, PON activity in NIDDM and, 599-600
- GF, *see* Growth factor
- GFR (glomerular filtration rate) following whole pancreas-kidney transplantation in IDDM, 1326, 1328

- GGT, *see* γ Glutamyl transferase
- GH, *see* Growth hormone
- GHBP (growth hormone-binding protein) in CRF children, 265
- GH/IGF-I/IGFBP3 (growth hormone/insulin-like growth factor-I/insulin-like growth factor-binding protein 3) axis in prepubertal children with β -thalassemia and/or CSS, 541-548
- GHRH, *see* Growth hormone-releasing hormone; Growth hormone-releasing hormone receptor
- GI hormones, *see* Gastrointestinal hormones
- GLcN, *see* Glucosamine
- Gliclazide, diabetic neuropathy in STZ-DM inhibited by, irrespective of blood glucose levels, 977-981
- Gln, *see* Glutamine
- Globulin, *see* Sex hormone-binding globulin in women
- Glomerular filtration rate (GFR) following whole pancreas-kidney transplantation in IDDM, 1326, 1328
- GLP-1 (glucagon-like peptide-1), effects of stimulation with glucose and, on insulin release in NIDDM, 1042-1047
- Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor)
- breast milk and/or formula effects on, during development, 22
 - bucladesine sodium effects on, 1006-1007
 - and cortisol response to ACTH, 1254
 - effects of, on plasma uridine concentrations, 695-698
 - effects of, on PP CHO metabolism in nondiabetics, 7-12
 - in NIDDM, effects of dietary protein restriction on, 1147
 - in PAM, 1264, 1265
 - in young children of NIDDM parents, 1000, 1001
 - in young IDDM adults, IGF-I effects on, 34, 1481-1489
 - see also* Fasting glucagon; Glucose, G effects on; Glutamine, G effects on; Hyperglucagonemia; Plasma glucagon
- Glucagon-like peptide-1 (GLP-1), effects of stimulation with glucose and, on insulin release in NIDDM, 1042-1047
- Glucocorticoid receptors, effects of hypercholesterolemia-inducing diet on expression of, 301-308
- Gluconeogenesis of hepatic and renal glutamine, glucagon effects on, in normal subjects, 1227-1232
- Glucosamine (GLcN)
- and beta-cell dysfunction in NIDDM, 573-577
 - effects of insulin and, on O-GlcNAc levels in muscle proteins, 449-455
- Glucosaminidase, N-acetyl- β -, in NIDDM, 363
- Glucose
- in adipocytes, ET-1 inhibition of insulin-stimulated uptake of, in adipocytes, 1468-1471
 - blood, *see* Blood glucose
 - body composition, insulin resistance and, 402, 404, 406
 - BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 - breast milk and/or formula effects on, during development, 22
 - bucladesine sodium effects on, 1006-1007
 - in cirrhosis, effects of zinc supplementation on disposal of, 792-798
 - in conscious subjects, *see* Conscious subjects, glucose in
 - contribution of, to glyceride-glycerol and FA synthesis with high-protein, carbohydrate-free diet, 1217-1221
 - cortisol, ACTH and, *see* Glucose, cortisol, ACTH and
 - and differential recovery of $^{13}\text{CO}_2$ from infused $[2-^{13}\text{C}]$ versus $[1-^{13}\text{C}]$ acetate, 549-554
 - exercise and, *see* Glucose in exercise
 - fasting, *see* Fasting glucose
 - following whole pancreas-kidney transplantation in IDDM, 1328
 - G and, *see* Glucose, G effects on
 - and GH deficiency, 1516
 - hepatic, *see* Hepatic glucose
 - homeostasis of neonatal, 1239-1244
- Glucose (Continued)
- and HRT effects on plasma lipids and Lps, 1224
 - in hyperinsulinemia, *see* Glucose in hyperinsulinemia
 - indomethacin effects on production of, in falciparum malaria, 217-222
 - leptin and, *see* Glucose, leptin and
 - metabolic disturbances of TGs and, predisposing to CHD, TNF α and, 113-118
 - peptin and, *see* glucose, peptin and
 - in NIDDM, *see* Glucose in NIDDM
 - NO-1886 effects on, in Leydig cell tumor-associated cachexia, 102
 - in nondiabetic Asian Indians, 231
 - in obesity, *see* Glucose in obesity
 - in PCOS, opioid tone and, 159
 - pioglitazone effects on metabolism of, in subjects on high-fructose diet, 1152-1155
 - PKW mitogen effects on, 76-77
 - plasma, *see* Plasma glucose
 - in post-small bowel resection enteral diet, 1367
 - regulation of FFA levels and oxidation of, by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of UCP-1 gene in FCHL, 1397-1402
 - restricted calorie intake effects on, in men and women, 429-434
 - in STZ-DM, continuous monitoring of, with ECU, 799-803
 - in young children of NIDDM parents, 1001
 - see also* $[^3\text{H}]$ Deoxyglucose; 2- $[^3\text{H}]$ Deoxyglucose; 3-Fluoro-3-deoxy-D-glucose; Glucose system, modeling of; Glucose tolerance; GLUT4; Hyperglycemia; Hypoglycemia
- Glucose, cortisol, ACTH
- effects of recurrent hypoglycemia on cortisol response to ACTH, 1254
 - stress and relationship of ACTH and cortisol to glucose and insulin and, in middle-aged men, 1440-1449
- Glucose, G effects on
- glutamine and, 716, 717, 719
 - HGP activation and deactivation in conscious subjects, 135-142
 - in nondiabetics, 8, 9
- Glucose, leptin effects on
- on adipocyte glucose metabolism, 1360-1365
 - on systemic glucose utilization in conscious subjects, 1274-1280
- Glucose in exercise
- aerobic exercise and weight loss effects on BP, glucose metabolism, and Lps in obese middle-aged hypertensive men, 1075-1082
 - glucose and AA effects on ureagenesis before and during exercise, 1303-1307
 - glucose effectiveness in endurance exercise measured with IVGTT, 190-194, 874-877
 - liver and muscle glucose disposal, 44-49
 - muscle glucose uptake and conversion to glycogen following exercise, 409-414
 - oxidation of, 779, 780
- Glucose fluxes, modeling of, 1020-1026
- in non-steady-state, 1024-1026
 - in steady-state, 1020-1024
- Glucose in hyperinsulinemia
- in acute hyperinsulinemia with losartan-treated hypertension, 293
 - in hyperinsulinemic obese premenopausal women, 14, 15
 - and in insulin resistance, 832, 834, 835
- Glucose intolerance, *see* Glucose tolerance
- Glucose in NIDDM
- acipimox effects on dyslipidemia and, 250-256
 - blood, *see* Blood glucose in NIDDM
 - dietary protein restriction altering metabolism of, but not protein metabolism, 1145-1151

- Glucose in NIDDM (*Continued*)
 effects of, on platelet 12-LOX activity, 259
 effects of Ca and, on pancreatic islet Ca^{2+} -ATPase, 185-189
 effects of stimulation with glucose and GLP-1 on insulin release in NIDDM, 1042-1047
 GSH effects on metabolism of, 993-997
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 increased HGP production and decreased hepatic glucose uptake in prediabetic stage of NIDDM, 908-914
 in older subjects, Pro-Z effects on metabolism of zinc, insulin and, 39-43
 plasma, *see* Plasma glucose in NIDDM
 serum fasting, perindopril effects on, 1202
 tHcy, microalbuminuria and, 916
 in young IDDM adults, IGF-I effects on, 34
- Glucose in obesity
 aerobic exercise and weight loss effects on BP, glucose metabolism, and Lps in obese middle-aged hypertensive men, 1075-1082
 effects of weight loss with meat-based or plant-based diet on, 1310
 plasma, *see* Plasma glucose in obesity
 stress effects on, 1385, 1387
- Glucose-6-phosphatase (G6Pase), activity of, in hypothalamus of obese subjects, 627-629
- Glucose-1-phosphate, RBC redox potential and synthesis of, 1425
- Glucose-6-phosphate (G6P), hydrolysis of, in hypothalamus of obese subjects, 627-629
- Glucose signaling, model of, 1027-1033
- Glucose system, modeling of, 1020-1026
 of glucose fluxes, *see* Glucose fluxes, modeling of
 of glucose and insulin signaling, 1027-1033
 minimal models, 490-492, 875
 as prototype, 1010-1011
- Glucose tolerance
 effects of stearic and oleic acid diets on S_1 and, in healthy women, 529-534
 verapamil and captopril effects on insulin action and, in insulin resistance, 982-987
see also Impaired glucose tolerance; Intravenous glucose tolerance test; Oral glucose tolerance test
- GLUT4
 insulin-stimulated recruitment of, to skeletal muscle cell surface, dexamethasone effects on, 3-6
 NIDDM effects on translocation of, 58
- Glutamine (Gln)
 in active celiac disease, whole-body protein metabolism assessed by kinetics of, 1429-1433
 and differential recovery of $^{13}\text{CO}_2$ from infused $[2-^{13}\text{C}]$ versus $[1-^{13}\text{C}]$ acetate, 549-554
 in exercise, glucose and AA infusion effects on, 1306
 in familial HALP and HBLP, 1164
 G effects on, *see* Glutamine, G effects on
 plasma, *see* Plasma glutamine
 in post-small bowel resection enteral diet, 1368
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- Glutamine (Gln), G effects on
 on gluconeogenesis of hepatic and renal glutamine, 1227-1232
 on glutamine uptake and release, 713-723
- γ (gamma) Glutamyl transferase (GGT)
 endotoxin effects on, 682
 in LT recipients, 201
- Glutathione (GSH)
 in CHD, 276
 and glucose metabolism in NIDDM, 993-997
 in retina of STZ-DM subjects, 269-272
- Glutathione peroxidase (GSH-Px) in Keshan disease, vitamin E and selenium effects on, 416
- Gluten-free diet in celiac disease, 1430
- Glycated Hb (hemoglobin)
 in NIDDM, *see* Glycated Hb in NIDDM
 in young children of NIDDM parents, 1000
- Glycated Hb (hemoglobin) in NIDDM
 acipimox effects on, 253
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
- Glycation end products, *see* Advanced glycation end products in DM
- Glyceraldehyde-3-phosphate dehydrogenase (GA3PDH)
 adipocyte, dexamethasone effects on, 1455-1461
 CHD and activity of, 657-662
- Glyceride-glycerol, glucose contribution to synthesis of, with HP,CHO-free diet, 1217-1221
- Glycerol
 in offspring of protein-malnourished subjects, 1452
see also Plasma glycerol
- Glycerol phosphate (glycerol-P), hydrolysis of, in hypothalamus of obese subjects, 627-629
- Glycine (Gly)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 in post-small bowel resection enteral diet, 1367, 1368
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
see also Hexanoylglycine; Isobutyrylglycine; Isovalerylglycine; D,L-Propargylglycine
- Glycogen
 effects of alcohol-related diols on, 1183-1184
 muscle, *see* Muscle glycogen
 perindopril effects on, in NIDDM with hypertension, 1202
- Glycolysis
 CHD and, 657-662
 GLcN effects on, 451-452
- Glycoprotein(s) (GP), serum, incorporation of dietary specific sugars into, 1501-1502
- Glycoprotein IIIa (GPIIIa) gene, smoking and, and TG-rich Lps, 1040-1041
- Glycosylation, dietary specific sugars for serum protein enzymatic, 1499-1503
- GnRH, *see* Gonadotropin-releasing hormone
- Gonadotropin, human chorionic, T response to, in recessive Robinow syndrome, 1337-1343
- Gonadotropin-releasing hormone (GnRH)
 Chansu effects on, 1213, 1214
 in recessive Robinow syndrome, 1337-1343
- Gout, serum $1,25(\text{OH})_2\text{D}_3$ in, 336-338
- GP (glycoprotein), serum, incorporation of dietary specific sugars into, 1501-1502
- G6P (glucose-6-phosphate), hydrolysis of, in hypothalamus of obese subjects, 627-629
- G6Pase (glucose-6-phosphatase), activity of, in hypothalamus of obese subjects, 627-629
- GPIIIa (glycoprotein IIIa) gene, smoking and, and TG-rich Lps, 1040-1041
- Graves' disease, Na^+/K^+ ATPase activity in RBCs of women on levothyroxine therapy following total thyroidectomy for, 1194-1198
- Growth and development
 breast milk and formula influence on hepatic HMG-CoA reductase and C7H mRNA but not on LDL receptor mRNA during, 20-26
 of CRF children, excessive dietary protein and suboptimal caloric intake effects on, before and during GH administration, 264-268

- Growth and development (*Continued*)
 renal, following unilateral nephrectomy, effects of immunosuppression on, 817-823
- Growth factor (GF)
 epidermal, effects of, on leptin release in adipocytes, 1457-1458
 plasma immunoreactive vascular endothelial, smoking relation to concentration of, 27-30
- Growth hormone (GH)
 hyperglucagonemia effects on, 499
 IGF-II, -III, IGFBP-1, -2, and -3 and bioactivity of, in prepubertal obese children, 1490-1493
 leptin and, *see* Leptin, GH and
 naloxone effects on response of, to melatonin and pyridostigmine in men, 814-818
 in PAM, 1265
 troglitazone effects on hepatic and peripheral insulin resistance induced by excess, 783-787
see also Growth hormone, cortisol and; Growth hormone, IGF-I and; Growth hormone, therapy with; Growth hormone-binding protein; Growth hormone/insulin-like growth factor-I/insulin-like growth factor-binding protein 3; Growth hormone-releasing hormone; Growth hormone-releasing hormone receptor
- Growth hormone (GH), cortisol and
 and cortisol response to ACTH, 1254
 GH therapy suppressing cortisol production in men, 1376-1378
- Growth hormone (GH), IGF-I and
 GH bioactivity and IGF-I in prepubertal obese children, 1490-1493
 in GH deficiency, 1516
 GH response to clonidine and serum IGF-I in recessive Robinow syndrome, 1337-1343
 GH therapy effects on, 1377
 in IDDM, *see* Growth hormone, IGF-I and, in IDDM
 prednisolone and GH effects on IGF-I, 84-85
 in women, GH relationship to HDL-C and apo A-I independently of IGF-I and insulin, 339-344
- Growth hormone (GH), IGF-I and, in IDDM
 IGF-I effects on insulin requirements due to GH pulsatility in young adults, 31-38
 low-dose IGF-I effects on GH in young IDDM adults, 1481-1489
- Growth hormone (GH), therapy with
 cortisol production suppressed by, in men, 1376-1378
 effects of sex, fasting and, on serum leptin and *Lep* mRNA in GH-deficient and healthy adults, 1514-1519
 prednisolone and GH effects on EE, 83-88
- Growth hormone-binding protein (GHBP) in CRF children, 265
- Growth hormone/insulin-like growth factor-I/insulin-like growth factor-binding protein 3 (GH/IGF-I/IGFBP3) axis in prepubertal children with β -thalassemia and/or CSS, 541-548
- Growth hormone-releasing hormone (GHRH), serum insulin but not leptin in association with spontaneous and GHRH-stimulated GH secretion in normal subjects with and without weight loss, 1127-1133
- Growth hormone-releasing hormone (GHRH) receptor, inhibition of signal transduction by splice variant of, expressed in pituitary adenoma, 804-808
- GSA (guanidosuccinic acid), nephrectomy effects on, 358, 359
- GSH, *see* Glutathione
- GSH-Px (glutathione peroxidase) in Keshan disease, vitamin E and selenium effects on, 416
- Guanidino compounds, nephrectomy effects on, 358-359
- γ (gamma) Guanidinobutyric acid (GBA), nephrectomy effects on, 358, 359
- β (beta) Guanidinopropionic acid, nephrectomy effects on, 358, 359
- Guanidosuccinic acid (GSA), nephrectomy effects on, 358, 359
- 7H, *see* Cholesterol 7 α -hydroxylase mRNA
- HALP, *see* Hyperalphalipoproteinemia
- Handgrip test, effects of parasympathetic dysfunction and hyperinsulinemia on hemodynamic response to, in NIDDM, 934-939
- Hb (hemoglobin)
 endotoxin effects on, 682
 in falciparum malaria, 219
 glycated, *see* Glycated Hb
- Hct and, related to insulin resistance and compensatory hyperinsulinemia in healthy non-obese subjects, 831-835
 in prepubertal children with β -thalassemia and/or CSS, 543
- HbA₁ (hemoglobin A₁)
 and cortisol response to ACTH, 1253
 in NIDDM, *see* HbA₁ in NIDDM
- HbA₁ (hemoglobin A₁) in NIDDM
 effects of dietary protein restriction on, 1147
 insulin versus sulfonyleurea therapy of NIDDM and, 640
- HbA_{1c} (hemoglobin A_{1c})
 in DM, blood and urine AGE products and, 1349; *see also* HbA_{1c} in IDDM; HbA_{1c} in NIDDM
 in hyperinsulinemia, plasma HcY concentrations and, 687
 in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- HbA_{1c} (hemoglobin A_{1c}) in IDDM
 CFA and, 504
 following whole pancreas-kidney transplantation in IDDM, 1328
 and insulin secretion and mode of therapy associated with leptin and AT, 1394
 urinary ET-1 and, 1409, 1410
- HbA_{1c} (hemoglobin A_{1c}) in NIDDM
 CFA and, 504
 CHD and, 1259, 1260
 in elderly subjects, Pro-Z effects on, 40
 GSH effects on, 994
 hemodynamic response to handgrip test and, 935, 936
 insulin Lispro versus regular insulin effects on lipid metabolism and, 372
 and insulin secretion and mode of therapy associated with leptin and AT, 1394
 LDL receptors, lipid metabolism and, 1071
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 platelet 12-LOX activity and, 258
 serum PON activity and, 599
 SPA relationship to NIDDM complications and, 703
 tHcy, microalbuminuria and, 916
 urinary and serum TM and, 363
- HBLP (hyperbetalipoproteinemia), familial, apo A-I and apo B synthesis in, 1160-1166
- HC (hydrocortisone), *see* Cortisol
- HCG (human chorionic gonadotropin), T response to, in recessive Robinow syndrome, 1337-1343
- HCl (hydrochloric acid), effects of, on renal and hepatic N metabolism, 163-167
- Hct, *see* Hematocrit
- HcY (homocysteine), *see* Plasma homocysteine
- HDL, *see* High-density lipoprotein
- HDL-C, *see* High-density lipoprotein-cholesterol
- Head and neck squamous cell carcinoma (HNSCC) cell lines, cytochrome P450-mediated RA oxidation by retinoids in, 955-958
- Healthy subjects, *see* Normal subjects
- Heart
 exercise effects on weight of, 191
 in NIDDM with hypertension, long-term effects of perindopril on, 1199-1204
see also Chronic heart failure; Coronary heart disease; Heart rate

- Heart rate (HR)
effects of lipolysis inhibition on, 1465
and exercise, β -adrenoceptor blockade effects on, 440
in Graves' disease, 1195
in NIDDM during handgrip test and at rest, 935, 936
in obesity, very-low-calorie diet effects on, 593
- Height
and BMD in prepubertal children with CSS, 541-548
of CRF children, 265
of elderly subjects, 196, 314
of exercising subjects, 378, 379, 440
of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
of obese women, and effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin, compared, 1309
of OC users, 281
of premenopausal IDDM subjects, 213
race and, of adolescent males, HDL-C and TG levels and, 516
see also Height of NIDDM subjects; Height of postmenopausal women
- Height of NIDDM subjects
and effects of dietary protein restriction, 1147
premenopausal and postmenopausal, 213
- Height of postmenopausal women
exercising, and AT as risk factor for CHD, 113
with IDDM and/or NIDDM, 213
- Hematocrit (Hct)
endotoxin effects on, 682
Hb and, related to insulin resistance and compensatory hyperinsulinemia in healthy non-obese subjects, 831-835
in hypoglycemia, 1472
in LT recipients, 201
- Hemodynamics
E effects on, 246, 247
hemodynamic response to isometric exercise in NIDDM, effects of parasympathetic dysfunction and hyperinsulinemia on, 934-939
IL-6 effects on, 1291
see also Blood flow; Blood pressure; Heart rate
- Hemoglobin, *see* Hb
- Heparin
effects of, on coronary artery SMC migration, 1065-1069
see also Postheparin lipids; Postheparin lipoprotein lipase
- Hepatic amino acids (AAs)
burn injury and transport of, 608-616
in exercise, glucose and AA infusion effects on, 1306
- Hepatic cholesterol (C)
abundant C7H mRNA effects on, 391-395
effects of vitamin C and dietary fat regulation of apo-containing Lps on, 883-891
- Hepatic failure following LT, serum IGFs and IGFbPs in, 200-206
- Hepatic glucose
disposal of, during exercise, 44-49
effects of positive and negative gradients of portal venous, and on uptake of, following glucose infusion in splanchnic bed of conscious subjects, 1295-1302
see also Hepatic glucose production
- Hepatic glucose production (HGP)
in exercise, glucose and AA infusion effects on, 1304-1305
G activation and deactivation of, in conscious subjects, 135-142
hepatic glucose uptake and increased, in prediabetic stage of NIDDM, 908-914
- Hepatic glutamine (Gln), glucagon effects on gluconeogenesis of, in normal subjects, 1227-1232
- Hepatic glycogen, effects of FFA elevation on, 1122-1123
- Hepatic HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase
BM 15.766 effects on, 880, 881
effects of vitamin C and dietary fat regulation of apo-containing Lps on, 886
see also Hepatic HMG-CoA reductase mRNA
- Hepatic HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase mRNA (messenger ribonucleic acid)
breast milk and formula influence on C7H mRNA and, but not on LDL receptor mRNA during development, 20-26
sex hormone effects of on, 393
- Hepatic 11 β -hydroxysteroid dehydrogenase 1 (11 β -HSD1) mRNA (messenger ribonucleic acid) in pubertal hypothyroid male subjects, T₄ and T effects on activity and, 474-478
- Hepatic insulin, model of extraction of, 1026-1027
- Hepatic insulin resistance induced by GH excess, troglitazone effects on, 783-787
- Hepatic lipase (HL) activity
cardioprotective profile in HALP associated with increased levels of HDL₂ and decreased, 965-973
ERT effects on, of, 676-677
GH levels in women correlated with, 340-342
- Hepatic lipids, hypercholesterolemia-inducing diet effects on, 304
- Hepatic N (nitrogen), HCl effects on metabolism of, 163-167
- Hepatic triacylglycerol (TAG), effects of vitamin C and dietary fat regulation of apo-containing Lps on, 886
- Hepatic urea production in exercise, glucose and AA effects on, 1304
- Hepatocytes
insulin effects on abundance of apobec-1 mRNA in, 869-873
tamoxifen effects on C synthesis in, 1504-1513
HepG2 cells, tamoxifen effects on C synthesis in, 1504-1513
- Hereditary galactosemia due to GALT deficiency, 1423-1428
- Heterozygous familial hypercholesterolemia, *see* Apheresis, LDL, in FH
- Heterozygous homocystinuria, 207-211
- Hexanoylglycine in ethylmalonic encephalopathy, 837
- Hexosamine, UDP-linked, GLcN effects on, 451
- Hexose, UDP-linked, GLcN effects on, 451
- HF, *see entries beginning with terms:* High-fat
- HGP, *see* Hepatic glucose production
- High-cholesterol, high-fat diet, extrahepatic sterol 27-hydroxylase activity and, 731-738
- High-density lipoprotein (HDL; α -lipoprotein)
BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
in hyperinsulinemia, plasma HcY concentrations and, 687
in IDDM, urinary ET-1 and, 1409
lipolysis stimulation in hypertriglyceridemia and production of small particles of, 234-242
plasma, *see* Plasma high-density lipoprotein
in postmenopausal women, 437, 438, 470
and serum uric acid levels in non-obese premenopausal women, 437, 438
in young children of NIDDM parents, 999
see also High-density lipoprotein in obesity; High-density lipoprotein-cholesterol; High-density lipoprotein; High-density lipoproteins; Hyperalphalipoproteinemia; Lipoprotein(a)
- High-density lipoprotein (HDL; α -lipoprotein) in obesity
effects of weight loss with meat-based or plant-based diet on, in obese women, 1310
serum, in hyperinsulinemic and insulinopenic NIDDM, 1318
- High-density lipoprotein-cholesterol (HDL-C)
in abdominal obesity, 1189, 1190
in CHD, *see* High-density lipoprotein-cholesterol in CHD
effects of stearic and oleic acid diets on, 532

- High-density lipoprotein-cholesterol (HDL-C) (*Continued*)
 exercise and, *see* High-density lipoprotein-cholesterol, exercise effects on
 in familial HALP and HBLP, 1162, 1163
 and family history of NIDDM, 523, 525
 in FCH, *see* High-density lipoprotein-cholesterol in FCH
 HCHF diet effects on, 733
 HRT effects on, 1224, 1225
 in hypercholesterolemia, *see* High-density lipoprotein-cholesterol in hypercholesterolemia
 in hypertriglyceridemia, gemfibrozil effects on, 236
 in insulin resistance, *see* High-density lipoprotein-cholesterol in insulin resistance
 in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
 NO-1886 effects on, in Leydig cell tumor-associated cachexia, 103
 OC effects on, 281
 plasma, *see* Plasma high-density lipoprotein-cholesterol
 race and, *see* High-density lipoprotein-cholesterol, race, sex and relationship of GH to apo A-I and, in women, independently of IGF-I and insulin, 339-344
 serum, *see* Serum high-density lipoprotein-cholesterol
 sex hormones effects on, 392
 short-term tall oil phytosterol administration effects on, 753-754
 in very old syndrome X subjects, 536, 537
see also High-density lipoprotein₂-cholesterol; High-density lipoprotein₃-cholesterol
- High-density lipoprotein-cholesterol (HDL-C), exercise effects on
 low-fat, high-fiber diet effects on, 386, 387
 menopausal status and, 378, 379
 in middle-aged obese hypertensive men, 1079
 in postmenopausal women, CHD and, 1119
- High-density lipoprotein-cholesterol (HDL-C), race, sex and
 in adolescent males, TG level and, 514-521
 in children, 360, 760
 of nondiabetics, relationship between insulin resistance and, 1176, 1177
- High-density lipoprotein-cholesterol (HDL-C) in CHD
 Lp(a) level and, 183
 in NIDDM, 1259, 1260
 plasma homocysteine and, 276
 in postmenopausal women, 1119
 and role of TNF α in TG and glucose metabolism, 114
- High-density lipoprotein-cholesterol (HDL-C) in FCH
 and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
 in nondiabetic FCH, 509, 510
- High-density lipoprotein-cholesterol (HDL-C) in hypercholesterolemia
 fat-modified diet effects on, 745
 LDL apheresis and, 865, 1060
 in polygenic hypercholesterolemia, 98
 in primary hypercholesterolemia, 562
- High-density lipoprotein-cholesterol (HDL-C) in insulin resistance
 body composition and, 402, 404, 406
 and in hyperinsulinemia, Hb, Hct and, 832, 834
 SHBG, race and, in insulin-resistant women, 72
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM
 ACE gene polymorphism in, *see* High-density lipoprotein-cholesterol in NIDDM, ACE gene polymorphism in
 acipimox effects on, 252
 in elderly subjects, Pro-Z effects on, 42
 hemodynamic response to handgrip test and, 935, 936
 serum, insulin secretion, therapy mode and, 1394
 serum PON activity and, 599
 and SPA relationship to NIDDM complications, 703
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM, ACE gene polymorphism in
 in CHD, 1259, 1260
 I/D polymorphism in NIDDM and nondiabetics with metabolic syndrome, 624
- High-density lipoprotein₁, *see* Lipoprotein(a)
- High-density lipoprotein₂ (HDL₂)
 cardioprotective profile in HALP associated with increased levels of, and decreased HL activity, 965-973
 in NIDDM, effects of insulin versus sulfonylurea on, 641
 plasma, *see* Plasma high-density lipoprotein₂
 serum, menopausal status and exercise effect on, 378, 379
see also High-density lipoprotein₂-cholesterol
- High-density lipoprotein₂-cholesterol (HDL₂-C)
 CHD and, 276, 1119
 in familial HALP and HBLP, 1162
 in middle-aged obese hypertensive men, 1079
- High-density lipoprotein₃ (HDL₃)
 in NIDDM, effects of insulin versus sulfonylurea on, 641
 plasma, *see* Plasma high-density lipoprotein₃
 serum, menopausal status and exercise effect on, 378, 379
see also High-density lipoprotein₃-cholesterol
- High-density lipoprotein₃-cholesterol (HDL₃-C)
 CHD and, 276, 1119
 in familial HALP and HBLP, 1162
- High-fat (HF) diet
 effects of high-sucrose and, on body composition, 1354-1359
 race and effects of LF versus, on S₁ and serum leptin in women, 1520-1524
see also High-fat diet-induced diabetes mellitus and obesity
- High-fat (HF) diet-induced diabetes mellitus (DM) and obesity
 high-monounsaturated fat diet-induced NIDDM and obesity, 724-730
 reversal of, 1089-1096
- High-fat, high-cholesterol diet, extrahepatic sterol 27-hydroxylase activity and, 731-738
- High-fat, mineral-imbalanced diet, dietary Cr effects on insulin resistance induced by, 396-400
- High-fiber, low-fat diet, effects of exercise and, in subjects with multiple CV disease risk factors, 384-390
- High-fructose diet, pioglitazone effects on glucose metabolism and muscle and liver insulin uptake with, 1152-1155
- High-protein, carbohydrate-free diet, glucose contribution to synthesis of FAs and glyceride-glycerol with, 1217-1221
- High-sucrose diet, effects of HF diet and, on body composition, 1354-1359
- Histidine (His)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- Histopathological changes due to nephrectomy, 355-361
- HK (hypokinesia), daily Mg supplementation effects on Mg deficiency during prolonged, 903-907
- HL, *see* Hepatic lipase activity
- HMG-CoA (hydroxymethylglutaryl coenzyme A) reductase
 lovastatin as inhibitor of, for primary hypercholesterolemia, apo E phenotype and Lp response to, 560-565
see also Brain HMG-CoA reductase; Hepatic HMG-CoA reductase
- HNSCC (head and neck squamous cell carcinoma) cell lines, cytochrome P450-mediated RA oxidation by retinoids in, 955-958
- Homeostasis of neonatal glucose, 1239-1244
- Homoarginine, nephrectomy effects on, 358-359
- Homocysteine, *see* Plasma homocysteine
- Homocyst(e)ine (tHcy), fasting and postmethionine, correlated with

- microalbuminuria and vascular damage in NIDDM and, 915-921
- Homocystinuria, CBS deficiency in, 207-211
- Homozygous familial hypercholesterolemia, *see* Apheresis, LDL, in FH
- Hormone replacement therapy, *see* Combined hormone replacement therapy; Estrogen replacement therapy in postmenopausal women
- Hot glucose minimal model, 490
- HP228 (peptide), effects of, on diabetic neuropathy, 650-656
- HPA (hypothalamic-pituitary-adrenal) axis in PCOS, 143-148
- HR, *see* Heart rate
- HRT (hormone replacement therapy), *see* Combined hormone replacement therapy; Estrogen replacement therapy in postmenopausal women
- 11 β -HSD1 (11 β -hydroxysteroid dehydrogenase 1) mRNA (messenger ribonucleic acid), hepatic, in pubertal hypothyroid male subjects, T₄ and T effects on activity of, 474-478
- Human chorionic gonadotropin (HCG), T response to, in recessive Robinow syndrome, 1337-1343
- Hydrochloric acid (HCl), effects of, on renal and hepatic N metabolism, 163-167
- Hydrocortisone, *see* Cortisol
- Hydrolysis, G6P and glycerol-P, in hypothalamus of obese subjects, 627-629
- β -Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone sulfate
- β (beta)-Hydroxybutyrate (BOHB)
and ketosis resistance in offspring of protein-malnourished subjects, 1450-1454
in PAM, 1265
plasma, *see* Plasma β -hydroxybutyrate
restricted caloric intake effects on, 430, 431
see also β -Hydroxybutyrate in IDDM; β -Hydroxybutyrate in NIDDM
- β (beta)-Hydroxybutyrate (BOHB) in IDDM
IGF-I effects on, in young IDDM adults, 34
plasma, and insulin secretion and therapy mode associated with leptin and AT, 1394
- β (beta)-Hydroxybutyrate (BOHB) in NIDDM
blood and fasting, acipimox effects on, 253
plasma, and insulin secretion and therapy mode associated with leptin and AT, 1394
- 7 α -Hydroxylase, *see* Cholesterol 7 α -hydroxylase mRNA
- 27-Hydroxylase, extrahepatic sterol, HCHF diet and activity of, 731-738
- Hydroxylation, Phe, relationship between plasma AAA concentrations and, 669-674
- Hydroxymethylglutaryl coenzyme A reductase, *see* HMG-CoA reductase
- 17-Hydroxyprogesterone in PCOS, opioid tone and, 159
- 11 β (beta)-Hydroxysteroid dehydrogenase 1 (11 β -HSD1) mRNA (messenger ribonucleic acid), hepatic, T and T₄ effects on activity and, in pubertal hypothyroid male subjects, 474-478
- 25-Hydroxyvitamin D (25-OHD)
in gout, 337
levels of vitamin K and, in osteopenic older men, 195-199
- Hyperalphalipoproteinemia (HALP)
cardioprotective profile in, associated with increased levels of HDL₂ and decreased HL activity, 965-973
familial, apo A-I and apo B synthesis in, 1160-1166
- Hyperbetalipoproteinemia (HBLP), familial, apo A-I and apo B synthesis in, 1160-1166
- Hypercholesterolemia
apo E phenotype and, *see* Apolipoprotein E phenotype in hypercholesterolemia
effects of diet inducing, on expression of RA, T₃, and glucocorticoid receptors, 301-308
ERT effects on antibodies against oxidized LDLs in postmenopausal women with CHD and, 675-680
- Hypercholesterolemia (*Continued*)
familial, *see* Apheresis, LDL, in FH
fat-modified diet effects on concentrations of serum phytosterols and serum C precursors in, 744-750
and hypocholesterolemic effects of Cholestol H, 959-964
polygenic, apo E genotype and cholesterogenesis in, 97-100
primary, *see* Primary hypercholesterolemia
- Hyperglucagonemia, dietary leucine kinetics and, 497-502
- Hyperglycemia
BMI and, associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in obese Jamaican women, 617-621
chronic, effects of, on arterial LDL metabolism and atherosclerosis, in STZ-DM, 947-954
effects of, on satiety, 321-324
at IDDM onset, 1206
- Hyperglycemic factor, *see* Glucagon
- Hyperinsulinemia
acute, *see* Acute hyperinsulinemia
effects of, on satiety, 321-324
insulin resistance and, *see* Hyperinsulinemia, insulin resistance and in NIDDM, *see* Non-insulin-dependent diabetes mellitus with hyperinsulinemia
sex hormones and, in obese premenopausal women, 13-19; *see also* Testosterone in hyperinsulinemia
- Hyperinsulinemia, insulin resistance and
compensatory hyperinsulinemia in healthy non-obese subjects, Hb and Hct related to, 831-835
in PCOS, opioid tone and, 158-162
- Hyperlipidemia
of preeclampsia, LDLs and VCAM-1 in, 1281-1288
see also Familial combined hyperlipidemia; Hyperalphalipoproteinemia; Hyperbetalipoproteinemia; Hypercholesterolemia; Hypertriglyceridemia
- Hyperprolactinemia, bone loss due to estrogen deficiency and, 425-428
- Hypertension
borderline, stress and relationship of ACTH and cortisol to insulin and glucose in middle-aged men with, 1440-1449
CAD, ACE genotype and, 622-624
CHD and, *see* Hypertension, CHD and
ET-1 in acute hyperinsulinemia and, treated with losartan, 292-296
in hypercholesterolemia, *see* Hypertension in hypercholesterolemia in IDDM, CFA relationship to gender, microangiopathy, neuropathy and, 503-507
with NIDDM, *see* Hypertension, NIDDM and
obese middle-aged men with, effects of aerobic exercise and weight loss on glucose metabolism, Lps and, 1075-1082
S₁ and, 493-496
- Hypertension, CHD and
Lp(a) level and, 183
in NIDDM, ACE gene polymorphism and, 1259
and role of TNF α in TG and glucose metabolism, 114
- Hypertension, NIDDM and
ACE gene polymorphism and, 1259, 120
CFA relationship to gender, microangiopathy, neuropathy and, 503-507
and long-term effects of perindopril on heart and metabolic parameters in, 1199-1204
- Hypertension in hypercholesterolemia
in primary hypercholesterolemia, 1099
severe heterozygous FH, 864
- Hyperthyroidism
³¹P MRS measuring metabolic efficiency of skeletal muscle in, 769-776
total plasma HcY in, 89-93
- Hypertriglyceridemia
fructose-induced, NO-1886 effects on, 149-153

- Hypertriglyceridemia (*Continued*)
 GA3PDH in, 659-660
 production of small HDL particles in, with lipolysis stimulation, 234-242
- Hyperuricemia, CHD and, 657-662
- Hypocholesterolemic effects of Cholestol H, 959-964
- Hypoglycemia
 muscle damage induced by, 1471-1476
 PKW mitogen effects on, 78
 recurrent, effects of, on cortisol response to ACTH in normal subjects, 1252-1259
 sex and adrenal catecholamine response to, 121-124
- Hypokinesia (HK), daily Mg supplementation effects on Mg deficiency during prolonged, 903-907
- Hypothalamic-pituitary-adrenal (HPA) axis in PCOS, 143-148
- Hypothalamic-pituitary-testicular function, effects of methanol extract of Chansu on, 1211-1216
- Hypothalamus
 activity of glucose-6-phosphatase in, in obesity, 627-629
 neonatal insulin treatment effects on, 857-858
- Hypothyroidism
 hormonal regulation of 18S RNA, *Lep* mRNA, and leptin release in adipocytes in, 1455-1461
 total plasma HcY in, 89-93
see also Thyroxine in hypothyroidism
- Hypoxanthine, *see* Plasma hypoxanthine; Urinary excretion, hypoxanthine
- Hypoxia, retina IGF-I mRNA, IGF-IR mRNA, and IGFBP-2 and -3 mRNA in, 1331-1336
- IAT, *see* Intraabdominal adipose tissue
- ICAM-1 (intercellular adhesion molecules-1), endothelial cell, linoleic acid and TNF α effects on, 566-572
- ICV (intracerebroventricular) leptin, effects of, on S_1 and systemic glucose utilization in conscious subjects, 1274-1280
- ICV (intracerebroventricular) methylatropine, effects of, on vagus nerve-mediated control of insulin secretion in obesity, 1169-1173
- I/D (insertion/deletion) polymorphism of ACE gene, metabolic syndrome and electrocardiographic CAD in Pima Indians associated with, 622-626
- IDDM, *see* Insulin-dependent diabetes mellitus
- IDL, *see* Intermediate-density lipoprotein
- IDL-C, *see* Intermediate-density lipoprotein-cholesterol
- IGF, *see* Insulin-like growth factor(s)
- IGFBPs, *see* Insulin-like growth factor-binding protein(s)
- IGT, *see* Impaired glucose tolerance
- IL, *see* Interleukin-6; Interleukin-8
- Ile, *see* Isoleucine
- IM (intramuscular) corticotropin 1-24 (ACTH 1-24), plasma cortisol response to, in healthy men, 1419-1422
- Immune parameters at IDDM onset, 1205-1210
- Immunopheresis, *see* Apheresis, LDL, in FH
- Immunoreactive vascular endothelial growth factor (IR-VEGF), plasma, smoking relation to concentration of, 27-30
- Immunosuppression
 effects of, on renal and serum IGF-I, IGFBPs, and renal growth following unilateral nephrectomy, 817-823
 following whole pancreas-kidney transplantation in IDDM, 1326
- Impaired glucose tolerance (IGT)
 insulin kinetics and action and muscle morphology in lean or slightly overweight subjects with, 848-854
 Japanese subjects with, Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 456-460
 in nondiabetic South Indians, CHD and, 230-233
- Implantable central venous access devices in children with metabolic diseases, 900-902
- Implementation of glucose minimal models with SAAM II, 490-492
- Indomethacin
 effects of, on glucose production in falciparum malaria, 217-222
 preadipocyte differentiation and, 463
- Inflammatory mediators
 of endothelial cells, linoleic acid and TNF α effects on, 566-572
see also Cytokines
- Injury, *see* Trauma and injury
- Inorganic phosphate (orthophosphate)
 blood, xylitol effects on, 741
 bucladesine sodium effects on, 1006-1007
 plasma, *see* Plasma inorganic phosphate
- Input-output modeling, 1018-1019
- Insertion/deletion (I/D) polymorphism of ACE gene, metabolic syndrome and electrocardiographic CAD in Pima Indians associated with, 622-626
- Insulin
 arterial, *see* Arterial insulin
 breast milk and/or formula effects on, during development, 22
 bucladesine sodium effects on, 1006-1007
 E release induced by, 243-249
 effects of, on abundance of apobec-1 mRNA in hepatocytes, 869-873
 effects of, on 18S RNA content of adipocytes in hypothyroidic subjects, 1456-1458
 effects of GLcN and, on O-GlcNAc levels in muscle proteins, 449-455
 ET-1 inhibition of glucose uptake in adipocytes stimulated by, 1468-1471
 fasting, *see* Fasting insulin
 in GH deficiency, 1516
 GLUT4 recruitment to skeletal muscle cell surface stimulated by, dexamethasone effects on, 3-6
 glutamine uptake and release and, 716
 and HRT effects on plasma lipids and Lps, 1224
 kinetics and action of, and muscle morphology in lean or slightly overweight IGT subjects, 848-854
Lep mRNA and, *see: Lep* mRNA, insulin and, in STZ-DM
 long-term alcohol intake effects on, at puberty, 1269-1273
 in nondiabetic South Indians, 230-233
 in PAM, 1265
 in PCOS, 159, 988-992
 pioglitazone effects on liver and muscle uptake of, in subjects on high-fructose diet, 1152-1155
 PKW mitogen effects on, 76-77
 plasma, *see* Plasma insulin
 in recurrent hypoglycemia, 1254
 regulation of adipocyte LPL activity by, via Wortmannin- and rapamycin-sensitive pathways, 555-559
 restricted caloric intake effects on, 429-434
 serum, *see* Serum insulin
 syndrome X-like alterations due to neonatal treatment with, 855-862
 tetrahydrobiopterin synthesis-dependent vasodilation induced by, 1037-1039
 and TNF α in CHD, 116
 in young children of NIDDM parents, 1001
see also Hyperinsulinemia; Insulin, stress and; Insulin-dependent diabetes mellitus; Insulin receptor isoform mRNA; Insulin release and secretion; Insulin resistance; Insulin system, modeling of; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus and entries beginning with terms: Insulin-like

- Insulin, stress and
in obesity, 1385
stress and relationship of ACTH and cortisol to glucose and, in middle-aged men, 1440-1449
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
insulin secretion and therapy mode association with serum leptin and AT in, 1391-1396
with and without microangiopathy, *see* Microangiopathy, IDDM with onset of, metabolic and immune parameters at, 1205-1210
plasma leptin in pregnant women with, 840-843
premenopausal and postmenopausal women with, DXA measuring body composition and AT distribution in, 212-216
regular insulin versus insulin Lispro effects on lipid metabolism in, 371-376
urinary ET-1 excretion in adolescents with, 1408-1412
whole pancreas-kidney transplantation for, proinsulin levels after, 1325-1330
young adults with, *see* Young adults with IDDM
- Insulin-like growth factor(s) (IGF)
serum, in hepatic failure following LT, 200-206
see also entries beginning with terms: Insulin-like growth factor
- Insulin-like growth factor-I (IGF-I)
abdominal obesity and, 1189, 1190
in children, 265, 310
GH and, *see* Growth hormone, IGF-I and
GH/IGF-I/IGFBP3 axis in prepubertal children with β -thalassemia and/or CSS, 541-548
in IDDM, *see* Insulin-like growth factor-I in young IDDM adults
mRNA of, in retina, hypoxia and, 1331-1336
pathway components of colon and small intestine, effects of dietary protein and TNF α on, in protein-depleted subjects, 345-350
plasma, diet and, 1107
renal, effects of immunosuppression on, following unilateral nephrectomy, and RMR in healthy adults, 1135, 1136
serum, *see* Serum insulin-like growth factor-I
- Insulin-like growth factor-I (IGF-I) in young IDDM adults
effects of, on insulin requirements due to GH pulsatility in, 31-38
effects of low-dose, on GH, S_1 , and glucagon levels, 1481-1489
- Insulin-like growth factor-I receptor (IGF-IR) mRNA (messenger ribonucleic acid) in retina, hypoxia and, 1331-1336
- Insulin-like growth factor-II (IGF-II), and GH bioactivity in prepubertal obese children, 1490-1493
- Insulin-like growth factor-III (IGF-III), and GH bioactivity in prepubertal obese children, 1490-1493
- Insulin-like growth factor-binding protein(s) (IGFBPs)
renal, effects of immunosuppression on, following unilateral nephrectomy, 817-823
see also Serum insulin-like growth factor-binding proteins and specific insulin-like growth factor-binding proteins
- Insulin-like growth factor-binding protein 1 (IGFBP-1), GH bioactivity, IGF-I, IGF-II and, in prepubertal obese children, 1490-1493
- Insulin-like growth factor-binding protein 2 (IGFBP-2)
GH bioactivity, IGF-I, IGF-II and, in prepubertal obese children, 1490-1493
mRNA of, in retina, hypoxia and, 1331-1336
- Insulin-like growth factor-binding protein 3 (IGFBP-3)
in CRF children, 265
dietary protein and TNF α effects on, in protein-depleted subjects, 346, 347
mRNA of, in retina, hypoxia and, 1331-1336
in prepubertal children, *see* Insulin-like growth factor-binding protein 3 in prepubertal children
- Insulin-like growth factor-binding protein 3 (IGFBP-3) in prepubertal children
GH bioactivity, IGF-I, IGF-II and, in prepubertal obese children, 1490-1493
GH/IGF-I/IGFBP3 axis in prepubertal children with β -thalassemia and/or CSS, 541-548
- Insulin-like growth factor-binding protein 4 (IGFBP-4), dietary protein and TNF effects on mRNA of, in protein-depleted subjects, 346, 347
- Insulin Lispro, effects of regular insulin versus, on lipid metabolism in IDDM, 371-376
- Insulin receptor (IR) isoform mRNA (messenger ribonucleic acid), liver and skeletal muscle, in NIDDM, 129-132
- Insulin release and secretion
in IDDM, association of therapy mode and, with AT and serum leptin in, 1391-1396
modeling of, 1026
in NIDDM, *see* Insulin release and secretion in NIDDM
in obesity, vagus nerve control of, 1167-1173
- Insulin release and secretion in NIDDM
association of therapy mode and, with AT and serum leptin in, 1391-1396
effects of stimulation with glucose and GLP-1 on, 1042-1047
- Insulin resistance, 396-408
acute, due to alcohol-related diols, 1180-1186
body composition and, related to aging, CV disease risk factors and, 401-408
due to high-fat, mineral-imbalanced diet, dietary Cr effects on, 396-400
hyperinsulinemia and, *see* Hyperinsulinemia, insulin resistance and I/D polymorphism of ACE gene and, 623
leptin response to fasting in obesity with, 125-128
in nondiabetic FCH subjects, minimal model in study of, 509-513
in PCOS, 158-162, 940-946
race and, *see* Insulin resistance, race and
troglitazone effects on, *see* Troglitazone effects on insulin resistance
Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects with, 456-460
verapamil and captopril effects on glucose tolerance and insulin action in, 982-987
in young children of NIDDM parents, 1000
see also Insulin sensitivity
- Insulin resistance, race and
and relationship between Lps and, in nondiabetics, 1174-1179
SHBG and, in insulin-resistant women, 70-74
- Insulin sensitivity (S_1)
body composition and, *see* Insulin sensitivity, body composition and effects of stearic and oleic acid diets on glucose tolerance and, in women, 529-534
hypertension and, 493-496
in IGT, insulin kinetics, muscle morphology and, 851
insulin action, fibrinolysis and, in nondiabetics and NIDDM with obesity, 1372-1375
leptin and, *see* Insulin sensitivity, leptin and
in young IDDM adults, low-dose IGF-I effects on, 1481-1489
see also Insulin resistance; Women, S_1 in
- Insulin sensitivity (S_1), body composition and
aging-related insulin resistance and, 402, 404, 406
relationship of plasma leptin to sex, puberty, EE and, in children, 309-312
- Insulin sensitivity (S_1), leptin and
ICV leptin effects on, in conscious subjects, 1274-1280
race and effects of HF versus LF diets on serum leptin and insulin sensitivity in women, 1520-1524
- Insulin signaling, model of, 1027-1033

- Insulin system, modeling of, 1026-1033
 of glucose and insulin signaling, 1027-1033
 of insulin fluxes, 1026-1027
- Insulinopenic non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), hyperinsulinemic and, in obese subjects, Lp alterations in, 1315-1324
- Intercellular adhesion molecules-1 (ICAM-1), linoleic acid and TNF α effects on endothelial cell, 566-572
- Interleukin-6 (IL-6), acute and delayed effects of single-dose, on thyroid function in healthy subjects, 1289-1293
- Interleukin-8 (IL-8), linoleic acid and TNF α effects on endothelial cell, 566-572
- Intermediate-density lipoprotein (IDL)
 fasting, in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373
 HRT effects on, 1224
see also Intermediate-density lipoprotein-cholesterol
- Intermediate-density lipoprotein-cholesterol (IDL-C)
 in familial HALP and HBLP, 1162
 insulin versus sulfonylurea therapy of NIDDM effects on, 641
- Intestinal adaptation after small bowel resection, enteral OKG effects on, 1366-1371
- Intestinal peptide, vasoactive, NO in PRL secretion stimulated by, in men, 897-899
- Intraabdominal adipose tissue (IAT)
 insulin resistance and, 402, 404, 406
 and RMR in healthy adults, 1135, 1136
- Intracerebroventricular (ICV) leptin, effects of, on S_1 and systemic glucose utilization in conscious subjects, 1274-1280
- Intracerebroventricular (ICV) methylatropine, effects of, on vagus nerve-mediated control of insulin secretion in obesity, 1169-1173
- Intramuscular (IM) corticotropin 1-24 (ACTH 1-24), plasma cortisol response to, in healthy men, 1419-1422
- Intravascular enzymes related to lipid transport, effects of menopausal status and exercise on, 377-383
- Intravenous glucose tolerance test (IVGTT)
 in fructose-induced hypertriglyceridemia, 149-153
 in glucose and insulin signaling modeling, 1028-1031
 measuring glucose effectiveness in endurance-trained subjects, 190-194, 874-877
 worsening of, in healthy subjects independently of obesity, 313-320
- IR (insulin receptor) isoform mRNA (messenger ribonucleic acid), liver and skeletal muscle, in NIDDM, 129-132
- ^{59}Fe (^{59}Fe), vanadate and uptake of, in adipocytes, 630-636
- IR-VEGF (immunoreactive vascular endothelial growth factor), plasma, smoking relation to concentration of, 27-30
- Ischemia, retinal, followed by recirculation, effects of, on retinal GSH levels in STZ-DM, 269-272
- Isobutyrylglycine in ethylmalonic encephalopathy, 837
- Isoleucine (Ile)
 abnormal metabolism of, in ethylmalonic encephalopathy, 836-839
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- Isomerase, protein disulfide, activity of, during fasting and refeeding, protein contents and, 1083-1088
- Isometric exercise, effects of parasympathetic dysfunction and hyperinsulinemia in NIDDM on hemodynamic response to, 934-939
- Isovalerylglycine in ethylmalonic encephalopathy, 837
- IVGTT, *see* Intravenous glucose tolerance test
- Jamaican women, hyperglycemia and BMI associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 617-621
- Japanese subjects
 G⁹⁹⁴ \rightarrow T missense mutation in PAF acetylhydrolase gene as risk factor for CAD in Japanese men, 177-181
 with NIDDM, *see* Japanese subjects with NIDDM
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects
- Japanese subjects with NIDDM
 IGT, and insulin resistance, Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 456-460
 platelet 12-LOX in, 257-263
- K (potassium)
 dietary, *see* Dietary K
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in hypoglycemia, 1472
 plasma, effects of lipolysis inhibition on, 1465
 serum, in Graves' disease, 1195
- Keshan disease (KD), effects of selenium and vitamin E on beta cell alterations induced by, 415-419
- Ketimine, cystathionine, in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238
- Ketoconazole, RA catabolism inhibited by, 956
- α (alpha)-Ketoglutarate, enteral ornithine, effects of, on intestinal adaptation after small bowel resection, 1366-1371
- α (alpha)-Keto- δ -guanidinovaleic acid (α -keto- δ -GVA), plasma and urine, nephrectomy effects on, 358-359
- Ketones
 effects of restricted caloric intake on, in men and women, 429-434
see also Ketones in IDDM and NIDDM, leptin and *and specific ketones; for example:* β -Hydroxybutyrate
- Ketones in IDDM and NIDDM, leptin and
 plasma total, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 serum leptin correlation with, 1392
- Ketoneuria at IDDM onset, 1206
- 6-Keto-prostaglandin F $_{1\alpha}$ (PGF $_{1\alpha}$), and SPA relationship to NIDDM complications, 703
- Ketosis resistance in offspring of protein-malnourished subjects, 1450-1454
- Kidney
 activity and content of PDI in, during fasting and refeeding, 1084-1085
 of D,L-propargylglycine-treated subjects, cystathionine, cystathionine ketamine, NAC-cysta, and PHTZDC in, 1233-1238
 proinsulin levels after whole pancreas-kidney transplantation, 1325-1330
see also entries beginning with term: Renal and element: Nephro-
- Kinase
 mitogen-activated protein, NIDDM effects on, 56
 serum creatine, in hypoglycemia, 1471-1476
see also Phosphokinase
- Kinetic homogeneity in compartmental modeling, defined, 1012
- Kinetics
 E, 245-246
 glucose, in NIDDM, effects of dietary protein restriction on, on, 1148
 glutamine, in active celiac disease, whole-body protein metabolism assessed by, 1429-1433
 of hepatic AA transport activation in burn injury, 611
 insulin, and muscle morphology in lean or slightly overweight IGT subjects, 848-854
 leucine, *see* Kinetics, leucine
 palmitate, OC effects on, 282
 Phe and tyrosine, 670-671
see also Tracer kinetics

- Kinetics, leucine**
 in active celiac disease, whole-body protein metabolism assessed by, 1429-1433
 dietary leucine, hyperglucagonemia and kinetics of, 497-502
 dietary protein restriction effects on, in NIDDM, 1147
 hyperglucagonemia and, 497-502
 Kuwaiti children, obese and non-obese, serum lipids and BP associated with fasting insulin levels in, 420-424
- Lactate**
 breast milk and/or formula effects on, during development, 22
 in PAM, 1265
 PKW mitogen effects on, 76-77
 plasma, *see* Plasma lactate
 Tolrestat and levels of, 1426
- Lactate dehydrogenase (LDH)**
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in Keshan disease, vitamin E and selenium effects on, 416, 417
 in LT recipients, 201
 serum, in hypoglycemia, 1471-1476
- Lactic acid**
 glucagon effects on concentrations of, 696, 697
 xylitol effects on, 741, 742
- Laminin, serum, in IDDM with and without microangiopathy, levels and molecular size of, 63-69**
- Late pregnancy, physiological FPG reduction in, 1142-1444**
- Lathosterol, relationship of, to apo E phenotype in hypercholesterol emia, 747**
- Lauric acid in diet regulating apo B-containing Lps, 884**
- LCAC (long-chain acyl coenzyme A), effects of FFA elevation on, 1122-1123**
- LCAT, *see* Lecithin:cholesterol acyltransferase**
- LCPUFAs (long-chain polyunsaturated fatty acids), skeletal muscle membrane, in young children, factors affecting, 106-112**
- LDH, *see* Lactate dehydrogenase**
- LDL, *see* Low-density lipoprotein**
- LDL-C, *see* Low-density lipoprotein-cholesterol**
- Lean body mass, *see* Fat-free mass**
- Lean subjects, *see* Non-obese subjects**
- Learning, abnormal cholesterol synthesis and retarded, 878-882**
- Lecithin:cholesterol acyltransferase (LCAT)**
 GH levels correlated with, 340-342
 HRT effects on, 1224
 menopausal status and exercise effects on, 378, 379
 plasma, effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 888
 and short-term estrogen-progestin replacement therapy in postmenopausal women, 297-300
- Lep gene (*ob* gene)**
 effects of enterohepatic circulation manipulation and bile acid composition on regulation of, 285-291
 expression of, *see* Lep mRNA
- Lep mRNA (messenger ribonucleic acid)**
 effects of enterohepatic circulation manipulation and bile acid composition on, 285-291
 effects of fasting, sex, and GH therapy on serum leptin and, in GH-deficient and healthy adults, 1514-1519
 hormonal regulation of, in adipocytes of hypothyroid subjects, 1455-1461
see also Lep mRNA, insulin and, in STZ-DM
- Lep mRNA (messenger ribonucleic acid), insulin and, in STZ-DM**
 food intake and insulin-dependent increase of, 603-607
 in insulin-treated and untreated STZ-DM and in nondiabetics, 594-591
- Leptin**
 expression of receptor isoforms of, in AT, 844-847; *see also* Adipose tissue
 response of, to fasting by obese insulin-resistant subjects, 125-128; *see also* Obesity
see also Adipocytes, leptin and; Glucose, leptin effects on; Lep gene; Leptin, GH and; Plasma leptin; Serum leptin
- Leptin, GH and**
 effects of fasting, sex, and GH therapy on Lep mRNA in GH-deficient and healthy adults, 1514-1519
 GH and prednisolone effects on EE and leptin levels, 83-88
 GH status, leptin levels, and RMR in normal subjects, 1134-1139
 in spontaneous and GHRH-stimulated GH secretion, serum insulin but not leptin associated with, in normal subjects with and without weight loss, 1127-1133
- Leucine (Leu)**
 endotoxin and metabolism of, in liver, 681-685
 in familial HALP and HBLP, 1164
 and G effects on glutamine uptake and release, 717, 719, 720
 kinetics of, *see* Kinetics, leucine
 plasma, *see* Plasma leucine
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- [¹³C]Leucine (Leu), GC/MS of, 708-709**
- Levothyroxine therapy following total thyroidectomy for Graves' disease, Na⁺, K⁺ ATPase activity in RBCs of women on, 1194-1198**
- Leydig cell tumors, cachexia associated with, NO-1886 effects on, 101-105**
- LF, *see* entries beginning with terms: Low-fat**
- LH, *see* Luteinizing hormone**
- O-Linked N-acetyl-glucosamine (O-GlcNAc), insulin and GLcN effects on level of, in muscle proteins, 449-455**
- Linoleate, effects of, on pancreatic islets following reoxygenation injury, 810-811**
- Linoleic acid**
 in diet regulating apo B-containing Lps, 884
 effects of, on endothelial cell inflammatory mediators, 566-572
 effects of, on pancreatic islets following reoxygenation injury, 810
 in fat-modified diet for hypercholesterolemia, 745, 748
- Lipase, *see* Hepatic lipase activity; Lipoprotein lipase activity**
- Lipids**
 fasting, *see* Fasting lipids
 hepatic, effects of hypercholesterolemia-inducing diet on, 304
 in IDDM, effects of regular insulin versus insulin Lispro on metabolism of, 371-376
 in insulin-resistant women, SHBG, race and, 72
 LDL receptors and metabolism of, in NIDDM with obesity, 1070-1074
 muscle, effects of elevated FFAs on synthesis of, 1121-1126
 oxidation of, during exercise, 779, 780
 plasma, *see* Plasma lipids
 in post-small bowel resection enteral diet, 1367
 PP, *see* Postprandial lipids
 serum, *see* Serum lipids
see also Hyperlipidemia; Phospholipids entries with element: Lip- and specific lipids
- Lipolysis**
 adipocyte, and adrenoceptor binding in obese postmenopausal women, AT distribution and, 467-473
 effects of inhibition of, on β_1 -adrenoceptor-mediated thermogenesis in men, 1462-1467
 stimulation of, in hypertriglyceridemia, production of small HDL particles and, 234-242
- Lipoperoxide in STZ-DM, gliclazide effects on, 978**

- Lipopolysaccharide (LPS), gliclazide effects serum TNF α activity enhanced by, in STZ-DM, 978-979
- Lipoprotein (Lp)
- aerobic exercise and weight loss effects on glucose metabolism, BP and, in obese hypertensive middle-aged men, 1075-1082
 - apo E phenotype and response of, to lovastatin or gemfibrozil for primary hypercholesterolemia, 560-565
 - apo B-containing, regulation of, by vitamin C level and dietary fat saturation, 883-891
 - in NIDDM, *see* Lipoprotein in NIDDM
 - plasma, *see* Plasma lipoprotein
 - race and relationship between insulin resistance and, in 1174-1179
 - TG-rich, smoking, GPIIIa gene and, 1040-1041
 - see also* High-density lipoprotein; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein A-I; Lipoprotein A-I:A-II; Lipoprotein lipase activity; Low-density lipoprotein and specific apolipoproteins
- Lipoprotein (Lp) in NIDDM
- alterations of, in hyperinsulinemic and insulinopenic NIDDM with obesity, 1315-1324
 - insulin versus sulfonylurea effects on, 641
- Lipoprotein(a) [Lp(a); high-density lipoprotein₁]
- in CHD, Lp(a) level and, 182-184, 276
 - in insulin resistance, *see* Lipoprotein(a) in insulin resistance
 - LDL apheresis and, *see* Lipoprotein(a) in FH, LDL apheresis and
 - in NIDDM, acipimox effects on, 252
 - plasma, niacin versus Niaspan effects on, in primary hypercholesterolemia, 1100
 - serum, menopausal status and exercise effects on, 378, 379
 - weight loss with meat-based or plant-based diet effects on, 1311
- Lipoprotein(a) [Lp(a); high-density lipoprotein₁] in FH, LDL apheresis and
- Lp(a) reduction with, 1058-1064
 - in severe FH, 865
- Lipoprotein(a) [Lp(a); high-density lipoprotein₁] in insulin resistance
- body composition, 402, 404, 406
 - effects of stearic and oleic acid diets on, 532
 - SHBG, race and, in insulin-resistant women, 72
- Lipoprotein A-I (LpA-I)
- plasma, in HALP, 968-970
 - serum, race and distribution of, in children, 757-763
- Lipoprotein A-I:A-II (LpA-I:A-II)
- plasma, in HALP, 968-970
 - serum, race and distribution of, in children, 757-763
- Lipoprotein lipase (LPL) activity
- activator of, *see* NO-1886
 - in adipocytes, *see* Lipoprotein lipase activity in adipocytes
 - ERT effects on, 676-677
 - GH levels in women correlated with, 340-342
 - in HALP, 969
 - menopausal status and exercise effect on, 378, 379
 - postheparin plasma, in IDDM, effects of insulin Lispro versus regular insulin on, 373
- Lipoprotein lipase (LPL) activity in adipocytes
- AT distribution and, 469
 - insulin regulation via Wortmannin- and rapamycin-sensitive pathways and, 555-559
- Lipoxygenase (LOX), LOX pathway of arachidonic acid metabolites in preadipocyte differentiation regulation, 461-466
- 12-Lipoxygenase (LOX), platelet, in Japanese NIDDM subjects, 257-263
- Lispro, effects of regular insulin versus, on lipid metabolism in IDDM, 371-376
- Liver
- activity and content of PDI in, during fasting and refeeding, 1084-1085
 - endotoxin and leucine metabolism in, 681-685
 - 3-FDG uptake by, enhanced by exercise, 44-49
 - in NIDDM, IR isoform mRNA in, 129-132
 - pioglitazone effects on insulin uptake by, in subjects on high-fructose diet, 1152-1155
 - of D,L-propargylglycine-treated subjects, cystathionine, cystathionine ketamine, NAc-cysta, and PHTZDC in, 1233-1238
 - see also* Liver transplantation; Organ weight, liver and *entries beginning with term: Enterohepatic and element: Hepat-*
 - Liver transplantation (LT), hepatic failure following, serum IGFs and IGFFBPs in, 200-206
 - Long-chain acyl coenzyme A (LCAC), effects of FFA elevation on, 1122-1123
 - Long-chain polyunsaturated fatty acids (LCPUFAs), skeletal muscle membrane, in young children, 106-112
 - Long-term effects
 - of alcohol intake on food intake, BW, plasma leptin, corticosterone, and insulin levels at puberty, 1269-1273
 - of LDL apheresis on plasma Lps and CHD in native vessels and coronary bypass in severe heterozygous FH, 863-868
 - of perindopril on metabolic parameters and heart in NIDDM with hypertension, 1199-1204
 - Losartan
 - ET-1 in acute hyperinsulinemia and hypertension treated with, 292-296
 - OT and AVP responses to, in men, 893-896
 - Lovastatin for primary hypercholesterolemia, apo E phenotype and Lp response to, 560-565
 - Low-density lipoprotein (LDL; β -lipoprotein)
 - arterial, chronic hyperglycemia effects on atherosclerosis and metabolism of, in STZ-DM, 947-954
 - BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 - in IDDM, *see* Low-density lipoprotein in IDDM
 - in men with abdominal obesity, 1189, 1190
 - in obese women, *see* Low-density lipoprotein in obese women
 - in postmenopausal women, *see* Low-density lipoprotein in postmenopausal women
 - race and, of nondiabetics, relationship between insulin resistance and, 1176, 1177
 - serum, in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 - and serum uric acid levels in non-obese premenopausal women, 437, 438
 - VCAM-1 and, in hyperlipidemia of preeclampsia, 1281-1288
 - see also* Apheresis, LDL, in FH; Apolipoprotein B, LDL; Hyperbetalipoproteinemia; Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor(s); Very-low-density lipoprotein
 - Low-density lipoprotein (LDL; β -lipoprotein) in IDDM
 - fasting, insulin Lispro and regular insulin effects on metabolism of, 372-373
 - urinary ET-1 and, 1409
 - Low-density lipoprotein (LDL; β -lipoprotein) in obese women, 470
 - effects of weight loss with meat-based or plant-based diet, 1310
 - Low-density lipoprotein (LDL; β -lipoprotein) in postmenopausal women hypercholesterolemic with CHD, effects of ERT on antibodies against oxidized LDLs in, 675-680
 - in non-obese women, 437, 438
 - in obese women, 470

- Low-density lipoprotein (LDL; β -lipoprotein) receptor(s)
 function of, in lipid metabolism of NIDDM patients, obesity and, 1070-1074
see also Low-density lipoprotein receptor mRNA
- Low-density lipoprotein (LDL; β -lipoprotein) receptor mRNA (messenger ribonucleic acid)
 amiodarone effects on, 1052-1057
 breast milk and formula effects on hepatic HMG-CoA and C7H mRNA but not on, during development, 20-26
- Low-density lipoprotein-cholesterol (LDL-C)
 in adolescent males, racial differences in, 516
 CHD and, *see* Low-density lipoprotein-cholesterol, CHD and
 effects of stearic and oleic acid diets on, 532
 in familial HALP and HBLP, 1162, 1163
 in FCH, 509
 GH levels in women correlated with, 340-342
 HCHF diet effects on, 733
 in hypercholesterolemia, *see* Low-density lipoprotein-cholesterol in hypercholesterolemia
 in insulin resistance, *see* Low-density lipoprotein-cholesterol in insulin resistance
 in middle-aged obese hypertensive men, 1079
 in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
 in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 plasma, *see* Plasma low-density lipoprotein-cholesterol
 serum, *see* Serum low-density lipoprotein-cholesterol
 sex hormones effects on, 392
 short-term tall oil phytosterol administration effects on, 753-754
 in very old syndrome X subjects, 536, 537
 in young children of NIDDM parents, 999
see also Very-low-density lipoprotein-cholesterol
- Low-density lipoprotein-cholesterol (LDL-C), CHD and
 ACE gene polymorphism with, in NIDDM, 1259, 1260
 in exercising postmenopausal women, 1119
- Lp(a) level and, 276
 as risk factor, 114
see also Very-low-density lipoprotein-cholesterol in CHD
- Low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia
 fat-modified diet effects on, 745
 in FH, LDL apheresis effects on, 865, 1060
 in polygenic hypercholesterolemia, 98
 in primary hypercholesterolemia, 562
- Low-density lipoprotein-cholesterol (LDL-C) in insulin resistance
 body composition and, related to aging, CV disease risk factors and, 402, 404, 406
 SHBG, race and, in insulin-resistant women, 72
- Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
 CHD and, 1259, 1260
 in elderly NIDDM subjects, Pro-Z effects on, 42
 insulin versus sulfonylurea therapy effects on, 641
 metabolic syndrome, I/D polymorphism of ACE gene and, 624
 serum PON activity and, 599
- Low-dose insulin-like growth factor-I (IGF-I) in young IDDM adults,
 effects of, on GH, S_i , and glucagon levels, 1481-1489
- Low-fat (LF) diet
 race and effects of HF versus, on S_i and serum leptin in women, 1520-1524
 reversal of HF diet-induced obesity and DM with, 1089-1096
- Low-fat, high-fiber diet, effects of exercise and, in subjects with
 multiple CV disease risk factors, 384-390
- Low glycemic diet, effects of, on risk factors for CHD, in women,
 1245-1251
- LOX, *see* Lipoxygenase; 12-Lipoxygenase
- Lp, *see* Lipoprotein
- Lp(a), *see* Lipoprotein(a)
- LpA-I, *see* Lipoprotein A-I
- LpA-I:A-II, *see* Lipoprotein A-I:A-II
- LPL, *see* Lipoprotein lipase activity
- LPS (lipopolysaccharide), glioclazide effects on serum TNF α activity
 enhanced by, in STZ-DM, 978-979
- LT (liver transplantation), hepatic failure following, serum IGFs and
 IGFFBPs in, 200-206
- Luteinizing hormone (LH)
 Chansu effects on, 1213, 1214
 in PCOS, 159, 941
 in recessive Robinow syndrome, 1337-1343
- Lymphocytes, 27-hydroxycholesterol effects on cholesterol synthesis
 in, 734
- Lysine (Lys)
 in diet regulating small intestinal cell turnover, 1106
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- β_2 -M, *see* β_2 -Microglobulin
- Magnesium, *see* Mg
- Magnetic resonance spectroscopy (MRS), ^{31}P , metabolic efficiency of
 skeletal muscle in hyperthyroidism measured with, 769-776
- Malaria, falciparum, indomethacin effects on glucose production in,
 217-222
- Male subjects, *see* Adolescents; Men; Sex
- Malic enzyme (ME), hypercholesterolemia-inducing diet effects on,
 306
- Maltodextrin in obesity- and DM-inducing diet, 1090
- MAPK (mitogen-activated protein kinase), NIDDM effects on, 56
- Mass spectrometry/gas chromatography (MS/GC) of metabolic tracers,
 706-712
- ME (malic enzyme), hypercholesterolemia-inducing diet effects on, 306
- Measurement equations in compartmental modeling, 1015
- Meat-based diet, weight loss with plant-based diet or, by obese women,
 effects of, on SAC, plasma lipids, BP, and plasma leptin,
 compared, 1308-1314
- Medroxyprogesterone (MPA), effects of, in hypercholesterolemic post-
 menopausal women on ERT, 677
- Melatonin (MEL), naloxone effects on GH response to pyridostigmine
 and, in men, 814-818
- Men
 adolescent, *see* Adolescents
 β_1 -adrenoceptor-mediated thermogenesis in, effects of lipolysis
 inhibition on, 1462-1467
 exercising, *see* Men, exercising
 GH therapy suppressing cortisol production in, 1376-1378
 hyperglucagonemia and dietary leucine kinetics in, 497-502
 Japanese, G 994 \rightarrow T missense mutation in PAF acetylhydrolase gene
 as risk factor for CAD in, 177-181
 middle-aged, *see* Middle-aged men
 naloxone effects on GH response to melatonin and pyridostigmine in,
 814-818
 NO in VIP-stimulated PRL secretion in, 897-899
 non-obese, *see* Non-obese subjects
 OT and AVP responses to angiotensin II type 1 receptor antagonist in,
 893-896
 plasma cortisol response to IM ACTH 1-24 in, 1419-1422
 restricted caloric intake effects on serum leptin, insulin, cortisol,
 glucose, ketones, and NEFAs in, 429-434

- Men (*Continued*)
see also Men, exercising; Men, obese; Men, older; Normal subjects;
 Sex and specific conditions
- Men, exercising
 middle-aged obese hypertensive, effects of aerobic exercise and weight loss on BP, glucose metabolism, and Lps in, 1075-1082
see also Exercise
- Men, obese
 with abdominal obesity related to anxiety and depression, endocrine and metabolic aberrations in, 1187-1193
 middle-aged hypertensive, effects of aerobic exercise and weight loss on BP, glucose metabolism, and Lps in, 1075-1082
 VAT accumulation effects on uric acid metabolism in, 929-933
see also Obesity
- Men, older
 osteopenic, vitamin K and 25-OHD levels in, 195-199
 relationship between fasting plasma insulin, anthropometrics, and metabolic parameters in very old men with syndrome X, 535-540
- Menaquinone-7 (MK-7), levels of vitamin K and, in osteopenic older men, 195-199
- Menopausal status
 effects of exercise and, on serum lipids and activities of intravascular enzymes related to lipid transport, 377-383
see also Postmenopausal women; Premenopausal women
- Messenger ribonucleic acid, *see* mRNA
- Metabolic diseases and aberrations
 children with, implantable central venous access devices in, 900-902
 in men with abdominal obesity related to anxiety and depression, 1187-1193
see also specific conditions
- Metabolic parameters
 long-term effects of perindopril in NIDDM with hypertension on, 1199-1204
 at onset of IDDM, 1205-1210
 relationship between fasting plasma insulin, anthropometrics and, in very old syndrome X subjects, 535-540
- Metabolic rate
 in NIDDM, BW and, 1146-1147
see also Resting metabolic rate
- Metabolic syndrome (syndrome X)
 electrocardiographic CAD and, in Pima Indians, associated with ACE gene polymorphism and plasma ACE levels, 622-626
 syndrome X-like alterations due to neonatal insulin treatment, 855-862
 in very old subjects, 535-540
- Metabolic tracers, *see* Tracer(s)
- Methanol extract of Chansu, effects of, on hypothalamic-pituitary-testicular function, 1211-1216
- Methionine (Met)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 microalbuminuria and vascular damage in NIDDM correlated with postmethionine load tHcy, 915-921
 plasma, *see* Plasma methionine
 in trauma, 226, 227
- DL-Methionine (Met)
 in high-monounsaturated fat diet, 725
 in obesity- and DM-inducing diet, 1090
- Methylatropine, ICV, effects of, on vagus nerve-mediated control of insulin secretion in obesity, 1169-1173
- Methylenetetrahydrofolate reductase (MTHFR) gene mutation, plasma Hcy levels related to folate status and, in healthy subjects, 1413-1418
- Methylguanidine (MG), nephrectomy effects on, 358-359
- Methylsuccinic acid (MSA), abnormal isoleucine metabolism and elevated EMA and, in ethylmalonic encephalopathy, 836-839
- Mevalonic acid (MVA), urinary excretion of, in polygenic hypercholesterolemia, 98
- MG (methylguanidine), nephrectomy effects on, 358-359
- Mg (magnesium)
 deficiency of, during prolonged restriction of motor activity, daily Mg supplementation effects on, 903-907
 dietary, in post-small bowel resection enteral diet, 1367
 in elderly NIDDM subjects, Pro-Z effects on, 41
- Microalbuminuria, vascular damage and, in NIDDM, fasting and postmethionine tHcy correlated with, 915-921
- Microangiopathy
 in NIDDM, CFA relationship to gender, hypertension, neuropathy and, 503-507
see also Microangiopathy, IDDM with
- Microangiopathy, IDDM with
 CFA relationship to gender, hypertension, neuropathy and, 503-507
 and without microangiopathy, levels and molecular size of serum laminin in, 63-69
- β_2 (beta₂)-Microglobulin
 in NIDDM, 363
 urinary excretion of, in newborns, 1345
- Middle-aged men
 effects of aerobic exercise and weight loss on BP, glucose metabolism, and Lps in obese hypertensive, 1075-1082
 stress and relationship of ACTH and cortisol to insulin and glucose in, 1440-1449
- Mild hyperprolactinemia, bone loss due to estrogen deficiency and, 426
- Milk
 skim, in diet regulating small intestinal cell turnover, 1106
see also Breast milk
- Minerals
 in diet regulating small intestinal cell turnover, 1106
 in HF diet, *see* Minerals in HF diet
 mix of, in regulation of apo B-containing Lps, 884
see also Bone mineral content; Bone mineral density and specific minerals
- Minerals in HF diet
 high-fat, mineral imbalanced diet, dietary Cr effects on insulin resistance induced by, 396-400
 high-monounsaturated fat diet, 725
- Minimal model analysis
 of FCH in nondiabetics with insulin resistance, 509-513
 of glucose, 490-492, 875
- Mitogen
 PK activated by, NIDDM effects on, 56
 PKW, metabolic effects of, 75-82
- MK-7 (menaquinone-7), levels of vitamin K and, in osteopenic older men, 195-199
- MNCs (mononuclear cells), cortisol effects on generation of free radicals by, 788-791
- MNCV (motor nerve conduction velocity) in STZ-DM, gliclazide effects on, 979
- Model, systems, *see* Systems model
- Molasses in diet regulating small intestinal cell turnover, 1106
- Molecular size of serum laminin in IDDM with and without microangiopathy, 63-69
- N-Monoacetylcystathionine (NAC-cysta) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238
- Mononuclear cells (MNCs), cortisol effects on generation of free radicals by, 788-791
- Monophosphate, *see* cAMP
- Monounsaturated fat diet, obesity and NIDDM induced by high-, 724-730

- Monounsaturated fatty acids (MUFAs)
 effects of exercise and, on PAI-1 activity, 385
 in skeletal muscle membrane PLs of young children, 108, 109
 in stearic and oleic acid diets, 531
- Morning pulsatile corticotropin (ACTH), release of cortisol and, in PCOS, 143-148
- Morphology
 of beta cells in Keshan disease, vitamin E and selenium effects on, 416-417
 insulin kinetics and muscle, in lean or slightly overweight IGT subjects, 848-854
- Motor activity, daily Mg supplementation effects on Mg deficiency during prolonged restriction of, 903-907
- Motor nerve conduction velocity (MNCV) in STZ-DM, gliclazide effects on, 979
- MPA (medroxyprogesterone), effects of, in hypercholesterolemic postmenopausal women on ERT, 677
- mRNA (messenger ribonucleic acid)
 apobec-1, insulin effects on abundance of, in hepatocytes, 869-873
 C7H, *see* Cholesterol 7 α -hydroxylase mRNA
 hepatic HMG-CoA reductase, *see* Hepatic HMG-CoA reductase mRNA
 hepatic 11 β -HSD1, in pubertal hypothyroid male subjects, T₄ and T effects on, 474-478
 IGF-I, IGF-IR, IGFBP-2 and -3, in retina, hypoxia and, 1331-1336
 IGFBP-4, effects of dietary protein and TNF on, in protein-depleted subjects, 346, 347
 LDL receptor, *see* Low-density lipoprotein receptor mRNA
 Lep, *see* Lep mRNA
 leptin receptor isoform, in AT, 844-847
 in NIDDM, liver and skeletal muscle IR isoform in, 129-132
 PPAR γ , in SAT and VAT, 1494-1498
 of RA, glucocorticoid, and T₃ receptors, hypercholesterolemia-inducing diet effects on, 301-308
 splice variant of pituitary adenoma GHRH receptor, inhibiting signal transduction, 804-808
- MRS (magnetic resonance spectroscopy), ³¹P, metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776
- MSA (methylsuccinic acid), abnormal isoleucine metabolism and elevated EMA and, in ethylmalonic encephalopathy, 836-839
- MS/GC (mass spectrometry/gas chromatography) of metabolic tracers, 706-712
- MTHFR (methylene tetrahydrofolate reductase) gene mutation, plasma HcY levels related to folate status and, in healthy subjects, 1413-1418
- MTS (tetrazolium salt; 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt), metabolic activation of beta cells and, 824-830
- Mucosal colonocyte brush-border enzymes, rectosigmoid, SCFA effects on, 133-134
- MUFAs, *see* Monounsaturated fatty acids
- Multicompartmental model
 in apo E metabolism study, 922-928
 of LDL apo B kinetics, 487-488
- Multiple cardiovascular (CV) disease risk factors, effects of low-fat, high-fiber diet and exercise in subjects with, 384-390
- Multiple tracer dilution technique in modeling of regional glucose fluxes in steady-state, 1021-1022
- Muscle
 exercise and glucose disposal by, 44-49
 FFA elevation effects on lipids in, 1121-1126
 hypoglycemia-induced damage to, 1471-1476
 insulin kinetics and action and morphology of, in lean or slightly overweight IGT subjects, 848-854
- Muscle (*Continued*)
 pioglitazone effects on insulin uptake by, in subjects on high-fructose diet, 1152-1155
 trauma effects on AAs in, 226, 227
see also Muscle glycogen; Skeletal muscle; Smooth muscle cells
- Muscle glycogen
 FFA elevation effects on synthesis of, 1121-1126
 muscle glucose conversion to, following exercise, 409-414
- Mutation
 G⁹⁹⁴ \rightarrow T missense, of PAF acetylhydrolase gene, as risk factor for CAD in Japanese men, 177-181
 MTHFR gene, plasma HcY levels related to folate status and, in healthy subjects, 1413-1418
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- MVA (mevalonic acid), urinary excretion of, in polygenic hypercholesterolemia, 98
- Myristic acid in regulation of apo B-containing Lps, 884
 [9,10-³H]Myristic acid in ethylmalonic encephalopathy, 837
- N (nitrogen)
 excretion of, by injured subjects, spermidine effects on, 224
 hepatic and renal, HCl effects on metabolism of, 163-167
 urea, *see* Urea nitrogen
- Na (sodium)
 bucladesine sodium effects on, 1006-1007
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in hypoglycemia, 1472
 in post-small bowel resection enteral diet, 1367
 serum, in Graves' disease, 1195
 very-low-calorie diet effects on balance of, in obesity, 593
see also Na⁺, K⁺ ATPase and entries beginning with term: Natriuretic
- Na⁺, K⁺ ATPase (sodium, potassium adenosine triphosphatase), activity of, in RBCs of women on levothyroxine therapy following total thyroidectomy for Graves' disease, 1194-1198
- NAC-cysta (N-monoacetylcystathionine) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238
- NaCl (salt) in obesity- and DM-inducing diet, 1090
- NADH-cytochrome C reductase in ethylmalonic encephalopathy, 837
- NAG, *see* N-Acetyl- β -glucosaminidase
- NaHCO₃ (sodium bicarbonate) in obesity- and DM-inducing diet, 1090
- Naloxone, effects of, on GH response to melatonin and pyridostigmine in men, 814-818
- Native vessels, long-term effects of LDL apheresis on plasma Lps and CHD in coronary bypass and, in severe heterozygous FH, 863-868
- Natriuretic factor, atrial, very-low-calorie diet effects on, in obesity, 592-597
- Natriuretic peptide, plasma brain, very-low-calorie diet effects on, in obesity, 592-597
- NE, *see* Norepinephrine
- NEFAs (nonesterified fatty acids), *see* Free fatty acids
- Negative portal venous and hepatic glucose gradients, effects of, on hepatic glucose uptake following glucose infusion in splanchnic bed of conscious subjects, 1295-1302
- Neonatal glucose homeostasis, 1239-1244
- Neonatal insulin treatment, syndrome X-like alterations due to, 855-862
- Nephrectomy
 biochemical changes due to, 355-361
 unilateral, effects of immunosuppression on renal and serum IGF-I, IGFbps, and renal growth following, 817-823
- Nephropathy
 diabetic, SPA relationship to, 702

- Nephropathy (*Continued*)
 with IDDM and NIDDM, and insulin secretion and therapy mode associated with leptin and AT, 1394
- Nervous system, autonomic, GH and prednisolone effects on, 84-85
- Neural tissue, DOPA synthesis in, effects of tyrosine-deficient TPN on, 168-176
- Neuropathy, *see* Diabetic neuropathy
- Newborns
 of protein-malnourished subjects, ketosis resistance in, 1450-1454
 urinary aquaporin-2 excretion and renal water channel expression in, 1344-1347
see also entries with term: Neonatal
- NF- κ B (nuclear factor- κ B), linoleic acid and TNF α effects on endothelial cell, 566-572
- Niacin, plain niacin versus time-release, for primary hypercholesterolemia, compared, 1097-1104
- Niaspan (time-release niacin), plain niacin versus, for primary hypercholesterolemia, compared, 1097-1104
- Nicotine, *see* Smoking
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nighttime pulsatile corticotropin (ACTH), release of cortisol and, in PCOS, 143-148
- Nitric oxide (NO) in VIP-stimulated PRL secretion in men, 897-899
- Nitric oxide synthase (NOS), insulin and production of, 1037-1039
- Nitrogen, *see* N
- NO (nitric oxide) in VIP-stimulated PRL secretion in men, 897-899
- NO-1886
 effects of, on cachexia associated with Leydig cell tumors, 101-105
 effects of, on fructose-induced hypertriglyceridemia, 149-153
- Noncholesterol sterols, relationship of, to apo E phenotype, 746, 747
- Nondiabetic subjects
 blood and urine AGE products fluorescence assays in, 1348-1353
 with FCH, minimal model in study of, 509-513
 G effects of PP CHO metabolism in, 7-12
 I/D polymorphism of ACE gene associated with metabolic syndrome and electrocardiographic CAD in nondiabetic Pima Indians, 622-626
 laminin in, 64, 66
 plasma HcY concentrations in, regulated by acute hyperinsulinemia, 686-689
 plasma IR-VEGF in, 28
 plasma leptin in, *see* Nondiabetic subjects, plasma leptin in
 proinsulin in, *see* Nondiabetic subjects, proinsulin in
 race and relationship between insulin resistance and Lps in, 1174-1179
 serum PON activity in, 598-602
- Nondiabetic subjects, plasma leptin in, 584-591
 in pregnant subjects, 840-843
- Nondiabetic subjects, proinsulin in
 following whole pancreas-kidney transplantation in, 1325-1330
 insulin and proinsulin concentrations in nondiabetic Asian Indians, 230-233
- Nonesterified fatty acids, *see* Free fatty acids
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus)
 ACE gene polymorphism with CHD in, 1258-1262
 aminoguanidine effects on role of AGE products in progression of, 1477-1480
 beta-cell function in, *see* Non-insulin-dependent diabetes mellitus, beta-cell function in
 family history of, *see* Family history of NIDDM
 fibrinolysis in, *see* Fibrinolysis in NIDDM
 glucose in, *see* Glucose in NIDDM
 high-monounsaturated fat diet-induced obesity and, 724-730
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) (*Continued*)
 hyperinsulinemia and, *see* Non-insulin-dependent diabetes mellitus with hyperinsulinemia
 hypertension with, *see* Hypertension, NIDDM and
 insulin secretion in, *see* Insulin release and secretion in NIDDM
 insulin signaling in adipocytes in, 54-62
 Japanese subjects with, *see* Japanese subjects with NIDDM
 liver and skeletal muscle IR isoform mRNA in, 129-132
 microalbuminuria and vascular damage in, fasting and postmethionine tHcy correlated with, 915-921
 models of, *see* Non-insulin-dependent diabetes mellitus, model(s) of
 with obesity, *see* Obesity, NIDDM with
 plasma IR-VEGF in, 28
 premenopausal and postmenopausal women with, DXA measuring body composition and AT in, 212-216
 Pro-Z effects on zinc insulin metabolism in older subjects with, 39-43
 serum PON activity relationship to complications of, 598-602
 SPA relationship to complications of, 699-705
 urinary and serum TM in, as marker for vascular endothelial injury, 362-365
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), beta-cell function in
 family history of NIDDM and, 522-528
 GLcN and beta-cell dysfunction in, 573-577
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), model(s) of
 hyperinsulinemic and insulinopenic obese NIDDM as, 1315-1324
 STZ-DM as, 663-668
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) with hyperinsulinemia
 acute hyperinsulinemia and regulation of plasma HcY concentrations, 686-689
 hyperinsulinemic and insulinopenic obese NIDDM subjects as models for, 1315-1324
 insulinopenic, with obesity, Lp alterations in, 1315-1324
 parasympathetic dysfunction and hyperinsulinemia effects on hemodynamic response to isometric exercise in, 934-939
- Non-obese subjects
 glucose-6-phosphatase activity in hypothalamus of, 627-629
 Hb and Hct related to compensatory hyperinsulinemia and insulin resistance in, 831-835
 with IGT, insulin kinetics and muscle morphology in, 848-854
 Kuwaiti children, serum lipids and BP associated with fasting insulin levels in, 420-424
 LDL receptors in lipid metabolism of, 1070-1074
 with metabolic syndrome and electrocardiographic CAD, I/D polymorphism of ACE gene and, 623
 NIDDM, platelet 12-LOX activity in, 259
 with PCOS, serum leptin in, 988-992
 premenopausal and postmenopausal, serum uric acid levels in, 435-438
 S₁ and hypertension in, 493-496
 stress-induced FFA release in, 1383-1390
- Nonparametric methods of input-output modeling, 1019
- Non-steady-state, glucose flux modeling in, 1024-1026
- Norepinephrine (NE; noradrenaline)
 in acute hyperinsulinemia with losartan-treated hypertension, 293
 and cortisol response to ACTH, 1254
 in obesity, *see* Norepinephrine in obesity
 plasma, *see* Plasma norepinephrine
 sex and response of, to hypoglycemia, 121-124
- Norepinephrine (NE; noradrenaline) in obesity
 stress effects on, 1387
 very-low-calorie diet effects on urinary excretion of, 594

- Normal pregnancy, first trimester of, physiological reduction of FPG in, 1140-1144
- Normal subjects
- acute and delayed single-dose IL-6 effects on thyroid function in, 1289-1293
 - apo E metabolism in, 922-928
 - beta-cell function in, 522-528
 - Ca and glucose effects on pancreatic islet Ca^{2+} -ATPase in, 185-189
 - cortisol in, *see* Normal subjects, cortisol in
 - dietary protein restriction effects, on glucose and protein metabolism in, 1145-1151
 - dietary specific sugars for serum protein enzymatic glycosylation in, 1499-1503
 - effects of fasting, sex, and GH therapy on serum leptin and *Lep* mRNA in, 1514-1519
 - G in, *see* Normal subjects, G in
 - GH in, *see* Normal subjects, GH and leptin in
 - HcY in, *see* Normal subjects, HcY in
 - hyperinsulinemia in, *see* Normal subjects, hyperinsulinemia in
 - insulin-induced release of epinephrine in, 243-249
 - LDL receptor function in, 1070-1074
 - leptin in, *see* Normal subjects, leptin in
 - leucine and glutamine kinetics in, 1429-1433
 - lipids in, *see* Normal subjects, lipids in
 - minimal model study of insulin resistance in, 508-513
 - mutations in, *see* Normal subjects, mutation(s) in
 - older, *see* Normal subjects, older
 - PAM in, 1263-1268
 - Phe hydroxylation and plasma AAAs in, 669-674
 - plasma IR VEGF in, smoking and, 27-30
 - platelet 12-LOX activity in, 257-263
 - role of glucose and glutamine in differential recovery of $^{13}\text{CO}_2$ from infused $[2\text{-}^{13}\text{C}]\text{acetate}$ versus $[1\text{-}^{13}\text{C}]\text{acetate}$ in, 549-554
 - serum 1,25(OH) $_2\text{D}_3$ in, 336-338
 - serum PON in, 598-602
 - serum and urinary TM in, 363-365
 - short-chain FA effects on rectosigmoid mucosal colonocyte brush-border enzymes in, 133-134
 - skeletal muscle energetics in, 769-776
 - SPA in, 699-705
 - TNF α role in TG and glucose metabolism disturbances in, 112-118
 - uric acid metabolism in, 929-933
 - worsening IVGTT in, independently of degree of obesity, 313-320
 - xylitol-induced increase in plasma and urinary excretion of uridine and purines in, 739-743
 - zinc supplementation effects on glucose disposal in, 792-798
 - see also* Adolescents; Children; Men; Women
- Normal subjects, cortisol in
- cortisol effects on free radical generation by MNCs, 788-791
 - nighttime and morning release of pulsatile ACTH and cortisol, 143-148
 - recurrent hypoglycemia effects on cortisol response to ACTH, 1252-1259
 - sex differences in cortisol production, 974-976
- Normal subjects, G in
- G effects on glutamine uptake and release, 713-723
 - G effects on plasma uridine, 695-698
 - G effects on renal and hepatic glutamine gluconeogenesis, 1227-1232
 - hyperglucagonemia and dietary leucine kinetics in, 497-502
- Normal subjects, GH and leptin in
- GH and prednisolone effects on EE and leptin levels in, 83-88
 - GH status, leptin levels, and RMR in, 1134-1139
 - serum insulin but not leptin associated with spontaneous or GHRH-stimulated GH secretion in, with and without weight loss, 1127-1133
- Normal subjects, HcY in
- plasma HcY related to folate status and MTHFR gene mutation, 1413-1418
 - total HcY, 915-921
 - total plasma HcY, 273-280
- Normal subjects, hyperinsulinemia in
- Hct and Hb related to insulin resistance and compensatory hyperinsulinemia, 831-835
 - hyperglycemia and hyperinsulinemia effects on satiety, 321-324
 - short-term hyperinsulinemia effects on T production in, 119-120
- Normal subjects, leptin in
- race and effects of high-fat versus low-fat diet on S_1 and leptin levels, 1520-1524
 - see also* Normal subjects, GH and leptin in
- Normal subjects, lipids in
- regular insulin versus Lispro on plasma lipid metabolism in, 371-376
 - tall oil phytosterol effects on plasma lipids in, 751-756
- Normal subjects, mutation(s) in
- G $^{994} \rightarrow$ T missense mutation of PAF acetylhydrolase gene in, as risk factor for CAD, 177-181
 - Trp 64 Arg mutation of β_3 -adrenoceptor gene, 456-460
- Normal subjects, older
- fasting plasma insulin, anthropometrics, and metabolic parameters in very old subjects, 535-540
 - relationship of aging, insulin resistance, and AT to risk factors for CV disease in, 401-408
 - see also* Men, older; Women, older
- Normoalbuminuria, IDDM with, serum laminin levels in, 64-65
- Normoponderal subjects, *see* Non-obese subjects
- Normotensive middle-aged men, stress and relationship of ACTH and cortisol with insulin and glucose in, 1440-1449
- NOS (nitric oxide synthase), insulin and production of, 1037-1039
- Nuclear factor- κB (NF- κB), linoleic acid and TNF α effects on endothelial cell, 566-572
- Numerical module of SAAM II, 485-486
- O $_2$ (oxygen) consumption, exercise and
- β -adrenoceptor blockade effects on EPOC and TG/FA cycling, 439-448
 - diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
 - see also* $\dot{V}\text{O}_{2\text{max}}$
- Oats and oat bran in diet regulating small intestinal cell turnover, 1106
- ob* gene, *see* *Lep* gene
- Obesity
- BP in, *see* Blood pressure in obesity
 - effects of, on insulin and proinsulin in nondiabetic Asian Indians, 230-233
 - effects of high-sucrose and/or HF diets on, 1354-1359
 - glucose in, *see* Glucose in obesity
 - high-fat diet-induced DM and, *see* High-fat diet-induced diabetes mellitus and obesity
 - hypertension and S_1 in, 493-496
 - hypothalamic G6Pase in, 627-629
 - insulin kinetics and muscle morphology in IGT subjects with slight, 848-854
 - with insulin resistance, leptin response to fasting in, 125-128; *see also* Leptin
 - Japanese subjects with moderate, Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 1528-1530
 - metabolic syndrome, electrocardiographic CAD, I/D polymorphism of ACE gene and, 623

Obesity (*Continued*)

- in NIDDM, *see* Obesity, NIDDM with
- stress-induced FFA release in, 1383-1390
- vagus nerve control of insulin secretion in, 1167-1173
- worsening of IVGTT in healthy subjects independently of, 313-320
- see also* Adipose tissue; Children, obese; Men, obese; Uric acid in obesity; Women, obese

Obesity, NIDDM with

- in high-monounsaturated fat diet-induced NIDDM, 724-730
- hyperinsulinemic and insulinopenic NIDDM, Lp alterations in, 1315-1324

LDL receptors, lipid metabolism and, 1070-1074

S₁, insulin action, and fibrinolysis in, 1372-1375

OCs (oral contraceptives), effects of, on FFA metabolism, 280-284

Offspring, *see* Newborns

O-GlcNAc (*O*-linked *N*-acetyl-glucosamine), insulin and GLCN effects on level of, in muscle proteins, 449-455

OGTT, *see* Oral glucose tolerance test

1,25(OH)₂D₃, *see* 1,25-Dihydroxyvitamin D₃

25-OHD, *see* 25-Hydroxyvitamin D

Oil

coconut, in obesity- and DM-inducing diet, 1090

olive, in high-monounsaturated fat diet, 725

short-term administration of tall oil phytosterol, effects of, on plasma lipids, 751-756

see also specific types of oils and fatty acids

OKG (ornithine α -ketoglutarate), enteral, effects of, on intestinal adaptation after small bowel resection, 1366-1371

Older subjects

NIDDM, Pro-Z effects on zinc, glucose, and insulin metabolism in, 39-43

see also Aging; Men, older; Very old subjects; Women, older

Oleic acid

in diet regulating apo B-containing Lps, 884

effects of diet with stearic acid and, on glucose tolerance and S₁ in healthy women, 529-534

in fat-modified diet for hypercholesterolemia, 745

in high-monounsaturated fat diet, 724-730

Olive oil in high-monounsaturated fat diet, 725

Opioid tone in hyperinsulinemia and insulin resistance in PCOS, 158-162

Optimal experimental design in compartmental modeling, 1018, 1028

Oral contraceptives (OCs), effects of, on FFA metabolism, 280-284

Oral glucose tolerance test (OGTT)

of elderly NIDDM subjects, Pro-Z effects on, 39-43

of insulin-resistant women, 70-74

of obese hypertensive middle-aged men, 1077

of PCOS subjects, 158-162

of subjects with family history of NIDDM, 523, 525

Organ weight

heart, 191

kidney, 164, 819, 822

liver, *see* Organ weight, liver

thyroid, 155

Organ weight, liver

endotoxin effects on, 683

fructose effects on, 150

in hyperinsulinemic versus insulinopenic hyperglycemia, 1317

oleic acid effects on, 726

Ornithine

endotoxin effects on, 683

in post-small bowel resection enteral diet, 1368

in trauma, 226, 227

Ornithine α -ketoglutarate (OKG), enteral, effects of, on intestinal adaptation after small bowel resection, 1366-1371

Orotic acid, effects of Triton WR 1339 and, on biliary and serum dolichols, 644-649

Orthophosphate, *see* Inorganic phosphate

Osteocalcin, serum, in ETA receptor antagonist-induced osteopenia, 1405

Osteopenia

in children, urinary collagen pyridinium cross-links and, 333-335

ETA receptor antagonist inducing, 1403-1407

in older men, vitamin K and 25-OHD levels in, 195-199

Osteoporosis in STZ-DM, xylitol effects on, 578-583

OT, *see* Oxytocin

Overweight, *see* Obesity

Oxidase, cytochrome, in ethylmalonic encephalopathy, 837

Oxidation

cytochrome P450-mediated RA, by retinoids in HNSCC cell lines, 955-958

of dietary specific sugars, 1499-1503

FA, during exercise, 442

glucose, regulation of FFA levels and, by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of UCP-1 gene in FHCL, 1397-1402

LDL, ERT effects on, 677

substrate, during exercise, diet selection and, 777-782

Oxidation-reduction (redox potential), elevated RBC, linked to galactonate synthesis, Tolrestat effects on, 1423-1428

Oxidized low-density lipoprotein (LDL), effects of ERT on antibodies against, in hypercholesterolemic postmenopausal women with CHD, 675-680

Oxygen, *see* O₂ consumption, exercise and

Oxytocin (OT)

effects of, on leptin release in adipocytes, 1457-1458

responses of AVP and, to angiotensin II type 1 receptor antagonist, in men, 893-896

P (phosphorus)

in post-small bowel resection enteral diet, 1367

see also P in osteopenia

P (phosphorus) in osteopenia

in ETA receptor antagonist-induced osteopenia, 1405

in osteopenic elderly men, 196

³¹P MRS (³¹phosphorus magnetic resonance spectroscopy), metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776

PAF (platelet-activating factor) acetylhydrolase gene, G⁹⁹⁴ \rightarrow T missense mutation in, as risk factor for CAD in Japanese men, 177-181

PAI (plasminogen activator inhibitor), and risk factor for CHD in exercising postmenopausal women, 1119

PAI-1, *see* Plasminogen activator inhibitor type 1

Palmitate

effects of, on pancreatic islets following reoxygenation injury, 810-811

OC effects on kinetics of, 282

[³H]Palmitate, GC/MS of, 707-709

Palmitic acid in regulation of apo B-containing Lps, 884

[9,10-³H]Palmitic acid in ethylmalonic encephalopathy, 837

PAM (postaggression metabolism) in healthy subjects, 1263-1268

Pancreas-kidney transplantation, whole, for IDDM, proinsulin levels after, 1325-1330

Pancreatic islets

Ca²⁺-ATPase of, in NIDDM, glucose and Ca effects on, 185-189

reoxygenation injury effects on response of, to fatty acids, 809-813

see also Beta cells

- Parameters in compartmental modeling, 1016-1019
 a posteriori identifiability and, 1016-1018
 parametric methods in input-output modeling, 1019
- Paraoxonase (PON), serum, relationship of, to NIDDM complications, 598-602
- Parasympathetic dysfunction, effects of hyperinsulinemia and, on hemodynamic response to isometric exercise in NIDDM, 934-939
- Parathyroid hormone (PTH)
 in CRF children, 265
 in gout, 337
 in prepubertal children with β -thalassemia and/or CSS, 543
- Parenteral nutrition (PN), total, effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176
- Parkinson's disease, CYP2D6 gene in, 94-96
- PCOS, *see* Polycystic ovary syndrome
- PDGF (platelet-derived growth factor), effects of, on coronary artery SMC migration, 1066
- PDH (phosphate dehydrogenase), *see* Glyceraldehyde-3-phosphate dehydrogenase
- PDI (protein disulfide isomerase), activity of, and protein contents during fasting and refeeding, 1083-1088
- Penile development in recessive Robinow syndrome, 1341
- Peptide(s)
 C-, *see* C-peptide
 effects of stimulation with glucose and GLP-1 on insulin release in NIDDM, 1042-1047
 HP228, effects of, on diabetic neuropathy, 650-656
 plasma brain natriuretic, very-low-calorie diet effects on, in obesity, 592-597
 vasoactive intestinal, NO in PRL secretion stimulated by, in men, 897-899
see also specific peptides
- Perhydro-1,4-thiazepine-3,5-dicarboxylic acid (PHTZDC) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238
- Perindopril, long-term effects of, on metabolic parameters and heart in NIDDM with hypertension, 1199-1204
- Peripheral insulin resistance induced by GH excess, troglitazone effects on, 783-787
- Peroxidase (Px), GSH, in Keshan disease, vitamin E and selenium effects on, 416
- Peroxisome proliferator-activated receptor γ (PPAR γ) gene, expression of, in SAT and VAT, 1494-1498
- PET technique in modeling of regional glucose fluxes in steady-state, 1022-1024
- PG(s) (prostaglandins), and preadipocyte differentiation, 461-466
- PGF $_{1\alpha}$ (6-keto-prostaglandin F $_{1\alpha}$), and SPA relationship to NIDDM complications, 703
- pH
 blood, HCl effects on, 164
 in CRF children, 265
 skeletal muscle, in hyperthyroidism, 771
- Phe, *see* Phenylalanine
- Phenotype, apo E, *see* Apolipoprotein E phenotype in hypercholesterolemia
- Phenylalanine (Phe)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 and G effects on glutamine uptake and release, 716, 717, 719
 reduced energy intake effects on, in obese children, 1438
 relationship between hydroxylation of, and plasma AAA concentrations, 669-674
 in trauma, 226, 227
- Phosphatase, *see* Alkaline phosphatase; ATPase; Glucose-6-phosphatase; Protein phosphatase-1; Protein phosphatase-2A
- Phosphate
 PO $_4$ in prepubertal children with β -thalassemia and/or CSS, 543, 545
 serum, in gout, 337
see also cAMP; Diphosphate; Galactose-1-phosphate; Galactose-1-phosphate uridylyltransferase deficiency; Glucose-1-phosphate; Glucose-6-phosphate; Glyceraldehyde-3-phosphate dehydrogenase; Glycerol phosphate; Inorganic phosphate; Phosphate dehydrogenase; Triphosphate
- Phosphate dehydrogenase, *see* Glyceraldehyde-3-phosphate dehydrogenase
- Phosphokinase
 creatine, in Keshan disease, vitamin E and selenium effects on, 416, 417
 serum, in Graves' disease, 1195
- Phospholipid transfer protein (PLTP) in HALP, 969
- Phospholipids (PLs)
 HRT effects on, 1224
 skeletal muscle membrane, factors affecting FA composition in, 106-112
see also Phospholipids, breast milk effects on
- Phospholipids (PLs), breast milk effects on
 and effects of formula during development, 23
 on skeletal muscle membrane PL FA composition, 106-112
- Phosphorus, *see* P; ^{31}P magnetic resonance spectroscopy
- PHTZDC (perhydro-1,4-thiazepine-3,5-dicarboxylic acid) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238
- Phylloquinone, levels of vitamin K and, in osteopenic older men, 195-199
- Physiological reduction of FPG in first trimester of normal pregnancy, 1140-1144
- Phytosterols, *see* Plant sterol(s)
- Pima Indians
 metabolic syndrome and electrocardiographic CAD in, associated with ACE gene polymorphism and plasma ACE levels, 622-626
 Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and plasma leptin in, 1525-1527
- Pioglitazone, effects of, on glucose metabolism and liver and muscle insulin uptake in subjects on high-fructose diet, 1152-1155
- Pituitary adenoma, inhibition of signal transduction by splice variant of GHRH receptor expressed in, 804-808
- Pituitary gland, *see* Hypothalamic-pituitary-adrenal axis; Hypothalamic-pituitary-testicular function; Pituitary adenoma
- PK (protein kinase), mitogen-activated, NIDDM effects on, 56
- PKW (pokeweed) mitogen, metabolic effects of, 75-82
- PL(s), *see* Phospholipids
- Plant-based diet, effects of weight loss with meat-based diet or, on SAC, plasma lipids, BP, and plasma leptin in obese women, compared, 1308-1314
- Plant sterol(s) (phytosterols), 744-756
 effects of short-term administration of tall oil, on plasma lipids, 751-756
 serum, fat-modified diet effects on concentrations of serum C precursors and, in hypercholesterolemia, 744-750
- Plant sterol 27-hydroxylase, extrahepatic, HCHF diet and activity of, 731-738
- Plasma alanine (Ala)
 endotoxin effects on, 683
 in trauma, 226
- Plasma amino acids (AAs)
 aromatic, relationship between Phe hydroxylation and concentrations of, 669-674
 endotoxin effects on, 683
see also specific amino acids

- Plasma angiotensin-converting enzyme (ACE), ACE gene polymorphism and levels of, associated with metabolic syndrome and electrocardiographic CAD in Pima Indians, 622-626
- Plasma apolipoprotein A-I (apo A-I)
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
in HALP, 968, 969
HRT effects on, 1224
in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma apolipoprotein A-I/B (apo A-I/B), HRT effects on, 1224
- Plasma apolipoprotein A-II (apo A-II) in HALP, 968, 969
- Plasma apolipoprotein B (apo B)
breast milk and/or formula effects on, during development, 22
effects of vitamin C and dietary fat regulation of apo-containing Lps on, 887-888
in HALP, 968, 969
HRT effects on, 1224
in hypercholesterolemia, *see* Plasma apolipoprotein B in hypercholesterolemia
- Plasma apolipoprotein B (apo B) in hypercholesterolemia
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma apolipoprotein E (apo E) in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma arginine (Arg)
endotoxin effects on, 683
in trauma, 226
- Plasma asparagine (Asn)
endotoxin effects on, 683
in trauma, 226
- Plasma aspartate, endotoxin effects on, 683
- Plasma brain natriuretic peptide (BNP), very-low-calorie diet effects on, in obesity, 592-597
- Plasma Ca (calcium) in elderly NIDDM subjects, Pro-Z effects on, 41
- Plasma cholesterol (C)
amiodarone effects on, 1053
breast milk and/or formula effects on, during development, 22
endotoxin effects on, 682
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
HCHF diet effects on, 733
ICV leptin effects on, 1277
in offspring of protein-malnourished subjects, 1452
short-term tall oil phytosterol administration effects on, 753-754
total, *see* Total plasma cholesterol
- Plasma cholesteryl ester transfer protein (CETP), effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 888
- Plasma corticosterone, ICV leptin effects on, 1277
- Plasma cortisol (hydrocortisone)
 β -adrenoceptor blockade effects on, 443
response of, to IM ACTH 1-24 in healthy men, 1419-1422
very-low-calorie diet effects on, in obesity, 594
- Plasma C-peptide
fibrinolysis in obese nondiabetics and in NIDDM, 1373
G effects on, in nondiabetics, 8
- Plasma creatinine
endotoxin effects on, 682
nephrectomy effects on, 356
- Plasma cysteine in trauma, 226
- Plasma endothelin-1 (ET-1), very-low-calorie diet effects on, in obesity, 592-597
- Plasma epinephrine (E; adrenaline)
GH and prednisolone effects on, 84-85
- Plasma epinephrine (E; adrenaline) (*Continued*)
OC effects on, 281-282
exercise effects on, 411, 443
- Plasma free fatty acids (FFAs; nonesterified fatty acids)
effects of lipolysis inhibition with acipimox on, in men, 1462-1467
ICV leptin effects on, 1277
in NIDDM, 250-256, 910
in offspring of protein-malnourished subjects, 1452
postexercise levels of, 411
- Plasma glucagon (G)
fasting, in prediabetic stage of NIDDM, 910
in offspring of protein-malnourished subjects, 1451
Phe hydroxylation and, 670
- Plasma glucose
and dexamethasone-induced insulin resistance, 352
effects of diet type and level of, on skeletal muscle membrane LCPUFAs in young children, 106-112
endotoxin effects on, 682
fasting, *see* Fasting plasma glucose
FFA elevation effects on, 1122
G and, *see* Plasma glucose, G and
GLCN effects on, 451
high-fat diet effects on, 1090
in hyperglycemia, 150, 322
in insulin resistance, 983
lipolysis inhibition effects on, 1465
in NIDDM, *see* Plasma glucose in NIDDM
in obesity, *see* Plasma glucose in obesity
OC effects on, 281-282
- Plasma glucose, G and
and effects of HGP activation and deactivation by G, 137-138
G effects on glucose in nondiabetics, 8
G effects on plasma uridine and, 695-696
- Plasma glucose in NIDDM
fibrinolysis in obese NIDDM subjects, 1373
in prediabetic stage of NIDDM, 910
see also Fasting plasma glucose in NIDDM
- Plasma glucose in obesity
and fibrinolysis in obese NIDDM and nondiabetic subjects, 1373
ICV methylatropine effects on, 1168-1170
- Plasma glutamate, endotoxin effects on, 683
- Plasma glutamine (Gln)
endotoxin effects on, 683
in trauma, 226
- Plasma glycerol
effects of lipolysis inhibition with acipimox on, in men, 1462-1467
ICV leptin effects on, 1277
- Plasma glycine (Gly)
endotoxin effects on, 683
in trauma, 226
- Plasma guanidino compounds, nephrectomy effects on, 358-359
- Plasma high-density lipoprotein (HDL)
breast milk and/or formula effects on, during development, 22
in IDDM, insulin Lispro and regular insulin effects on metabolism of, 373
- Plasma high-density lipoprotein-cholesterol (HDL-C)
and chronic hyperglycemia effects in STZ-DM, 949
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
in HALP, 968
in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma high-density lipoprotein₂ (HDL₂)
in IDDM, insulin Lispro and regular insulin effects on metabolism of, 373
see also Plasma high-density lipoprotein₂ in hypercholesterolemia

- Plasma high-density lipoprotein₂ (HDL₂) in hypercholesterolemia
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma high-density lipoprotein₃ (HDL₃)
in HALP, 968-969
in IDDM, insulin Lispro and regular insulin effects on metabolism of, 373
see also Plasma high-density lipoprotein₃ in hypercholesterolemia
- Plasma high-density lipoprotein₃ (HDL₃) in hypercholesterolemia
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma high-density lipoprotein₃-cholesterol (HDL₃-C) in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma histidine (His)
endotoxin effects on, 683
in trauma, 226
- Plasma homocysteine (HcY)
acute hyperinsulinemia regulating concentrations of, in nondiabetic subjects but not in NIDDM, 686-689
in healthy subjects, levels of, related to folate status and MTHFR gene mutation, 1413-1418
see also Total plasma homocysteine
- Plasma β (beta)-hydroxybutyrate (BOHB)
ICV leptin effects on, 1277
in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
- Plasma 27-hydroxycholesterol, protein level and, 733-734
- Plasma hypoxanthine
bucladesine sodium effects on concentrations of, 1005-1008
glucagon effects on, 696
xylitol effects on concentrations of, 739-743
- Plasma immunoreactive vascular endothelial growth factor (IR-VEGF), smoking relation to concentration of, 27-30
- Plasma inorganic phosphate
glucagon effects on concentrations of, 696, 697
xylitol effects on, 742
- Plasma insulin
 β -adrenoceptor blockade effects on, 443
and dexamethasone-induced insulin resistance, 352
effects of lipolysis inhibition on, 1465
effects of weight loss with meat-based or plant-based diet on, 1311
in exercise, *see* Plasma insulin in exercise
fasting, *see* Fasting plasma insulin
FFA elevation effects on, 1122
and fibrinolysis in obese nondiabetics, 1373
G and, in nondiabetics, 8
high-fat diet effects on, 1090
hyperglucagonemia effects on, 499
in hyperinsulinemia, 322
ICV leptin effects on, 1277
in NIDDM *see* Plasma insulin in NIDDM
NO-1886 effects on, in hypertriglyceridemia, 150
in offspring of protein-malnourished subjects, 1451
Phe hydroxylation and, 670
in STZ-DM, plasma leptin, *Lep* mRNA and, 604-606
- Plasma insulin in exercise
arterial, glucose and AA infusion effects on, 1305, 1306
and liver 3-FDG uptake, 46
muscle glucose uptake and conversion to glycogen and, 411
- Plasma insulin in NIDDM
fibrinolysis and, 1373
- Plasma insulin in NIDDM (*Continued*)
in prediabetic stage of NIDDM, 910
see also Fasting plasma insulin in NIDDM
- Plasma insulin-like growth factor-I (IGF-I), diet and concentrations of, 1107
- Plasma intermediate-density lipoprotein-cholesterol (IDL-C), ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- Plasma isoleucine (Ile)
endotoxin effects on, 683
in trauma, 226
- Plasma K (potassium), effects of lipolysis inhibition on, 1465
- Plasma ketones, total, in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
- Plasma lactate
effects of lipolysis inhibition on, 1465
in ethylmalonic encephalopathy, 837
fasting, in prediabetic stage of NIDDM, 910
ICV leptin effects on, 1277
postexercise levels of, 411
- Plasma lactic acid, xylitol effects on, 741
- Plasma lecithin:cholesterol acyltransferase (LCAT), effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 888
- Plasma leptin
Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, in Pima Indians, 1525-1527
see also Plasma leptin in STZ-DM, insulin and; Puberty, plasma leptin and; Women, plasma leptin in
- Plasma leptin in STZ-DM, insulin and
food intake and insulin-dependent increase in *Lep* mRNA and, 603-607
in insulin-treated and untreated STZ-DM and in nondiabetics, 584-591
- Plasma leucine (Leu)
effects of dietary protein restriction in NIDDM on, 1147
endotoxin effects on, 683
in trauma, 226
- Plasma lipids
combined HRT effects on, 1222-1226
effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 887-888
ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 676-677
gemfibrozil effects on, 236
in obese women, effects of weight loss with meat-based or plant-based diet on SAC, BP, plasma leptin and, 1308-1314
short-term tall oil phytosterol administration effects on, 751-756
see also specific lipids
- Plasma lipoprotein (Lp)
combined HRT effects on, 1222-1226
plasma 27-hydroxycholesterol, sterol 27-hydroxylase and, 734
in severe heterozygous FH, long-term effects of LDL apheresis on CHD and, in native vessels and coronary bypass, 863-868
short-term tall oil phytosterol administration effects on, 753-754
- Plasma lipoprotein(a) [Lp(a)] in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma lipoprotein A-I (LpA-I) in HALP, 968-970
- Plasma lipoprotein A-I:A-II (LpA-I:A-II) in HALP, 968-970
- Plasma low-density lipoprotein-cholesterol (LDL-C)
in HALP, 968
HRT effects on, 1224
in hypercholesterolemia, *see* Plasma low-density lipoprotein-cholesterol in hypercholesterolemia

- Plasma low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia (*Continued*)
- Plasma low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia
- in hypercholesterolemic postmenopausal women with CHD, effects of ERT on, 677
 - in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma lysine (Lys)
- endotoxin effects on, 683
 - in trauma, 226
- Plasma methionine (Met)
- endotoxin effects on, 683
 - in trauma, 226
- Plasma Mg (magnesium)
- in elderly NIDDM subjects, Pro-Z effects on, 41
 - Mg supplementation effects on, 905-906
- Plasma norepinephrine (NE; noradrenaline)
- GH and prednisolone effects on, 84-85
 - OC effects on, 281-282
 - postexercise levels of, 411, 443
- Plasma ornithine
- endotoxin effects on, 683
 - in trauma, 226
- Plasma phenylalanine (Phe)
- endotoxin effects on, 683
 - in trauma, 226
- Plasma plasminogen activator inhibitor type 1 (PAI-1)
- effects of low-fat, high-fiber diet and exercise on, in subjects with multiple CV disease risk factors, 384-390
 - in very old syndrome X subjects, 535-540
- Plasma postheparin lipoprotein lipase (LPL) in IDDM, effects of insulin
- Lispro versus regular insulin on activity of, 373
- Plasma proline (Pro) in trauma, 226
- Plasma pyruvate
- in ethylmalonic encephalopathy, 837
 - fasting, in prediabetic stage of NIDDM, 910
- Plasma pyruvic acid, xylitol effects on, 741
- Plasma renin activity (PRA), perindopril effects on, in NIDDM with hypertension, 1202
- Plasma serine (Ser)
- endotoxin effects on, 683
 - in trauma, 226
- Plasma taurine
- endotoxin effects on, 683
 - in trauma, 226
- Plasma threonine (Thr)
- endotoxin effects on, 683
 - in trauma, 226
- Plasma triacylglycerol (TAG), effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 887
- Plasma triglycerides (TGs)
- breast milk and/or formula effects on, during development, 22
 - chronic hyperglycemia effects on, in STZ-DM, 949
 - endotoxin effects on, 682
 - fasting, *see* Fasting plasma triglycerides
 - FFA elevation effects on, 1122
 - HRT effects on, 1224
 - in hypercholesterolemia, *see* Plasma triglycerides in hypercholesterolemia
 - ICV leptin effects on, 1277
 - in NIDDM, *see* Plasma triglycerides in NIDDM
 - NO-1886 effects on, in hypertriglyceridemia, 151
 - in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- Plasma triglycerides (TGs) (*Continued*)
- in offspring of protein-malnourished subjects, 1452
 - short-term tall oil phytosterol administration effects on, 753-754
- Plasma triglycerides (TGs) in hypercholesterolemia
- in hypercholesterolemic postmenopausal women with CHD, ERT effects on, 677
 - in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- Plasma triglycerides (TGs) in NIDDM
- fasting plasma, in prediabetic stage of NIDDM, 910
 - with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- Plasma tryptophan (Trp), endotoxin effects on, 683
- Plasma tyrosine (Tyr)
- endotoxin effects on, 683
 - Phe hydroxylation and, 670, 671
 - in trauma, 226
- Plasma urea
- endotoxin effects on, 682
 - in exercise, glucose and AA effects on, 1304
 - nephrectomy effects on, 356
- Plasma urea nitrogen, very-low-calorie diet effects on, in obesity, 593
- Plasma uric acid
- bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on, 696
- Plasma uridine
- bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on concentrations of, 695-698
 - xylitol effects on concentrations of, 739-743
- Plasma valine (Val)
- endotoxin effects on, 683
 - in trauma, 226
- Plasma very-low-density lipoprotein (VLDL)
- in IDDM, insulin Lispro and regular insulin effects on metabolism of, 374
 - in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
 - in STZ-DM, chronic hyperglycemia effects on, 949
- Plasma very-low-density lipoprotein-cholesterol (VLDL-C), ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- Plasma volume, very-low-calorie diet effects on, in obesity, 593-594
- Plasma xanthine
- bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on, 696
 - xylitol effects on concentrations of, 739-743
- Plasma zinc (Zn) in cirrhosis, effects of zinc supplementation on glucose disposal in, 794
- Plasminogen activator, *see* Plasminogen activator inhibitor; Plasminogen activator inhibitor type 1; Tissue plasminogen activator
- Plasminogen activator inhibitor (PAI), and risk factor for CHD in exercising postmenopausal women, 1119
- Plasminogen activator inhibitor type 1 (PAI-1)
- in NIDDM, 624, 641
 - in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 - see also* Plasma plasminogen activator inhibitor type 1
- Plasminogen activator inhibitor type 1 (PAI-1) antigen, fibrinolysis in obese nondiabetics and in NIDDM, 1373, 1374
- Platelet(s), endotoxin effects on, 682
- Platelet-activating factor (PAF) acetylhydrolase gene, G⁹⁹⁴ → T missense mutation in, as risk factor for CAD in Japanese men, 177-181
- Platelet aggregation, spontaneous, relationship of NIDDM complications to, 699-705

- Platelet-derived growth factor (PDGF), effects of, on coronary artery SMC migration, 1066
- Platelet 12-lipoxygenase (LOX) in Japanese NIDDM subjects, 257-263
- PLTP (phospholipid transfer protein) in HALP, 969
- PN (parenteral nutrition), total, effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176
- Pokeweed (PKW) mitogen, metabolic effects of, 75-82
- Polycystic ovary syndrome (PCOS)
- insulin resistance, *see* Polycystic ovary syndrome with insulin resistance
 - morning and nighttime pulsatile ACTH and cortisol release in, 143-148
 - serum leptin in obese women with, correlated with BW and AT distribution but not with androgen and insulin levels, 988-992
- Polycystic ovary syndrome (PCOS) with insulin resistance in fibroblasts of PCOS subjects, 940-946
- and hyperinsulinemia, opioid tone in, 158-162
- Polygenic hypercholesterolemia, apo E genotype and cholesterologenesis in, 97-100
- Polymorphism
- ACE gene, *see* Angiotensin-converting enzyme gene polymorphism
 - apo E, and Lp response to lovastatin or gemfibrozil for hypercholesterolemia, 563
 - PON, serum PON activity in NIDDM and, 598-602
 - see also* Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- Polyunsaturated fatty acids (PUFAs)
- effects of exercise and, on PAI-1, 385
 - skeletal muscle membrane long-chain, in young children, 106-112
 - in stearic and oleic acid diets, 531
- n-3 and n-6 Polyunsaturated fatty acids (PUFAs), skeletal muscle membrane PL content of, in young children, 108, 109
- PON (paraoxonase), serum, relationship of, to NIDDM complications, 598-602
- Portal venous and hepatic glucose gradients, effects of positive and negative, on hepatic glucose uptake following glucose infusion in splanchnic bed of conscious subjects, 1295-1302
- Positive portal venous and hepatic glucose gradients, effects of, on hepatic glucose uptake following glucose infusion in splanchnic bed of conscious subjects, 1295-1302
- Postaggression metabolism (PAM) in healthy subjects, 1263-1268
- Postexercise O₂ (oxygen) consumption, excess, β -adrenoceptor blockade effects on TG/FA cycling and, 439-448
- Postheparin lipids, gemfibrozil effects on, 236-238
- Postheparin lipoprotein lipase (LPL), plasma, in IDDM, effects of insulin Lispro versus regular insulin on activity of, 373
- Postmenopausal women
- non-obese, serum uric acid levels in, 435-438
 - see also* Adipose tissue distribution in postmenopausal women; Estrogen replacement therapy in postmenopausal women
- Postmethionine load homocysteine (tHcy), correlation between microalbuminuria and vascular damage in NIDDM and, 915-921
- Postprandial (PP) blood glucose in IDDM and NIDDM, CFA and, 504
- Postprandial (PP) carbohydrates (CHOs), G effects of metabolism of, in nondiabetics, 7-12
- Postprandial (PP) glycemia in NIDDM subjects, hemodynamic response to handgrip test and, 935, 936
- Postprandial (PP) insulin in NIDDM subjects, hemodynamic response to handgrip test and, 935, 936
- Postprandial (PP) lipids
- gemfibrozil effects on, 236, 238
 - in IDDM, insulin Lispro versus regular insulin effects on, 374
- Potassium, *see* K
- PP, *see* entries beginning with term: Postprandial
- PP-1 (protein phosphatase-1), NIDDM effects on, 56
- PP-2A (protein phosphatase-2A), NIDDM effects on, 56
- PPAR γ (peroxisome proliferator-activated receptor γ) gene, expression of, in SAT and VAT, 1494-1498
- PRA (plasma renin activity), perindopril effects on, in NIDDM with hypertension, 1202
- Preadipocytes
- differentiation of, arachidonic acid metabolites of COX and LOX pathways in regulation of, 461-466
 - see also* Adipocytes
- Prediabetic stage of NIDDM, increased HGP production and decreased hepatic glucose uptake in, 908-914
- Prednisolone
- effects of CsA and, on renal and serum IGF-I, IGFbPs, and renal growth following unilateral nephrectomy, 817-823
 - effects of GH and, on EE and leptin levels, 83-88
- Preeclampsia, LDL and VCAM-1 in hyperlipidemia of, 1281-1288
- Pregnancy
- nondiabetic and IDDM, plasma leptin in, 840-843
 - normal, physiological reduction of FPG in first trimester of, 1140-1144
 - preeclamptic, LDL and VCAM-1 in hyperlipidemia of, 1281-1288
- Premenopausal women
- IDDM or NIDDM, DXA measuring body composition and AT in, 212-216
 - non-obese, serum uric acid levels in, 435-438
 - obese hyperinsulinemic, sex hormones in, 13-19
- Prepubertal children
- obese, *see* Prepubertal children, obese
 - plasma leptin in, 309-312
 - with β -thalassemia and/or CSS, BMD in, 541-548
 - see also* Young children
- Prepubertal children, obese
- GH bioactivity, IGF-I, IGF-II, IGFbP-1, -2, and -3 in, 1490-1493
 - Kuwaiti, association of fasting insulin with serum lipids and BP in, 420-424
- Preterm infants, urinary collagen pyridinium cross-links in osteopenic, 333-335
- Primary hypercholesterolemia
- apo E phenotype and Lp response to lovastatin or gemfibrozil for, 560-565
 - time-release niacin versus plain niacin for, compared, 1097-1104
- PRL (prolactin), NO in VIP-stimulated secretion of, in men, 897-899
- Progesterone in CETP regulation in female transgenic subjects, 1048-1051
- Proinsulin
- in IDDM after whole pancreas-kidney transplantation, 1325-1330
 - in NIDDM, 640, 1001
 - in nondiabetics, *see* Nondiabetics, proinsulin in
 - see also* Des-31,32 proinsulin; Des-32,33 proinsulin; Fasting proinsulin
- Prolactin (PRL), NO in VIP-stimulated secretion of, in men, 897-899
- Proline (Pro)
- in familial HALP and HBLP, 1164
 - in post-small bowel resection enteral diet, 1368
 - reduced energy intake effects on, in obese children, 1438
 - in trauma, 226, 227
- Promoter variant A-3826G of UCP-1 gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402
- Prone position, DEXA assessment of body composition in supine and, 1379-1382
- D,L-Propargylglycine, cystathionine, cystathionine ketamine, NAc-cysta, and PHTZDC in liver and kidney of subjects treated with, 1233-1238
- Prostaglandins (PGs), and preadipocyte differentiation, 461-466

- Prostate powder (Pro-Z), effects of, on zinc, glucose, and insulin metabolism in older NIDDM subjects, 39-43
- Protein
- HRT effects on, 1224
 - LDL receptor, amiodarone effects on expression of, 1052-1057
 - serum, dietary specific sugars for enzymatic glycosylation of, 1499-1503
 - skeletal muscle, insulin and GLcN effects on O-GlcNAc level in, 449-455
 - see also* Dietary protein; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s); Lipoprotein; Total protein; Transfer protein; Whole-body protein and specific proteins
- Protein disulfide isomerase (PDI), protein contents and activity of, during fasting and refeeding, 1083-1088
- Protein 1 gene, promoter variant A-3826G of uncoupling, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402
- Protein phosphatase-1 (PP-1), NIDDM effects on, 56
- Protein phosphatase-2A (PP-2A), NIDDM effects on, 56
- Prothrombin
- in cirrhosis, effects of zinc supplementation on, 793
 - in LT recipients, 201
- Pro-Z (prostate powder), effects of, on zinc, glucose, and insulin metabolism in older NIDDM subjects, 39-43
- Psychosocial stress, *see* Stress
- PTH, *see* Parathyroid hormone
- PTLP (phospholipid transfer protein) in HALP, 969
- Puberty
- testicular size and function during, in recessive Robinow syndrome, 1342
 - see also* Adolescents; Prepubertal children; Puberty, plasma leptin and
- Puberty, plasma leptin and
- long-term alcohol intake effects on plasma leptin at puberty, 1269-1273
 - relationship of plasma leptin level to sex, body composition, S₁, EE, and pubertal status, 309-312
- PUFAs, *see* Polyunsaturated fatty acids
- Pulsatile corticotropin (ACTH) and cortisol, nighttime and morning release of, in PCOS, 143-148
- Pulse rate, *see* Heart rate
- Purines
- effects of energy intake and, on small intestinal cell proliferation, differentiation, and apoptosis, 1105-1111
 - see also* Plasma hypoxanthine; Plasma uridine; Plasma xanthine; Uric acid; Urinary excretion, hypoxanthine; Urinary excretion, uridine; Urinary excretion, xanthine
- Putrescine in post-small bowel resection enteral diet, 1368
- Px (peroxidase), GSH, in Keshan disease, vitamin E and selenium effects on, 416
- Pyridinium cross-links, collagen, in osteopenic preterm infants, urinary excretion of, 333-335
- Pyridostigmine
- effects of, on TSH response to TRH in endogenous depression and subclinical thyrotoxicosis, 50-53
 - naloxone effects on GH response to melatonin and, in men, 814-818
- Pyruvate
- in PAM, 1265
 - plasma, *see* Plasma pyruvate
 - Tolrestat effects on levels on, 1426
- Pyruvate carboxylase in ethylmalonic encephalopathy, 837
- Pyruvate dehydrogenase in ethylmalonic encephalopathy, 837
- Pyruvic acid
- glucagon effects on concentrations of, 696, 697
 - xylitol effects on, 741, 742
- RA, *see* All-trans-retinoic acid; All-trans-retinoic acid receptors
- Race and ethnicity
- Asian Indian subjects, *see* Asian Indians
 - and distribution of serum LpA-I and LpA-I:A-II in children, 757-763
 - and effects of HF versus LF diets on S₁ and serum leptin in women, 1520-1524
 - HDL-C and *see* High-density lipoprotein-cholesterol, race, sex and insulin resistance and, *see* Insulin resistance, race and
 - Jamaican women, hyperglycemia and BMI associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 617-621
 - Japanese subjects, *see* Japanese subjects
 - Pima Indians, *see* Pima Indians
 - serum lipids and BP associated with fasting insulin levels in obese and non-obese Kuwaiti children, 420-424
 - of young children of NIDDM parents, 998-1004
- Rapamycin-sensitive pathways, insulin regulation of LPL activity in adipocytes via, 555-559
- RBCs, *see* Red blood cell(s)
- Recessive Robinow syndrome, endocrine functions with, 1337-1343
- Recirculation, effects of ischemia followed by, on GSH level in retina of STZ-DM subjects, 269-272
- Recombinant human growth hormone, *see* Growth hormone
- Recombinant human insulin-like growth factor-I, *see* Insulin-like growth factor-I
- Rectosigmoid mucosal colonocyte brush-border enzymes, SCFA effects on, 133-134
- Recurrent hypoglycemia, effects of, on cortisol response to ACTH in normal subjects, 1252-1259
- Red blood cell(s) (RBCs)
- elevated redox potential of, linked to galactonate synthesis, Tolrestat effects on, 1423-1428
 - of women on levothyroxine therapy following total thyroidectomy for Graves' disease, Na⁺, K⁺ ATPase activity in, 1194-1198
 - see also* Red blood cell count; Red blood cell folate
- Red blood cell (RBC) count, endotoxin effects on, 682
- Red blood cell (RBC) folate, MTHFR gene mutation and, 1415, 1417
- Redox potential, elevated RBC, linked to galactonate synthesis, Tolrestat effects on, 1423-1428
- Reductase, *see* Cytochrome C reductase; HMG-CoA reductase; Methylenetetrahydrofolate reductase gene mutation; NADH-cytochrome C reductase
- Refeeding, activity of PDI during fasting and, protein contents and, 1083-1088
- Regional adipose tissue distribution, *see* Adipose tissue distribution
- Regional blood flow in exercise, glucose and AA infusion effects on, 1305, 1306
- Regional glucose fluxes in steady-state, modeling of, 1021-1022
- Renal blood flow, glucagon effects on, 1228
- Renal failure
- biochemical changes due to nephrectomy for, 355-361
 - children with chronic, excessive dietary protein and suboptimal caloric intake effects on growth of, before and during GH therapy, 264-268
- Renal glutamine, glucagon effects on gluconeogenesis of, in normal subjects, 1227-1232
- Renal growth following unilateral nephrectomy, effects of immunosuppression on, 817-823
- Renal insulin-like growth factor (IGF-I), effects of immunosuppression on, following unilateral nephrectomy, 817-823
- Renal insulin-like growth factor-binding proteins (IGFBPs), effects of immunosuppression on, following unilateral nephrectomy, 817-823
- Renal N (nitrogen), HCl effects on metabolism of, 163-167

- Renal transplantation, whole pancreas and, for IDDM, proinsulin levels after, 1325-1330
- Renal water channel, urinary aquaporin-2 excretion and expression of, in newborns, 1344-1347
- Renin-aldosterone system, very-low-calorie diet effects on, in obesity, 593-594
- Renin in IDDM, urinary ET-1 and, 1409, 1410
- Reoxygenation injury, effects of, on pancreatic islet response to FAs, 809-813
- Reproductive function, neonatal insulin treatment effects on, 857
- Resection, small bowel, enteral OKG effects on intestinal adaptation after, 1366-1371
- Respiratory gas exchange, NO-1886 effects on, in hypertriglyceridemia, 151
- Resting metabolic rate (RMR)
in healthy adults, GH status, leptin levels and, 1134-1139
in NIDDM, effects of dietary protein restriction and, 1147
- Resting O₂ (oxygen) uptake, β -adrenoceptor blockade effects on, 444-445
- Resting skeletal muscle, metabolic efficiency of, in hyperthyroidism measured with ³¹P MRS, 771, 773
- Retarded learning, abnormal cholesterol synthesis and, 878-882
- Retina
GSH levels in, in STZ-DM, effects of ischemia followed by recirculation on, 269-272
IGF-I mRNA, IGF-IR mRNA, and IGFBP-2 and -3 mRNA in, under hypoxic conditions, 1331-1336
- Retinoic acid, *see* All-trans-retinoic acid; All-trans-retinoic acid receptors
- Retinoids, cytochrome P450-mediated RA oxidation by, in HNSCC cell lines, 955-958
- Retinol (vitamin A), response to sucrose and deficiency in, 1-2
- Retinopathy, *see* Diabetic retinopathy
- Reversal of high-fat diet-induced obesity and DM, 1089-1096
- rhGH (recombinant human growth hormone), *see* Growth hormone
- rhIGF-I (recombinant human insulin-like growth factor-I), *see* Insulin-like growth factor-I
- Ribonucleic acid, *see* mRNA
- Risk factors for CHD
metabolic disturbances of glucose and TG predisposing to CHD, TNF α role in, 113-118
in NIDDM, 1260
see also Risk factors for CHD in women
- Risk factors for CHD in women
low glycemic diet effects on, 1245-1251
in postmenopausal exercising women, AT as, 1112-1120
- Risk factors for CV disease
and aging relationship to insulin resistance and body composition, 401-408
for CAD in Japanese men, G⁹⁹⁴ \rightarrow T missense mutation in PAF acetylhydrolase gene as, 177-181
multiple, effects of low-fat, high-fiber diet and exercise in subjects with, 384-390
in NIDDM, effects of insulin versus sulfonylurea therapy on, 637-643
see also Risk factors for CHD
- RMR, *see* Resting metabolic rate
- RNA (ribonucleic acid), *see* mRNA
- Robinow syndrome, recessive, endocrine functions with, 1337-1343
- S, *see* Sucrose
- S_i, *see* Insulin sensitivity
- 18S RNA (ribonucleic acid), hormonal regulation of *Lep* mRNA, leptin release and, in adipocytes of hypothyroidic subjects, 1455-1461
- SAAM (Simulation, Analysis, and Modeling) II software, 484-492
- SAC (systemic arterial compliance), weight loss with meat-based or plant-based diet effects on BP, plasma leptin, and plasma lipids in women, compared, 1308-1314
- Safety of niacin and Niaspan, 1101-1102
- SAT, *see* Subcutaneous adipose tissue
- Satiety, hyperglycemia and hyperinsulinemia effects on, 321-324
- Saturated fatty acids (SFAs)
effects of exercise and, on PAI-1 activity, 385
in skeletal muscle membrane PLs of young children, 108, 109
in stearic and oleic acid diets, 531
- SBP (systolic blood pressure), *see* Blood pressure
- SCC (squamous cell carcinoma) cell lines, head and neck, cytochrome P450-mediated RA oxidation by retinoids in, 955-958
- SCFAs (short-chain fatty acids), effects of, on rectosigmoid mucosal colonocyte brush-border enzymes, 133-134
- SCI (spinal cord injury), acute, serum lipids following, 367-370
- Sedentary subjects, glucose effectiveness in, measured with IVGTT, 874-877
- Selenium, effects of vitamin E and, on Keshan disease-induced beta-cell alterations, 415-419
- Semistarvation of obese subjects, effects of, on vasoactive and volume regulatory hormones, and BP in, 592-597
- Serine (Ser)
endotoxin effects on, 683, 684
in familial HALP and HBLP, 1164
reduced energy intake effects on, in obese children, 1438
in trauma, 226, 227
- Serum alanine aminotransferase (SGPT)
in hypoglycemia, 1471-1476
niacin and Niaspan effects on, 1101
- Serum alkaline phosphatase (ALP) in CRF children, 265
- Serum apolipoprotein(s) (apo)
in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
see also specific apolipoproteins
- Serum apolipoprotein A-I (apo A-I), menopausal status and exercise effects on, 378, 379
- Serum apolipoprotein B (apo B)
in hyperlipidemia of preeclampsia, 1284
menopausal status and exercise effects on, 378, 379
- Serum aspartate aminotransferase (SGOT)
in hypoglycemia, 1471-1476
niacin and Niaspan effects on, 1101
- Serum Ca (calcium)
in ETA receptor antagonist-induced osteopenia, 1405
in gout, 337
- Serum cholesterol (C)
CHD, Lp(a) levels and, 183
in hypercholesterolemia, fat-modified diet effects on concentrations of serum phytosterols and precursors of, 744-750
nicotine effects on, 155, 156
in obese NIDDM subjects, LDL receptors and metabolism of, 1071
see also Serum high-density lipoprotein-cholesterol; Serum low-density lipoprotein-cholesterol; Total serum cholesterol
- Serum cobalamin in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
- Serum C-peptide (connecting peptide)
in IDDM, fasting, and insulin secretion and mode of therapy associated with leptin and AT, 1394
see also Serum C-peptide in NIDDM
- Serum C-peptide (connecting peptide) in NIDDM
acipimox effects on, 253
fasting, and insulin secretion and mode of therapy associated with leptin and AT, 1394
- Serum creatine kinase (CK) in hypoglycemia, 1471-1476

- Serum creatinine
 in DM, blood and urine AGE products and, 1349
 in gout, 337
 in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
 in IDDM, *see* Serum creatinine in IDDM
 VAT accumulation effects on, in obese men, 930
- Serum creatinine in IDDM
 and proinsulin levels following whole pancreas-kidney transplantation, 1326, 1328
 urinary ET-1 and, 1409, 1410
- Serum cytokines, level of, in burn injury, 612
- Serum 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃] in gout, 336-338
- Serum dolichols, effects of Triton WR 1339 and orotic acid on, 644-649
- Serum folate in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
- Serum free fatty acids (FFAs)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 in hyperlipidemia of preeclampsia, 1284
- Serum glucose, fasting, perindopril effects on, in NIDDM with hypertension, 1202
- Serum glutamate pyruvate transaminase, *see* Alanine aminotransferase
- Serum glutamic-oxaloacetic transaminase, *see* Aspartate aminotransferase
- Serum glycoprotein(s) (GPs), incorporation of dietary specific sugars into, 1501-1502
- Serum high-density lipoprotein (HDL) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
- Serum high-density lipoprotein-cholesterol (HDL-C)
 following acute SCI, 367-370
 in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 menopausal status and exercise effects on, 378, 379
 VAT accumulation effects on, in obese men, 930
- Serum high-density lipoprotein₂ (HDL₂), menopausal status and exercise effects on, 378, 379
- Serum high-density lipoprotein₃ (HDL₃), menopausal status and exercise effects on, 378, 379
- Serum insulin
 fasting, perindopril effects on, in NIDDM with hypertension, 1202
 in GH deficiency, 1517
 but not leptin in association with spontaneous and GHRH-stimulated GH secretion in normal subjects with and without weight loss, 1127-1133
 in STZ-DM, glielazide effects on, 978, 979
- Serum insulin-like growth factor(s) (IGF) in hepatic failure following LT, 200-206
- Serum insulin-like growth factor-I (IGF-I)
 GH response to clonidine and, in recessive Robinow syndrome, 1337-1343
 immunosuppression effects on, following unilateral nephrectomy, 817-823
- Serum insulin-like growth factor-binding proteins (IGFBPs)
 in hepatic failure following LT, 200-206
 immunosuppression effects on, following unilateral nephrectomy, 817-823
- Serum K (potassium) in Graves' disease, 1195
- Serum lactate dehydrogenase (LDH) in hypoglycemia, 1471-1476
- Serum laminin in IDDM with and without microangiopathy, levels and molecular size of, 63-69
- Serum leptin
 effects of fasting, sex, and GH therapy on, in GH-deficient and healthy adults, 1514-1519
 insulin secretion and therapy mode association with AT and, in IDDM and NIDDM, 1391-1396
- Serum leptin (*Continued*)
 restricted caloric intake effects on, 429-434
 in women, *see* Women, serum leptin in
- Serum lipids
 BP and, associated with fasting insulin levels in obese and non-obese Kuwaiti children, 420-424
 following acute SCI, 367-370
 hypercholesterolemia-inducing diet effects on, 304
 in IDDM, leptin correlation with, 1392
 menopausal status and exercise effects on intravascular enzymes related to transport of, 377-383
 in NIDDM, *see* Serum lipids in NIDDM
 and Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457-458
see also specific lipids
- Serum lipids in NIDDM
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 leptin correlation with, 1392
- Serum lipoprotein (Lp)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
see also specific serum lipoproteins
- Serum lipoprotein(a) [Lp(a)], menopausal status and exercise effects on, 378, 379
- Serum lipoprotein A-I (LpA-I), race and distribution of, in children, 757-763
- Serum lipoprotein A-I:A-II (LpA-I:A-II), race and distribution of, in children, 757-763
- Serum low-density lipoprotein (LDL) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
- Serum low-density lipoprotein-cholesterol (LDL-C)
 following acute SCI, 367-370
 in hyperlipidemia of preeclampsia, 1284
 menopausal status and exercise effect on, 378, 379
- Serum Na (sodium) in Graves' disease, 1195
- Serum osteocalcin in ETA receptor antagonist-induced osteopenia, 1405
- Serum P (phosphorus) in ETA receptor antagonist-induced osteopenia, 1405
- Serum paraoxonase (PON), relationship of, to NIDDM complications, 598-602
- Serum phosphate in gout, 337
- Serum phosphokinase in Graves' disease, 1195
- Serum phytosterols (plant sterols), fat-modified diet effects on concentrations of serum C precursors and, in hypercholesterolemia, 744-750
- Serum protein, enzymatic glycosylation of, dietary specific sugars for, 1499-1503
- Serum thrombomodulin (TM) in NIDDM, as marker for vascular endothelial injury, 362-365
- Serum thyroxine (T₄)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
- Serum triglycerides (TGs)
 in hyperlipidemia of preeclampsia, 1284
 in IDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 menopausal status and exercise effects on, 378, 379
 in NIDDM, *see* Serum triglycerides in NIDDM
 VAT accumulation effects, in obese men, 930, 931
- Serum triglycerides (TGs) in NIDDM
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 and insulin secretion and mode of therapy associated with leptin and AT, 1394
- Serum triiodothyronine (T₃)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317

- Serum triiodothyronine (T_3) (*Continued*)
 in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
- Serum tumor necrosis factor α ($TNF\alpha$), gliclazide effects on LPS-induced enhanced activity of, in STZ-DM, 978-979
- Serum urea, HCl effects on, 164
- Serum uric acid
 in gout, 337
 in non-obese premenopausal and postmenopausal women, 435-438
 VAT accumulation effects on, in obese men, 930
- Serum very-low-density lipoprotein (VLDL) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
- Severe familial hypercholesterolemia, *see* Apheresis, LDL, in FH
- Severe hyperprolactinemia, bone loss due to estrogen deficiency and, 426
- Sex
 and adrenal catecholamine response to hypoglycemia, 121-124
 body composition, *see* Sex, body composition and
 of celiac disease patients, 1430
 of CHD subjects, plasma total HcY and, 274
 of cirrhotic subjects, 793
 and cortisol, *see* Sex, cortisol and
 and dietary specific sugars for serum protein enzymatic glycosylation, 1500
 of DM subjects, blood and urine AGE products and, 1349; *see also* Sex of IDDM subjects; Sex of NIDDM subjects
 effects of fasting, GH therapy and, on serum leptin and *Lep* mRNA in GH-deficient and healthy adults, 1514-1519
 of endogenous depression subjects, 51
 of familial HALP and HBLP subjects, 1162
 and family history of NIDDM, 523
 fasting insulin levels, BP, serum lipids and, 422
 and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398
 of HALP subjects, 968
 of hypercholesterolemic subjects, *see* Sex of hypercholesterolemic subjects
 of hyperthyroidic and hypothyroidic subjects, 90, 91
 of hypertriglyceridemic subjects, 236
 of IGT subjects, insulin kinetics, muscle morphology and, 850
 of nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 of obese subjects, *see* Sex of obese subjects
 race and, *see* Sex, race and
 and RMR, 1135
 of Robinow syndrome patients, 1341
 of subjects with multiple CV disease risk factors, diet and exercise effects on, 386, 387
 Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526
 of young children of NIDDM parents, 999
see also Men; Women
- Sex, body composition and
 insulin resistance and, 402, 404, 406
 relationship of plasma leptin in children to puberty, S_i , EE, and body composition, 309-312
- Sex, cortisol and
 cortisol response to ACTH, 1253
 and differences in cortisol production, 974-976
- Sex, race and
 and distribution of serum LpA-I and LpA-I:A-II, 758-761
 of nondiabetics, relationship between Lps and insulin resistance and, 1176, 1177
see also High-density lipoprotein-cholesterol, race, sex and
- Sex hormone(s)
 effects of, on C7H mRNA, 391-395
 hyperinsulinemia and, in obese premenopausal women, 13-19
 race and, in adolescent males, HDL-C and TG level and, 514-521
see also Sex steroids and specific sex hormones
- Sex hormone-binding globulin (SHBG) in women
 in hyperinsulinemic obese premenopausal women, 13-19
 insulin resistance, race and, 70-74
 with PCOS, 159, 990
- Sex of hypercholesterolemic subjects
 efficacy of plain niacin versus Niaspan and, 1099
 fat-modified diet effects on serum cholesterol and plant sterol concentrations and, 745
 with FH, LDL apheresis and, 1059
 polygenic hypercholesterolemic subjects, 98
 primary hypercholesterolemic subjects, 561
 with severe heterozygous FH and, 864, 866
- Sex of IDDM subjects
 CFA relationship to microangiopathy, neuropathy and, 503-507
 and proinsulin levels following whole pancreas-kidney transplantation, 1326
 and urinary ET-1 excretion, 1409
- Sex of NIDDM subjects
 acipimox effects and, 251
 CFA relationship to hypertension, microangiopathy, neuropathy and, 503-507
 and GSH effects on glucose metabolism in NIDDM, 994
 hemodynamic response to handgrip test and, 935, 936
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 and mode of therapy associated with leptin and AT, 1394, 1395
 obese, S_i , insulin action, fibrinolysis and, 1372-1375
 platelet 12-LOX activity and, 259, 260
 serum PON activity and, 599
 SPA relationship to NIDDM complications and, 701-703
 Trp 64 Arg mutation of β_3 -adrenoceptor gene and, 457
- Sex of obese subjects
 of healthy elderly subjects, IVGTT and, 314, 315, 317
 with NIDDM, S_i , insulin action, fibrinolysis and, 1372-1375
 prepubertal, GH bioactivity and, 1491
- Sex steroids
 regulating CETP in female transgenic subjects, 1048-1051
see also specific sex steroids
- SFAs, *see* Saturated fatty acids
- SGOT, *see* Serum aspartate aminotransferase
- SGPT, *see* Serum alanine aminotransferase
- SHBG, *see* Sex hormone-binding globulin in women
- Short-chain fatty acids (SCFAs), effects of, on rectosigmoid mucosal colonocyte brush-border enzymes, 133-134
- Short stature, constitutional, BMD in prepubertal children with, 541-548
- Short-term estrogen-progestin replacement therapy in postmenopausal women, LCAT during, 297-300
- Short-term hyperinsulinemia, effects of, on T production in healthy men, 119-120
- Short-term tall oil phytosterol administration, effects of, on plasma lipids, 751-756
- Side effects, *see* Adverse effects
- Signal transduction, inhibition of, by splice variant of GHRH receptor expressed in pituitary adenoma, 804-808
- Simulation, Analysis, and Modeling (SAAM) II software, 484-492
- Simulation studies, 478-492
 of LDL apo B metabolism following apheresis, 478-483
 with SAAM II software, 484-492
see also Systems model

- Single-dose interleukin-6 (IL-6), acute and delayed effects of, on thyroid function in healthy subjects, 1289-1293
- Sitosterol, relationship of, to apo E phenotype in hypercholesterolemia, 747
- 16:0, *see* Palmitic acid; [9,10-³H]Palmitic acid
- Skeletal muscle
- in hyperthyroidism, ³¹P MRS measuring metabolic efficiency of, 769-776
 - in NIDDM, IR isoform mRNA in, 129-132
 - verapamil and captopril effects in, 982-987
 - see also* Skeletal muscle cell surface; Skeletal muscle membrane phospholipids; Skeletal muscle proteins
- Skeletal muscle cell surface, insulin-stimulated GLUT4 recruitment to, dexamethasone effects on, 3-6
- Skeletal muscle membrane phospholipids (PLs), factors affecting FA composition in, in young children, 106-112
- Skeletal muscle proteins, insulin and GLcN effects on *O*-GlcNAc level in, 449-455
- Skim milk in diet regulating small intestinal cell turnover, 1106
- Small intestine (small bowel)
- effects of energy intake and purines on cell proliferation, cell differentiation, and apoptosis in, 1105-1111
 - enteral OKG effects on intestinal adaptation after resection of, 1366-1371
 - of protein-depleted subjects, effects of dietary protein and TNF on IGF-I pathway components in, 345-350
- SMCs (smooth muscle cells), coronary artery, heparin effects on migration of, 1065-1069
- Smoking
- CHD and, *see* Smoking, CHD and
 - effects of, on thyroid function, 154-157
 - ERT efficacy and, 677-678
 - and hyperinsulinemia, plasma HcY concentrations and, 687
 - maternal, and FPG reduction in pregnancy, 1141
 - by non-obese postmenopausal women, serum uric acid levels and, 437
 - by premenopausal women, 16, 437
 - and primary hypercholesterolemia, 1099
 - relationship of, to plasma IR-VEGF concentration, 27-30
 - TG-rich Lps, GPIIIa gene and, 1040-1041
- Smoking, CHD and
- Lp(a) level and, 183
 - in NIDDM, ACE gene polymorphism and, 1259, 1260
 - plasma homocysteine and, 274
 - and role of TNF α in TG and glucose metabolism, 114
- Smooth muscle cells (SMCs), coronary artery, heparin effects on migration of, 1065-1069
- Sodium, *see* Na
- Sodium bicarbonate (NaHCO₃) in obesity- and DM-inducing diet, 1090
- Somatoliberin in PAM, 1264
- South Asians, *see* Asian Indians
- Soybean oil
- in diet regulating small intestinal cell turnover, 1106
 - in obesity- and DM-inducing diet, 1090
- SPA (spontaneous platelet aggregation), relationship of NIDDM complications to, 699-705
- Spectrometry, gas chromatography and mass, of metabolic tracers, 706-712
- Spectroscopy, ³¹P MRS, metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776
- Spermidine, effects of, on protein utilization in trauma and injury, 223-229
- Spinal cord injury (SCI), acute, serum lipids following, 367-370
- Splanchnic bed of conscious subjects, effects of positive and negative portal venous and hepatic glucose gradients on hepatic glucose uptake following glucose infusion in, 1295-1302
- Splice variant of GHRH receptor expressed in pituitary adenoma, signal transduction inhibited by, 804-808
- Spontaneous platelet aggregation (SPA), relationship of NIDDM complications to, 699-705
- Squalene, relationship of, to apo E phenotype in hypercholesterolemia, 747
- Squamous cell carcinoma (SCC) cell lines, head and neck, cytochrome P450-mediated RA oxidation by retinoids in, 955-958
- Starch
- in high-monounsaturated fat diet, 725
 - in NIDDM diet, 664
- Starvation, effects of semistarvation on vasoactive and volume regulatory hormones, and BP in obese subjects, 592-597
- Steady-state, modeling of glucose fluxes in, 1020-1024
- Stearic acid
- effects of oleic acid and, on glucose tolerance and S_i in healthy women, 529-534
 - in regulation of apo B-containing Lps, 884
- Steroids, *see specific steroids; for example:* Sex steroids
- Sterol(s), *see* Plant sterol(s); Plant sterol 27-hydroxylase and *specific sterols*
- Strenuous (endurance) exercise, IVGTT measuring, glucose effectiveness in, 190-194, 874-877
- Streptozotocin-induced diabetes mellitus (STZ-DM)
- chronic hyperglycemia effects on arterial LDL metabolism and atherosclerosis in, 947-954
 - continuous glucose monitoring with ECU in, 799-803
 - diabetic neuropathy in, inhibited by gliclazide irrespective of blood glucose levels, 977-981
 - as model of NIDDM pathology, 663-668
 - plasma leptin, *see* Plasma leptin in STZ-DM, insulin and retinal GSH levels in, 269-272
 - xylitol supplementation effects on osteoporosis in, 578-583
- Stress
- FFA release induced by, in obesity, 1383-1390
 - and relationship of ACTH and cortisol with insulin and glucose in middle-aged men, 1440-1449
- Structural modeling, defined, 1009
- STZ-DM, *see* Streptozotocin-induced diabetes mellitus
- Subclinical thyrotoxicosis, pyridostigmine effects on TSH response to TRH in, 50-53
- Subcutaneous adipose tissue (SAT)
- effects of HF versus LF diets on S_i and serum leptin and, in women, race and, 1521
 - insulin resistance and, 402, 404, 406
 - in obesity, *see* Subcutaneous adipose tissue in obesity
 - and RMR in healthy adults, 1135
- Subcutaneous adipose tissue (SAT) in obesity
- in obese women with PCOS, serum leptin in, 989, 990
 - PPAR γ gene expression in, 1494-1498
- Substrates
- oxidation of, during exercise, diet selection and, 777-782
 - see also specific substrates*
- Sucrose (S)
- effects of high-sucrose and HF diets on body composition, 1354-1359
 - in high-monounsaturated fat diet, 725
 - in obesity- and DM-inducing diet, 1090
 - vitamin A deficiency and response to, 1-2
- Sugars
- dietary specific, for serum protein enzymatic glycosylation, 1499-1503
 - see also specific sugars*

- Sulfonylurea, effects of NIDDM therapy with insulin versus, on cardiovascular risk factors and fibrinolysis, 637-643
- Supine position, DEXA assessment of body composition in prone and, 1379-1382
- Supplementation
 daily Mg, effects of, on Mg deficiency during prolonged restriction of motor activity, 903-907
 spermidine, in trauma, effects of, on protein, 223-229
 xylitol, effects of, on osteoporosis in STZ-DM, 578-583
 zinc, effects of, on glucose disposal in cirrhosis, 792-798
- Sympathetic effects of insulin, 247
- Syndrome X, *see* Metabolic syndrome
- Synthase
 citrate, in ethylmalonic encephalopathy, 837
 cystathionine- β -, deficiency of, in homocystinuria, 207-211
 nitric oxide, insulin and production of, 1037-1039
- Systemic arterial compliance (SAC), BP, plasma leptin, and plasma lipids in women, effects of weight loss with meat-based or plant-based diet on, compared, 1308-1314
- Systemic glucose, ICV leptin effects on utilization of, in conscious subjects, 1274-1280
- Systems model, 1009-1035
 input-output modeling, 1018-1019
 validation of, 1019
 see also Compartmental modeling; Glucose system, modeling of; Insulin system, modeling of; Minimal model analysis; Simulation studies
- Systolic blood pressure, *see* Blood pressure
- T, *see* Testosterone
- T₃, *see* Triiodothyronine
- T₄, *see* Thyroxine
- T cells, PKW mitogen stimulating, 79
- TAG, *see* Triacylglycerol
- Tall oil phytosterols, effects of short-term administration of, on plasma lipids, 751-756
- Tamoxifen, effects of, on C synthesis in HepG2 cells and hepatocytes, 1504-1513
- Tanner stage of breast development with recessive Robinow syndrome, 1341, 1342
- TAT, *see* Tyrosine aminotransferase
- Taurine
 plasma, *see* Plasma taurine
 in trauma, 226, 227
- TC, *see* Total cholesterol
- Testicular function
 hypothalamic-pituitary-, effects of methanol extract of Chansu on, 1211-1216
 size and, during puberty in recessive Robinow syndrome, 1342
- Testosterone (T)
 Chansu effects on secretion of, 1213-1214
 effects of T₄ and, on hepatic 11 β -HSD1 mRNA and activity in pubertal hypothyroid male subjects, 474-478
 in men with abdominal obesity, 1189, 1190
 in osteopenic elderly men, 196
 in PCOS, 159, 941
 and plasma leptin in children, 310
 response of, to HCG in recessive Robinow syndrome, 1337-1343
 see also Testosterone in hyperinsulinemia
- Testosterone (T) in hyperinsulinemia
 in obese premenopausal women, 13-19
 short-term hyperinsulinemia effects on T production in healthy men, 119-120
- Tetrahydrobiopterin (BH₄), insulin-induced vasodilation dependent on synthesis of, 1037-1039
- Tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt; MTS), metabolic activation of beta cells and, 824-830
- TGs, *see* Triglycerides
- β (beta)-Thalassemia, BMD in prepubertal children with, 541-548
- tHcy [homocyst(e)ine], fasting and postmethionine, correlated with microalbuminuria and vascular damage in NIDDM and, 915-921
- Thermogenesis
 β_1 -adrenoceptor-mediated, in men, effects of lipolysis inhibition on, 1462-1467
 see also entries beginning with term: Energy and element: Cal-
- Threonine (Thr)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
- Thrombomodulin (TM), serum and urinary, in NIDDM, as marker for vascular endothelial injury, 362-365
- Thromboxane B₂ (TXB₂), and SPA relationship to NIDDM complications, 703
- Thyroid function
 acute and delayed effects of single-dose IL-6 on, in healthy subjects, 1289-1293
 GH and prednisolone effects on, 85, 86
 in Graves' disease, 1196
 nicotine effects on, 154-157
 see also Hyperthyroidism; Hypothyroidism
- Thyroid hormones
 effects of, on PDI, 1085
 see also Thyroxine; Triiodothyronine
- Thyroidectomy, total, for Graves' disease, Na⁺, K⁺ ATPase activity in RBCs of women on levothyroxine therapy following, 1194-1198
- Thyrotoxicosis, subclinical, pyridostigmine effects on TSH response to TRH in, 50-53
- Thyrotropin (TSH; thyroid-stimulating hormone)
 amiodarone effects on, 1053
 GH and prednisolone effects on, 86
 nicotine effects on, 155, 156
 in prepubertal children with β -thalassemia and/or CSS, 543
 pyridostigmine effects on response of, to TRH in endogenous depression and subclinical thyrotoxicosis, 50-53
- Thyrotropin-releasing hormone (TRH), pyridostigmine effects on TSH response to, in endogenous depression and subclinical thyrotoxicosis, 50-53
- Thyroxine (T₄)
 amiodarone effects on, 1053
 breast milk and/or formula effects on, during development, 22
 GH and prednisolone effects on, 86
 in Graves' disease, 1196
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 nicotine effects on, 155, 156
 and RMR in healthy adults, 1135
 serum, *see* Serum thyroxine
 see also Thyroxine in hypothyroidism
- Thyroxine (T₄) in hypothyroidism
 effects of T and, on hepatic 11 β -HSD1 mRNA and activity in pubertal hypothyroid male subjects, 474-478
 serum, plasma HcY and, 90, 91
- Time-release niacin (Niaspan), plain niacin versus, for primary hypercholesterolemia, compared, 1097-1104
- Tissue-plasminogen activator (t-PA)
 in exercising postmenopausal women, CHD and, 1119
 see also Tissue-plasminogen activator in NIDDM, fibrinolysis in

- Tissue-plasminogen activator (t-PA) in NIDDM, fibrinolysis in insulin versus sulfonylurea therapy effects on, 641 and in obese nondiabetics, 1373, 1374
- TM (thrombomodulin), serum and urinary, in NIDDM, as marker for vascular endothelial injury, 362-365
- TNF, *see* Tumor necrosis factor; Tumor necrosis factor α
- Tobacco, *see* Smoking
- α Tocopherol, *see* Vitamin E
- Tolerance to niacin and Niaspan, 1101
- Tolrestat, effects of, on elevated RBC redox potential linked to galactonate synthesis of, 1423-1428
- Total amino acids (AAs)
endotoxin effects on, 684
in exercise, glucose and AA infusion effects on, 1306
- Total bilirubin
in elderly NIDDM subjects, Pro-Z effects on, 42
in LT recipients, 201
- Total cholesterol (TC)
BP and, associated with fasting insulin levels, 421, 422
breast milk and/or formula effects on, during development, 22, 23
in FCH, *see* Total cholesterol in FCH
GH levels in women correlated with, 341, 342
in Graves' disease, 1195
in hypercholesterolemia, *see* Total cholesterol in hypercholesterolemia
in insulin resistance, *see* Total cholesterol in insulin resistance
LDL apheresis effects on, 865
menopausal status and exercise effect on, 378, 379
in NIDDM, *see* Total cholesterol in NIDDM
in nondiabetics, *see* Total cholesterol in nondiabetics
sex hormones effects on, 392
short-term tall oil phytoosterol administration effects on, 753-754
stearic and oleic acid effects on, 532
and Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457-458
in very old syndrome X subjects, 536
in young children of NIDDM parents, 999
see also Total plasma cholesterol; Total serum cholesterol
- Total cholesterol (TC) in FCH
FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene and, 1398-1400
in nondiabetic FCH, 509, 510
- Total cholesterol (TC) in hypercholesterolemia
fat-modified diet effects on, 745
in polygenic hypercholesterolemia, 98
in primary hypercholesterolemia, 562
- Total cholesterol (TC) in insulin resistance
body composition and, related to aging, CV disease risk factors and, 402, 404, 406
SHBG, race and, in insulin-resistant women, 72
- Total cholesterol (TC) in NIDDM
CHD and, 1119, 1260
insulin versus sulfonylurea therapy effects on, 641
in familial HALP and HBLP, 1162, 1163
fibrinolysis and, in obese subjects, 1373
hemodynamic response to handgrip test and, 935, 936
high-monounsaturated fat diet effects on, 726
with metabolic syndrome, I/D polymorphism of ACE gene and, 624
plasma, effects of weight loss with meat-based versus plant-based diet on, 1310
serum PON activity and, 599
and SPA relationship to NIDDM complications, 703
tHcy, microalbuminuria and, 916
see also Total serum cholesterol in NIDDM
- Total cholesterol (TC) in nondiabetics
with metabolic syndrome, 624
in nondiabetic FCH, 509, 510
in obese nondiabetics, fibrinolysis and, 1373
- Total cysteine in CHD, 276
- Total insulin-like growth factor-I (IGF-I), GH levels in women correlated with, 340
- Total parenteral nutrition (TPN), effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176
- Total plasma cholesterol (C)
in HALP, 968
HRT effects on, 1224
in middle-aged obese hypertensive men, 1079
in obese women, effects of weight loss with meat-based or plant-based diet on, 1310
in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
in STZ-DM, chronic hyperglycemia effects on, 949
- Total plasma homocysteine (HcY)
in CHD, 273-279
in hyperthyroidism and hypothyroidism, 89-93
- Total plasma ketones in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
- Total protein
blood, in elderly NIDDM subjects, Pro-Z effects on, 42
NO-1886 effects on, in Leydig cell tumor-associated cachexia, 102
in post-small bowel resection enteral diet, 1368
- Total serum cholesterol (C)
following acute SCI, 367-370
in hyperlipidemia of preeclampsia, 1284
in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
in IDDM, and mode of therapy associated with leptin and AT, 1394
in NIDDM, *see* Total serum cholesterol in NIDDM
VAT accumulation effects on, in obese men, 930, 931
- Total serum cholesterol (C) in NIDDM
acipimox effects on, 252
and mode of therapy associated with leptin and AT, 1394
- Total thyroidectomy for Graves' disease, Na^+ , K^+ ATPase activity in RBCs of women on levothyroxine therapy following, 1194-1198
- Total triglycerides (TGs)
in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
in NIDDM, effects of insulin versus sulfonylurea therapy on, 641
- t-PA, *see* Tissue plasminogen activator
- TPN (total parenteral nutrition), effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176
- Tracee model in compartmental modeling, 1012-1013
- Tracer(s)
GC/MS of, 706-712
see also entries beginning with term: Tracer and specific tracers
- Tracer compartmental model, 1013-1014
- Tracer dilution technique, multiple, in modeling of regional steady-state glucose fluxes, 1021-1022
- Tracer kinetics, 478-492
of LDL apo B metabolism following apheresis, 478-483
studies of, with SAAM II software, 484-492
- Tracer probe in systems model, 1009
- Tracer-tracee compartmental model, 1014-1015
- Training, *see* Exercise
- Transaminases, *see* Aminotransferases

- Transfer protein
 phospholipid, in HALP, 969
 see also Cholesteryl ester transfer protein
- [¹²⁵I]-Transferrin, vanadate and binding of, in adipocytes, 630-636
- Transgenic subjects, female, sex steroids regulating CETP in, 1048-1051
- Transplantation
 liver, hepatic failure following, serum IGFs and IGFbps in, 200-206
- whole pancreas-kidney, for IDDM, proinsulin levels after, 1325-1330
- Trauma and injury
 acute spinal cord, serum lipids following, 367-370
- hepatic AA transport in burn injury, 608-616
- and PAM in healthy subjects, 1263-1268
- reoxygenation, effects of, on pancreatic islet response to fatty acids, 809-813
- spermidine supplement effects on protein in, 223-229
- vascular endothelial, urinary and serum TM in NIDDM as marker for, 362-365
- TRG, *see* Troglitazone effects on insulin resistance
- TRH (thyrotropin-releasing hormone), pyridostigmine effects on TSH response to, in endogenous depression and subclinical thyrotoxicosis, 50-53
- Triacylglycerol (TAG)
 effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 886-888
- in obese women, effects of weight loss with meat-based or plant-based diet on, 1310
- Triglycerides (TGs)
 in CHD, *see* Triglycerides in CHD
- exercise and, *see* Triglycerides, exercise and
- in familial HALP and HBLP, 1162
- and family history of NIDDM, 523, 525
- fasting, *see* Fasting triglycerides
- in FCH, *see* Triglycerides in FCH
- and fibrinolysis in obese nondiabetics, 1373
- GH levels in women correlated with, 340-342
- in Graves' disease, 1195
- HDL-C levels and, in adolescent males, race and, 514-521
- hepatic, breast milk and/or formula effects on, during development, 23
- HRT effects on, 1224
- in hypercholesterolemia, *see* Triglycerides in hypercholesterolemia
- in hyperinsulinemia, *see* Triglycerides in hyperinsulinemia
- in IDDM, *see* Triglycerides in IDDM
- in insulin resistance, *see* Triglycerides in insulin resistance
- in Kuwaiti children, BP and, associated with fasting insulin levels, 421, 422
- LDL apheresis effects on, 865
- Lps rich in, smoking, GPIIIa gene and, 1040-1041
- in NIDDM, *see* Triglycerides in NIDDM
- NO-1886 effects on, in Leydig cell tumor-associated cachexia, 103
- in nondiabetics, *see* Triglycerides in nondiabetics
- in obese men, *see* Triglycerides in obese men
- OC effects on, 281
- plasma, *see* Plasma triglycerides
- race and, *see* Triglycerides, race, sex and
- serum, *see* Serum triglycerides
- and serum uric acid levels in non-obese premenopausal women, 437, 438
- sex hormones effects on, 392
- total, *see* Total triglycerides
- and Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457-458
- in very old syndrome X subjects, 536
- see also* Hypertriglyceridemia
- Triglycerides (TGs), exercise and
 β -adrenoceptor blockade effects on EPOC and TG/FA cycling, 439-448
- AT and, and CHD in postmenopausal women, 1119
- diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
- menopausal status and exercise effects on serum TGs, 378, 379; *see also* Triglycerides in postmenopausal women
- Triglycerides (TGs), race, sex and
 of nondiabetics, relationship between insulin resistance and, 1176, 1177
- and relation of LpA-I and LpA-I:A-II to, in children, 760
- Triglycerides (TGs) in CHD
 AT and, and CHD in postmenopausal women, 1119
- ERT effects on plasma, in hypercholesterolemic postmenopausal women, 677
- fasting, as risk factor for CHD, 1246
- metabolic disturbances of glucose and, predisposing to CHD, TNF α and, 113-118
- in NIDDM, 1259, 1260
- total plasma HcY and, 276
- Triglycerides (TGs) in FCH
 in nondiabetic FCH, 509-511
- total, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
- Triglycerides (TGs) in hypercholesterolemia
 ERT effects on, 677
- fat-modified diet effects on, 745
- in FH, LDL apheresis effects on, 1060
- plasma, *see* Plasma triglycerides in hypercholesterolemia
- in polygenic hypercholesterolemia, 98
- in primary hypercholesterolemia, 562
- Triglycerides (TGs) in hyperinsulinemia
 insulin resistance and, 832, 834, 835
- in obese premenopausal women, 687
- Triglycerides (TGs) in IDDM
 and CFA, 504
- Lispro effects on, 372-374
- urinary ET-1 and, 1409, 1410
- Triglycerides (TGs) in insulin resistance
 body composition and, related to aging, CV disease risk factors and, 402, 404, 406
- SHBG, race and, in insulin-resistant women, 72
- Triglycerides (TGs) in NIDDM
 acipimox effects on, 252
- CFA and, 504
- CHD and, 1259, 1260
- in elderly subjects, Pro-Z effects on, 42
- hemodynamic response to handgrip test and, 935, 936
- high-monounsaturated fat diet effects on, 726, 727
- LDL receptors and metabolism of, 1071
- plasma, *see* Plasma triglycerides in NIDDM
- with obesity, *see* Triglycerides in obese NIDDM subjects
- serum, *see* Serum triglycerides in NIDDM
- serum PON activity and, 599
- and SPA relationship to NIDDM complications, 703
- total, effects of insulin versus sulfonylurea therapy on, 641
- Triglycerides (TGs) in nondiabetics, 231
- with FCH, 509-511
- relationship between insulin resistance and, 1176, 1177
- Triglycerides (TGs) in obese men
 with abdominal obesity, 1189, 1190
- middle-aged hypertensive, 1079

- Triglycerides (TGs) in obese NIDDM subjects and fibrinolysis, 1373
in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
- Triglycerides (TGs) in postmenopausal women
ERT effects on plasma, in hypercholesterolemic postmenopausal women, 677
in exercising postmenopausal women, AT, CHD and, 1119
non-obese women, serum uric acid and, 437, 438
regional differences in adrenoceptor binding an AT cell lipolysis in obese women, 470
- Triiodothyronine (T_3)
amiodarone effects on, 1053
breast milk and/or formula effects on, during development, 22
GH and prednisolone effects on, 86
in Graves' disease, 1196
in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
nicotine effects on, 155, 156
and RMR in healthy adults, 1135
serum, *see* Serum triiodothyronine
- Triiodothyronine (T_3) receptors, effects of hypercholesterolemia-inducing diet on expression of, 301-308
- Triphosphatase, *see* ATPase
- Triphosphate, adenosine, skeletal muscle, in hyperthyroidism, 771, 774-775
- Triton WR 1339, effects of orotic acid and, on biliary and serum dolichols, 644-649
- Troglitazone (TRG; CS-045) effects on insulin resistance
on dexamethasone-induced insulin resistance, 351-354
on hepatic and peripheral insulin resistance induced by GH excess, 783-787
- Trp 64 Arg mutation of β_3 -adrenoceptor gene
hyperglycemia and BMI associated with, in Jamaican women, 617-621
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects
- Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects
with IGT, NIDDM, and insulin resistance, 456-460
moderately overweight, 1528-1530
- Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
and plasma leptin in Pima Indians, 1525-1527
and promoter variant A-3826G of UCP-1 gene in FCHL, regulation of FFA levels and glucose oxidation in, 1397-1402
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene
- Tryptophan
endotoxin effects on, 683, 684
reduced energy intake effects on, in obese children, 1438
- TSH, *see* Thyrotropin
- Tumor necrosis factor (TNF)
effects of antibodies to, on hepatic AA transport in burn injury, 612
effects of dietary protein and, on colon and small intestine IGF-I pathway components in protein-depleted subjects, 345-350
- Tumor necrosis factor α (TNF α)
effects of, on inflammatory mediators of endothelial cells, 566-572
and role of TGs and glucose metabolic disturbances in predisposition to CHD, 113-118
serum, glitazide effects on LPS-induced enhanced activity of, in STZ-DM, 978-979
- TXB2 (thromboxane B2), and SPA relationship to NIDDM complications, 703
- Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type I receptor antagonist of angiotensin II, *see* Angiotensin II type 1 receptor antagonist
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Tyrosine (Tyr)
endotoxin effects on, 683, 684
- Tyrosine (Tyr) (*Continued*)
in familial HALP and HBLP, 1164
kinetics of, 670-671
TPN deficient in, effect of, on DOPA synthesis in neural tissue and activities of, 168-176
reduced energy intake effects on, in obese children, 1438
in trauma, 226, 227
- Tyrosine aminotransferase (TAT)
and effects of tyrosine-deficient TPN on DOPA synthesis in neural tissue, 168-176
hypercholesterolemia-inducing diet effects on, 306
- UCP-1 (uncoupling protein 1) gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402
- UDP (uridine diphosphate)-linked hexosamine (and hexose), GLcN effects on, 451
- Uncoupling protein 1 (UCP-1) gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402
- Unilateral nephrectomy, effects of immunosuppression on renal and serum IGF-I, IGFBPs, and renal growth following, 817-823
- Urate production
metabolic control of, 658
sites of, 657-658
- Urea
in PAM, 1265
plasma, *see* Plasma urea
serum, HCl effects on, 164
see also [$^{15}\text{N}_2$]Urea; Urea nitrogen; Ureagenesis; Urinary excretion, urea
- [$^{15}\text{N}_2$]Urea, GC/MS of, 708
- Urea nitrogen
blood, in elderly NIDDM subjects, Pro-Z effects on, 42
plasma, very-low-calorie diet effects on, in obesity, 593
- Ureagenesis, glucose and AA effects on, before and during exercise, 1303-1307
- Uric acid
in CHF, anaerobic threshold and, 1156-1159
hyperuricemia and CHD, 657-662
see also Plasma uric acid; Serum uric acid; Uric acid in obesity; Urinary excretion, uric acid
- Uric acid in obesity
VAT accumulation effects on metabolism of, 929-933
very-low-calorie diet effects on, 593
- Uridine, *see* Plasma uridine; Urinary excretion, uridine
- Uridine diphosphate (UDP)-linked hexosamine (and hexose), GLcN effects on, 451
- Uridyltransferase, galactose-1-phosphate (GALT), deficiency in, hereditary galactosemia due to, 1423-1428
- Urinary excretion
of AGE products in DM, fluorescence assay of, 1348-1353
aquaporin-2, and renal water channel expression in newborns, 1344-1347
Ca, hyperprolactinemia effects on, 426
of collagen pyridinium cross-links in osteopenic preterm infants, 333-335
creatinine, effects of reduced energy intake on, 1437
of dopamine, E, and NE, in obesity, very-low-calorie diet effects on, 594
ET-1, in IDDM adolescents and young adults, 1408-1412
free cortisol, in AIDS patients, 690-694
of guanidino compounds, nephrectomy effects on, 358-359

Urinary excretion (*Continued*)

- Mg, effects of Mg supplementation on, 905, 906
- MVA, in polygenic hypercholesterolemia, 98
- N, in injury, spermidine effects on, 224
- Na, Cl, and inorganic phosphate, bucladesine effects on, 1007
- see also* Urinary excretion, albumin; Urinary excretion, hypoxanthine; Urinary excretion, uric acid; Urinary excretion, uridine; Urinary excretion, xanthine; Urinary excretion in NIDDM and entries ending with suffix: -uria
- Urinary excretion, albumin
 - in NIDDM, *see* Urinary excretion, albumin, in NIDDM
 - plasma IR-VEGF and, 28
 - relationship between ET-1 excretion and, in IDDM adolescents and young adults, 1408-1412
 - TM and, 363
 - see also* Microalbuminuria; Normoalbuminuria
- Urinary excretion, albumin, in NIDDM
 - CHD and, 1259, 1260
 - insulin versus sulfonylurea therapy and, 639
 - microalbuminuria and vascular damage in NIDDM, fasting and postmethionine tHcy correlated with, 915-921
- Urinary excretion, hypoxanthine
 - bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on, 696
 - xylitol-induced increase in, 739-743
- Urinary excretion, urea
 - in exercise, glucose and AA effects on, 1304
 - in injury, spermidine effects on, 224
- Urinary excretion, uric acid
 - bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on, 696
- Urinary excretion, uridine
 - bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on, 696
 - xylitol-induced increase in, 739-743
- Urinary excretion, xanthine
 - bucladesine sodium effects on concentrations of, 1005-1008
 - glucagon effects on, 696
 - xylitol-induced increase in, 739-743
- Urinary excretion in NIDDM
 - albumin, *see* Urinary excretion, albumin, in NIDDM
 - CV risk factors, fibrinolysis and, 639
 - of glucose, zinc, Ca, and Mg in elderly NIDDM subjects, Pro-Z effects on, 41
 - of TM, as potential marker for vascular endothelial injury, 362-365
- $\dot{V}O_2$
 - OC effects on, 281
 - see also* $\dot{V}O_{2\max}$
- $\dot{V}O_{2\max}$
 - exercise and, *see* $\dot{V}O_{2\max}$ in exercise
 - in postmenopausal obese women, adrenoceptor binding and adipocyte lipolysis and, 469
 - and RMR in healthy adults, 1135, 1136
- $\dot{V}O_{2\max}$ in exercise
 - β -adrenoceptor blockade effects on EPOC and, 440
 - in endurance exercise, 875
 - menopausal status and exercise effects on, 378, 379
 - in postmenopausal women, 1113
- Vagus nerve, control of insulin secretion by, in obesity, 1167-1173
- Validation of systems model, 1019
- Valine (Val)
 - endotoxin effects on, 683, 684
 - in familial HALP and HBLP, 1164

Valine (Val) (*Continued*)

- reduced energy intake effects on, in obese children, 1438
- in trauma, 226, 227
- Vanadate, [125 I]-transferrin binding and ^{59}Fe uptake in adipocytes stimulated by, 630-636
- Vascular cell adhesion molecule-1 (VCAM-1), LDL and, in hyperlipidemia of preeclampsia, 1281-1288
- Vascular damage, microalbuminuria and, in NIDDM, fasting and postmethionine tHcy correlated with, 915-921
- Vascular endothelium, *see* entries beginning with term: Endothelial
- Vasoactive intestinal peptide (VIP), NO in PRL secretion stimulated by, in men, 897-899
- Vasoactive regulatory hormones, changes in volume regulatory hormones, BP and, in obese subjects on very-low-calorie diet, 592-597
- Vasodilation, insulin-induced, dependent on synthesis of BH_4 , 1037-1039
- Vasopressin, *see* Arginine vasopressin
- VCAM-1 (vascular cell adhesion molecule-1), LDL and, in hyperlipidemia of preeclampsia, 1281-1288
- VEGF (vascular endothelial growth factor), plasma immunoreactive, smoking relation to concentration of, 27-30
- Venous access devices, implantable central, in children with metabolic diseases, 900-902
- Verapamil, effects of captopril and, on glucose tolerance and insulin action in insulin resistance, 982-987
- Very-low-calorie diet, effects of, on BP, vasoactive regulatory hormones, and volume regulatory hormones in obesity, 592-597
- Very-low-density lipoprotein (VLDL)
 - BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 - in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-374
 - plasma, *see* Plasma very low-density lipoprotein
 - serum in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 - see also* Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein-cholesterol (VLDL-C)
 - in CHD, *see* Very-low-density lipoprotein-cholesterol in CHD
 - effects of stearic and oleic acid diets on, 532
 - in familial HALP and HBLP, 1162
 - HCHF diet effects on, 733
 - in NIDDM, effects of insulin versus sulfonylurea on, 641
 - race and, of nondiabetics, relationship between insulin resistance and, 1176
 - in young children of NIDDM parents, 999
- Very-low-density lipoprotein-cholesterol (VLDL-C) in CHD
 - Lp(a) level and, 276
 - metabolic disturbances of, predisposing to CHD, 114
 - plasma, ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- Very old subjects with syndrome X, relationship between fasting plasma insulin, anthropometrics, and metabolic parameters in, 535-540
- VIP (vasoactive intestinal peptide), NO in PRL secretion stimulated by, in men, 897-899
- Visceral adipose tissue (VAT)
 - and effects of HF versus LF diets on S_1 and serum leptin in women, race and, 1521
 - see also* Visceral adipose tissue in obesity
- Visceral adipose tissue (VAT) in obesity
 - effects of accumulation of, on uric acid metabolism in obese men, 929-933
 - in obese women with PCOS, serum leptin and, 989, 990
 - PPAR γ gene expression in, 1494-1498

- Vitamin(s)
 in diet regulating apo B-containing Lps, 884
 in diet regulating small intestinal cell turnover, 1106
 in high-monounsaturated fat diet, 725
 in obesity- and DM-inducing diet, 1090
see also specific vitamins
- Vitamin A (retinol), response to sucrose and deficiency in, 1-2
- Vitamin B₁₂
 in homocystinuria, 208
 in NIDDM, tHcy, microalbuminuria and, 916
see also Vitamin B₁₂, plasma HcY and
- Vitamin B₁₂, plasma HcY and
 and plasma HcY related to folate status and MTHFR gene mutation in healthy subjects, 1415
 total plasma HcY and serum cobalamin level in hyperthyroidism and hypothyroidism, 90, 91
- Vitamin C (ascorbic acid)
 effects of exercise and, on PAI-1 activity, 385
 regulation of apo B-containing Lps with dietary fat saturation and, 883-891
- Vitamin D, *see specific vitamin D metabolites*
- Vitamin E (α tocopherol)
 effects of exercise and, on PAI-1 activity, 385
 effects of selenium and, on Keshan disease-induced beta cell alterations, 415-419
- Vitamin K in osteopenic older men, 195-199
- VLDL, *see* Very-low-density lipoprotein
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- Volume regulatory hormones, changes in vasoactive regulatory hormones, BP and, in obese subjects on very-low-calorie diet, 592-597
- Waist-to-hip ratio (WHR)
 body composition, insulin resistance and, 402, 404, 406
 exercise and, *see* Waist-to-hip ratio, exercise and
 and family history of NIDDM, 523, 525
 of FCH subjects, *see* Waist-to-hip ratio of FCH subjects
 and HRT effects on plasma lipids and Lp, 1224
 of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 of hyperinsulinemic subjects, plasma HcY concentrations and, 687
 of IGT subjects, insulin kinetics, muscle morphology and, 850
 of Kuwaiti children, 421, 422
 of men with abdominal obesity, 1189, 1190
 of NIDDM subjects, *see* Waist-to-hip ratio of NIDDM subjects
 of nondiabetic Asian Indians, 231
 of obese women, *see* Waist-to-hip ratio of obese women
 of PCOS subjects, 941
 of postmenopausal women, *see* Waist-to-hip ratio of postmenopausal women
 in pregnant women, 1141
 of premenopausal women, *see* Waist-to-hip ratio of premenopausal women
 race and, *see* Waist-to-hip ratio, race and
 as risk factor for CHD, 1141, 1246
 of very old syndrome X subjects, 536, 537
 of young children of NIDDM parents, 999
- Waist-to-hip ratio (WHR), exercise and
 effects of menopausal status and exercise on, 386, 387
 endurance exercise effects on, 875
- Waist-to-hip ratio (WHR), race and
 effects of HF versus LF diets on S₁ and serum leptin and, 1521
 relationship between insulin resistance and, in nondiabetics, 1176, 1177
- Waist-to-hip ratio (WHR) of FCH subjects
 and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
 in nondiabetics, 509, 510
- Waist-to-hip ratio (WHR) of NIDDM subjects
 as CV disease risk factor, 639
 DEXA measurement of, 213
- Waist-to-hip ratio (WHR) of obese women
 effects of weight loss with meat-based or plant-based diet on, 1309, 1310
 of PCOS women, serum leptin and, 989
 postmenopausal, 469
 premenopausal, 14, 16
- Waist-to-hip ratio (WHR) of postmenopausal women
 DEXA measurement of, 213
 obese, 469
- Waist-to-hip ratio of premenopausal women
 DEXA measurement of, 213
 obese, 14, 16
- WAT (white adipose tissue), NO-1886 effects on, in hypertriglyceridemia, 150
- Water channel, renal, urinary aquaporin-2 excretion and expression of, in newborns, 1344-1347
- WBC (white blood cell) count, endotoxin effects on, 682
- Weight loss
 effects of aerobic exercise and, on BP, glucose metabolism, and Lps in obese hypertensive middle-aged men, 1075-1082
 serum insulin but not leptin associated with spontaneous and GHRH-stimulated GH secretion in normal subjects with and without, 1127-1133
 very-low-calorie diet and, 593
see also Weight loss, plasma leptin and
- Weight loss, plasma leptin and
 effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin in obese women, compared, 1308-1314
 in insulin-treated and untreated STZ-DM subjects, 585
- Well-mixed in compartmental modeling, defined, 1012
- Wheat (and wheat bran) in diet regulating small intestinal cell turnover, 1106
- White adipose tissue (WAT), NO-1886 effects on, in hypertriglyceridemia, 150
- White blood cell (WBC) count, endotoxin effects on, 682
- White subjects, *see* Race and ethnicity
- Whole-body glucose fluxes in steady-state, modeling of, 1020-1021
- Whole-body protein, 1429-1439
 metabolism of, in active celiac disease assessed by leucine and glutamine kinetics, 1429-1433
 reduced energy intake effects on utilization of, in obese children, 1434-1439
- Whole pancreas-kidney transplantation for IDDM, proinsulin levels after, 1325-1330
- WHR, *see* Waist-to-hip ratio
- Withdrawal
 from acipimox, 254
 from Niaspan, 1101-1102
- Women
 on levothyroxine therapy following total thyroidectomy for Graves' disease, RBC Na⁺.K⁺ ATPase activity in, 1194-1198
 non-obese, *see* Non-obese subjects
 relationship of GH to HDL-C and apo A-I independently of IGF-I and insulin in, 339-344
 restricted caloric intake effects on insulin, cortisol, glucose, ketones, and NEFAs in, 429-434

Women (*Continued*)

see also Lecithin:cholesterol acyltransferase; Menopausal status; Normal subjects; Pregnancy; Risk factors for CHD in women; Sex; Sex hormone-binding globulin in women; Women, exercising; Women, plasma leptin in; Women, obese; Women, older; Women, S₁ in; Women, serum leptin in *and specific conditions*

Women, exercising

menopausal status and exercise effects on intravascular enzymes related to lipid transport, 377-383

postmenopausal, influence of AT on risk factors for CHD in, 1112-1120

see also Exercise

Women, obese

effects of weight loss with meat-based or plant-based diet on BP, SAC, plasma leptin, and plasma lipids in, 1308-1314

hyperinsulinemic premenopausal, sex hormones in, 13-19

Jamaican, hyperglycemia and BMI associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 617-621

with PCOS, serum leptin in, correlated with BW and AT distribution but not with androgen and insulin levels, 988-992

postmenopausal, adrenoceptor binding and adipocyte lipolysis in, AT distribution and, 467-473

see also Obesity

Women, older

very old women with syndrome X, relationship between fasting plasma insulin, anthropometrics, and metabolic parameters in, 535-540

see also Older subjects

Women, plasma leptin in

effects of weight loss with meat-based or plant-based diet on BP, SAC, plasma lipids, and plasma leptin, 1308-1314

in pregnant nondiabetic and IDDM women, 840-843

Women, S₁ in

glucose tolerance and S₁, effects of stearic and oleic acid diets on, 529-534

race and effects of HF versus LF diets on S₁ and serum leptin, 1520-1524

Women, S₁ in (*Continued*)

at risk for CHD, effects of low glycemic diet on, 1245-1251

and serum uric acid levels in non-obese premenopausal and postmenopausal women, 437, 438

Women, serum leptin in

correlated with BW and AT distribution but not with androgen and insulin levels in obese PCOS women, 988-992

race and effects of HF versus LF diets on S₁ and serum leptin, 1520-1524

restricted calorie intake effects on, 429-434

Wortmannin-sensitive pathways, insulin regulation of LPL activity in adipocytes via, 555-559

Xanthine, see Plasma xanthine; Urinary excretion, xanthine

X-ray absorptiometry, see Dual-energy x-ray absorptiometry, assessment of body composition with

Xylitol

effects of supplementation with, on osteoporosis in STZ-DM, 578-583

plasma concentrations and urinary excretion of uridine and purine bases and, 739-743

Yeast, brewer's, in diet regulating small intestinal cell turnover, 1106

Young adults with IDDM

urinary ET-1 excretion in, 1408-1412

see also Insulin-like growth factor-I in young IDDM adults

Young children

effects of diet type and plasma glucose level on LCPUFAs in skeletal muscle membrane of, 106-112

of NIDDM parents, race and characteristics of, 998-1004

see also Prepubertal children

Zinc (Zn)

effects of supplementation with, on glucose disposal in cirrhosis, 792-798

Pro-Z effects on glucose and insulin metabolism in older NIDDM subjects, 39-43